Synthesis and properties of linear and cyclic peptoids by De Cola, Chiara
UNIVERSITA' DEGLI STUDI DI SALERNO                     









Synthesis and properties of 
linear and cyclic peptoids
-X Cycle- Nuova serie (2008-2011) 
 
 
Tutor: Prof. Francesco De Riccardis            PhD candidate: Chiara De Cola 
 Co-tutor: Prof. Irene Izzo 






CHAPTER 1: INTRODUCTION, 3 
1.1  PEPTIDOMIMETICS, 5 
1.2  PEPTOIDS: A PROMISING CLASS OF PEPTIDOMIMETICS, 9 
1.3 CONFORMATIONAL STUDIES OF PEPTOIDS, 11 
1.4 PEPTOIDS’ APPLICATIONS, 14 
1.5 PEPTOID SINTHESYS, 39 
1.6 SYNTHESYS OF PNA MONOMERS AND OLIGOMERS, 41 
1.7 AIMS OF THE WORK, 49 
 
CHAPTER 2: CARBOXYALKYL PEPTOID PNAS: SYNTHESIS AND HYBRIDIZATION PROPERTIES, 51 
2.1 INTRODUCTION, 51 
2.2. RESULTS AND DISCUSSION, 55 
2.3. CONCLUSIONS, 60 
2.4 EXPERIMENTAL SECTION, 60 
 
CHAPTER 3: STRUCTURAL ANALYSIS OF CYCLOPEPTOIDS AND THEIR COMPLEXES, 80 
3.1 INTRODUCTION, 80 
3.2. RESULTS AND DISCUSSION, 85 
3.3. CONCLUSIONS, 102 
3.4 EXPERIMENTAL SECTION, 103 
 
CHAPTER 4: CATIONIC CYCLOPEPTOIDS AS POTENTIAL MACROCYCLIC NONVIRAL VECTORS, 115 
4.1 INTRODUCTION, 115 
4.2. RESULTS AND DISCUSSION, 122 
4.3. CONCLUSIONS, 125 
4.4 EXPERIMENTAL SECTION, 125 
 
CHAPTER 5: COMPLEXATION WITH GD(III) OF CARBOXYETHYL CYCLOPEPTOIDS AS POSSIBLE CONTRAST AGENTS 
IN MRI, 132 
5.1 INTRODUCTION, 132 
5.2 LARIAT ETHER AND CLICK CHEMISTRY, 135 
5.3 RESULTS AND DISCUSSION, 141 
5.4 EXPERIMENTAL SECTION, 145 
 
CHAPTER 6: CYCLOPEPTOIDS AS MIMETIC OF NATURAL DEFENSINS, 157 
6.1 INTRODUCTION, 157 
6.2 RESULTS AND DISCUSSION, 162 
6.3 CONCLUSIONS, 167 










List of abbreviations 
Cbz              Benzyl chloroformate 
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PyBOP     benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
 PNA           Peptide nucleic acid 
 t-Bu            terz-Butyl 







 1. Introduction 
 
 
“Giunto a questo punto della vita, quale chimico, davanti alla tabella del Sistema Periodico, o agli indici 
monumentali del Beilstein o del Landolt, non vi ravvisa sparsi i tristi brandelli, o i trofei, del proprio passato 
professionale? Non ha che da sfogliare un qualsiasi trattato, e le memorie sorgono a grappoli: c’è fra noi chi ha 
legato il suo destino, indelebilmente, al bromo o al propilene o al gruppo –NCO o all’acido glutammico; ed ogni 
studente in chimica, davanti ad un qualsiasi trattato, dovrebbe essere consapevole che in una di quelle pagine, forse in 
una sola riga o formula o parola, sta scritto il suo avvenire, in caratteri indecifrabili, ma che diventeranno chiari 
<<POI>>: dopo il successo o l’errore o la colpa, la vittoria o la disfatta. 
Ogni chimico non più giovane, riaprendo alla pagina << verhangnisvoll >> quel medesimo trattato, è percosso 
da amore o disgusto, si rallegra o si dispera.”. 
 
Da “Il Sistema Periodico”, Primo Levi. 
 
Proteins are vital for essentially every known organism. The development of a deeper understanding 
of protein–protein interactions and the design of novel peptides, which selectively interact with proteins 
are fields of active research.  
One way how nature controls the protein functions within living cells is by regulating protein–
protein interactions. These interactions exist on nearly every level of cellular function which means they 
are of key importance for virtually every process in a living organism.  Regulation of the protein-protein 
interactions plays a crucial role in unicellular and multicellular organisms, including man, and 
represents the perfect example of molecular recognition
1
.  
Synthetic methods like the solid-phase peptide synthesis (SPPS) developed by B. Merrifield
2
 made it 
possible to synthesize polypeptides for pharmacological and clinical testing as well as for use as drugs 
or in diagnostics. 
As a result, different new peptide-based drugs are at present accessible for the treatment of prostate 
and breast cancer, as HIV protease inhibitors or as ACE inhibitors to treat hypertension and congestive 
heart failures, to mention only few examples
1
. 
Unfortunately, these small peptides typically show high conformational flexibility and a low in-vivo 
stability which hampers their application as tools in medicinal diagnostics or molecular biology. A 
major difficulty in these studies is the conformational flexibility of most peptides and the high 
dependence of their conformations on the surrounding environment which often leads to a 
conformational equilibrium. The high flexibility of natural polypeptides is due to the multiple 
conformations that are energetically possible for each residue of the incorporated amino acids. Every 
amino acid has two degrees of conformational freedom, N–Cα (Φ) and Cα–CO (Ψ) resulting in 
approximately 9 stable local conformations
1
. For a small peptide with only 40 amino acids in length the 
                                                 
1
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number of possible conformations which need to be considered escalates to nearly 1040
3
. This 
extraordinary high flexibility of natural amino acids leads to the fact that short polypeptides consisting 
of the 20 proteinogenic amino acids rarely form any stable 3D structures in solution
1
. There are only 
few examples reported in the literature where short to medium-sized peptides (<30–50 amino acids) 
were able to form stable structures. In most cases they exist in aqueous solution in numerous 
dynamically interconverting conformations. Moreover, the number of stable short peptide structures, 
which are available is very limited, because of the need to use amino acids having a strong structure 
inducing effect like for example helix-inducing amino acids as leucine, glutamic acid or lysine. In 
addition, it is dubious whether the solid state conformations determined by X-ray analysis are identical 
to those occurring in solution or during the interactions of proteins with each other
1
. Despite their wide 
range of important bioactivities, polypeptides are generally poor drugs. Typically, they are rapidly 
degraded by proteases in vivo, and are frequently immunogenic. 
This fact has inspired prevalent efforts to develop peptide mimics for biomedical applications, a task 
that presents formidable challenges in molecular design.  
 
1.1 Peptidomimetics 
One very versatile strategy to overcome such drawbacks is the use of peptidomimetics
4
. These are 
small molecules, which mimic natural peptides or proteins and thus produce the same biological effects 
as their natural role models. 
They also often show a decreased activity in comparison to the protein from which they are derived. 
These mimetics should have the ability to bind to their natural targets in the same way as the natural 
peptide sequences, from which their structure was derived, do and should produce the same biological 
effects. It is possible to design these molecules in such a way that they show the same biological effects 
as their peptide role models but with enhanced properties like a higher proteolytic stability, higher 
bioavailability and also often with improved selectivity or potency. This makes them interesting targets 
for the discovery of new drug candidates. 
For the progress of potent peptidomimetics, it is required to understand the forces that lead to 
protein–protein interactions with nanomolar or often even higher affinities. 
These strong interactions between peptides and their corresponding proteins are mainly based on side 
chain interactions indicating that the peptide backbone itself is not an absolute requirement for high 
affinities. 
This allows chemists to design peptidomimetics basically from any scaffold known in chemistry by 
replacing the amide backbone partially or completely by other structures. Peptidomimetics, furthermore, 
can have some peculiar qualities, such as a good solubility in aqueous solutions, access to facile 
sequences-specific assembly of monomers containing chemically diverse side chains and the capacity to 
form stable, biomimetic folded structures
5
.  
Most important is that the backbone is able to place the amino acid side chains in a defined 3D-
position to allow interactions with the target protein, too. Therefore, it is necessary to develop an idea of 
the required structure of the peptidomimetic to show a high activity against its biological target. 
                                                 
3 J. Venkatraman, S. C. Shankaramma, P. Balaram, Chem. Rev. 2001, 101, 3131–3152. 
4 J. A. Patch, K. Kirshenbaum, S. L. Seurynck, R. N. Zuckermann and A. E. Barron, in Pseudo-peptides in Drug 




The most significant parameters for an optimal peptidomimetics are: stereochemistry, charge and 
hydrophobicity, and these parameters can be examined by systematic exchange of single amino acids 
with modified amino acid. As a result, the key residues, which are essential for the biological activity, 
can be identified. As next step the 3D arrangement of these key residues needs to be analyzed by the use 
of compounds with rigid conformations to identify the most active structure
1
. In general, the 
development of peptidomimetics is based mainly on the knowledge of the electronic, conformational 
and topochemical properties of the native peptide to its target.  
Two structural factors are particularly important for the synthesis of peptidomimetics with high 
biological activity: firstly the mimetic has to have a convenient fit to the binding site and secondly the 
functional groups, polar and hydrophobic regions of the mimetic need to be placed in defined positions 
to allow the useful interactions to take place
1
. 
One very successful approach to overcome these drawbacks is the introduction of conformational 
constraints into the peptide sequence. This can be done for example by the incorporation of amino acids, 
which can only adopt a very limited number of different conformations, or by cyclisation (main chain to 
main chain; side chain to main chain or side chain to side chain).
5
 
Peptidomimetics, furthermore, can contain two different modifications: amino acid modifications or 
peptides‘ backbone modifications. 
Figure 1.1 reports the most important ways to modify the backbone of peptides at different positions. 
 
 





                                                 
5a) C. Toniolo, M. Goodman, Introduction to the Synthesis of Peptidomimetics, in: Methods of Organic Chemistry: 
Synthesis of Peptides and Peptidomimetics (Ed.: M. Goodman), Thieme, Stuttgart, New York, 2003, vol. E22c, p. 
1–2; b) D. J. Hill, M. J. Mio, R. B. Prince, T. S. Hughes, J. S. Moore, Chem. Rev. 2001, 101, 3893–4012. 




Backbone peptides modifications are a method for synthesize optimal peptidomimetics, in particular 
is possible: 
 the replacement of the α-CH group by nitrogen to form azapeptides, 
 the change from amide to ester bond to get depsipeptides, 
 the exchange of the carbonyl function by a CH2 group, 
 the extension of the backbone (β-amino acids and γ-amino acids), 
 the amide bond inversion (a retro-inverse peptidomimetic), 
 The carba, alkene or hydroxyethylene groups are used in exchange for the amide bond.  
 The shift of the alkyl group from α-CH group to α-N group. 
Most of these modifications do not guide to a higher restriction of the global conformations, but they 
have influence on the secondary structure due to the altered intramolecular interactions like different 
hydrogen bonding. Additionally, the length of the backbone can be different and a higher proteolytic 




1.2 Peptoids: A Promising Class of Peptidomimetics. 
If we shift the chain of α-CH group by one position on the peptide backbone, we produced the 
disappearance of all the intra-chain stereogenic centers and the formation of a sequence of variously 
substituted N-alkylglycines (figure 1.2). 
 
Figure 1.2. Comparison of a portion of a peptide chain with a portion of a peptoid chain. 
 
Oligomers of N-substituted glycine, or peptoids, were developed by Zuckermann and co-workers in 
the early 1990‘s
7
. They were initially proposed as an accessible class of molecules from which lead 
compounds could be identified for drug discovery. 
Peptoids can be described as mimics of α-peptides in which the side chain is attached to the 
backbone amide nitrogen instead of the α-carbon (figure 1.2). These oligomers are an attractive scaffold 
for biological applications because they can be generated using a straightforward, modular synthesis that 
allows the incorporation of a wide variety of functionalities
8
. Peptoids have been evaluated as tools to 
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 R. J. Simon, R. S. Kania, R. N. Zuckermann, V. D. Huebner, D. A. Jewell, S. Banville, S. Ng, L.Wang, S. 
Rosenberg, C. K. Marlowe, D. C. Spellmeyer, R. Tan, A. D. Frankel, D. V. Santi, F. E. Cohen and P. A. Bartlett, 






 and also hold significant promise for therapeutic applications due to 
their enhanced proteolytic stabilities
8
 and increased cellular permeabilities
9
 relative to α-peptides. 
Biologically active peptoids have also been discovered by rational design (i.e., using molecular 
modeling), and were synthesized either individually or in parallel focused libraries
10
. For some 
applications, a well-defined structure is also necessary for peptoid function to display the functionality 
in a particular orientation, or to adopt a conformation that promotes interaction with other molecules. 
However, in other biological applications, peptoids lacking defined structures appear to possess superior 
activities over structured peptoids.  
This introduction will focus primarily on the relationship between peptoid structure and function. A 
comprehensive review of peptoids in drug discovery, detailing peptoid synthesis, biological 





Since then, significant advances have been made in these areas, and new applications 
for peptoids have emerged. In addition, new peptoid secondary structural motifs have been reported, as 
well as strategies to stabilize those structures. Lastly, the emergence of peptoid with tertiary structures 
has driven chemists towards new structures with peculiar properties and side chains. Peptoid monomers 
are linked through polyimide bonds, in contrast to the amide bonds of peptides. Unfortunately, peptoids 
do not have the hydrogen of the peptide secondary amide, and are consequently incapable of forming 
the same types of hydrogen bond networks that stabilize peptide helices and β-sheets. 
The peptoids oligomers backbone is achiral; however stereogenic centers can be included in the side 
chains to obtain secondary structures with a preferred handedness
4
. In addition, peptoids carrying N-
substituted versions of the proteinogenic side chains are highly resistant to degradation by proteases, 





1.3 Conformational studies of peptoids 
The fact that peptoids are able to form a variety of secondary structural elements, including helices 
and hairpin turns, suggests a range of possible conformations that can allow the generation of functional 
folds.
11 
Some studies of molecular mechanics, have demonstrated that peptoid oligomers bearing bulky 
chiral (S)-N-(1-phenylethyl) side chains would adopt a polyproline type I helical conformation, in 




Kirshenbaum at al.12 has shown agreement between theoretical models and the trans amide of N-
aryl peptoids, and suggested that they may form polyproline type II helices. Combined, these studies 
suggest that the backbone conformational propensities evident at the local level may be readily 
translated into the conformations of larger oligomers chains. 
N-α-chiral side chains were shown to promote the folding of these structures in both solution and the 
solid state, despite the lack of main chain chirality and secondary amide hydrogen bond donors crucial 
to the formation of many α-peptide secondary structures.  
                                                 
8 S. M. Miller, R. J. Simon, S. Ng, R. N. Zuckermann, J. M. Kerr, W. H. Moos, Bioorg. Med. Chem. Lett., 1994, 4, 
2657–2662. 
9 Y. U.Kwon and T. Kodadek, J. Am. Chem. Soc., 2007, 129, 1508–1509.  
10 T. Hara, S. R. Durell, M. C. Myers and D. H. Appella, J. Am. Chem. Soc., 2006, 128, 1995–2004. 





While computational studies initially suggested that steric interactions between N-α-chiral aromatic 
side chains and the peptoid backbone primarily dictated helix formation,
 
both intra- and intermolecular 
aromatic stacking interactions
12
 have also been proposed to participate in stabilizing such helices
13
. 
In addition to this consideration, Gorske et al.
14
 selected side chain functionalities to look at the 
effects of four key types of noncovalent interactions on peptoid amide cis/trans equilibrium: (1) n→π* 
interactions between an amide and an aromatic ring (n→π*Ar), (2) n→π* interactions between two 
carbonyls (n→π* C=O), (3) side chain-backbone steric interactions, and (4) side chain-backbone 




       
A                                         B 
Figure 1.3. A: (Left) n→π*Ar interaction (indicated by the red arrow) proposed to increase of 
Kcis/trans (equilibrium constant between cis and trans conformation) for peptoid backbone amides. (Right) 
Newman projection depicting the n→π*Ar interaction. B: (Left) n→π*C=O interaction (indicated by 
the red arrow) proposed to reduce Kcis/trans for the donating amide in peptoids. (Right) Newman 
projection depicting the n→π*C=O interaction. 
 
Other classes of peptoid side chains have been designed to introduce dipole-dipole, hydrogen 
bonding, and electrostatic interactions stabilizing the peptoid helix. 
In addition, such constraints may further rigidify peptoid structure, potentially increasing the ability 
of peptoid sequences for selective molecular recognition. 
In a relatively recent contribution Kirshenbaum
15 
reported that peptoids undergo to a very efficient 
head-to-tail cyclisation using standard coupling agents. The introduction of the covalent constraint 
enforces conformational ordering, thus facilitating the crystallization of a cyclic peptoid hexamer and a 
cyclic peptoid octamer. 
Peptoids can form well-defined three-dimensional folds in solution, too. In fact, peptoid oligomers 
with α-chiral side chains were shown to adopt helical structures 
16
; a threaded loop structure was formed 
                                                 
12 C. W. Wu, T. J. Sanborn, R. N. Zuckermann, A. E. Barron, J. Am. Chem. Soc. 2001, 123, 2958–2963. 
13  T. J. Sanborn, C. W. Wu, R. N. Zuckermann, A. E. Barron, Biopolymers, 2002, 63, 12–20. 
14
 B. C. Gorske, J. R. Stringer, B. L. Bastian, S.  A. Fowler,  H. E. Blackwell , J. Am. Chem. Soc., 2009, 131, 
16555–16567. 
15 S. B. Y. Shin, B. Yoo, L. J. Todaro, K. Kirshenbaum, J. Am. Chem. Soc., 2007, 129, 3218-3225. 
16 (a) K. Kirshenbaum, A. E. Barron, R. A. Goldsmith, P. Armand, E. K. Bradley, K. T. V. Truong, K. A. Dill, F. E. 
Cohen, R. N. Zuckermann, Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4303–4308. (b) P. Armand, K. Kirshenbaum, R. 
A. Goldsmith, S. Farr-Jones, A. E. Barron, K. T. V. Truong, K. A. Dill, D. F. Mierke, F. E. Cohen, R. N. 
Zuckermann, E. K. Bradley, Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4309–4314. (c) C. W. Wu, K. Kirshenbaum, T. 





by intramolecular hydrogen bonds in peptoid nonamers
20
; head-to-tail macrocyclizations provided 
conformationally restricted cyclic peptoids.  
These studies demonstrate the importance of (1) access to chemically diverse monomer units and (2) 
precise control of secondary structures to expand applications of peptoid helices.  
The degree of helical structure increases as chain length grows, and for these oligomers becomes 
fully developed at length of approximately 13 residues. Aromatic side chain-containing peptoid helices 
generally give rise to CD spectra that are strongly reminiscent of that of a peptide α-helix, while peptoid 
helices based on aliphatic groups give rise to a CD spectrum that resembles the polyproline type-I 
helical. 
 
1.4 Peptoids’ Applications. 
The well-defined helical structure associated with appropriately substituted peptoid oligomers can be 
employed to construct compounds that closely mimic the structures and functions of certain bioactive 
peptides. In this paragraph, are shown some examples of peptoids that have antibacterial and 
antimicrobial properties, molecular recognition properties, of metal complexing peptoids, of catalytic 
peptoids, and of peptoids tagged with nucleobases. 
 
1.4.1 Antibacterial and antimicrobial properties 
The antibiotic activities of structurally diverse sets of peptides/peptoids derive from their action on 
microbial cytoplasmic membranes. The model proposed by Shai–Matsuzaki–Huan
17
 (SMH) presumes 
alteration and permeabilization of the phospholipid bilayer with irreversible damage of the critical 
membrane functions. Cyclization of linear peptide/peptoid precursors (as a mean to obtain 
conformational order), has been often neglected
18
, despite the fact that nature offers a vast assortment of 
powerful cyclic antimicrobial peptides
19
. However, macrocyclization of N-substituted glycines gives 
                                                 
17 (a) Matsuzaki, K. Biochim. Biophys. Acta 1999, 1462, 1; (b) Yang, L.; Weiss, T. M.; Lehrer, R. I.; Huang, H. W. 
Biophys. J. 2000, 79, 2002; (c) Shai, Y. Biochim.Biophys. Acta 1999, 1462, 55. 
18 Chongsiriwatana, N. P.; Patch, J. A.; Czyzewski, A. M.; Dohm, M. T.; Ivankin, A.; Gidalevitz, D.; Zuckermann, 
R. N.; Barron, A. E. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2794. 
19 Interesting examples are: (a) Motiei, L.; Rahimipour, S.; Thayer, D. A.; Wong, C. H.; Ghadiri, M. R. Chem. 
Commun. 2009, 3693; (b) Fletcher, J. T.; Finlay, J. A.; Callow, J. A.; Ghadiri, M. R. Chem. Eur. J. 2007, 13, 4008; 
(c) Au, V. S.; Bremner, J. B.; Coates, J.; Keller, P. A.; Pyne, S. G. Tetrahedron 2006, 62, 9373; (d) Fernandez-
Lopez, S.; Kim, H.-S.; Choi, E. C.; Delgado, M.; Granja, J. R.; Khasanov, A.; Kraehenbuehl, K.; Long, G.; 
Weinberger, D. A.; Wilcoxen, K. M.; Ghadiri, M. R. Nature 2001, 412, 452; (e) Casnati, A.; Fabbi, M.; Pellizzi, N.; 
Pochini, A.; Sansone, F.; Ungaro, R.; Di Modugno, E.; Tarzia, G. Bioorg. Med. Chem. Lett. 1996, 6, 2699; (f) 
Robinson, J. A.; Shankaramma, C. S.; Jetter, P.; Kienzl, U.; Schwendener, R. A.; Vrijbloed, J. W.; Obrecht, D. 






, showing reduced conformational freedom
21 




Antimicrobial peptides (AMPs) are found in myriad organisms and are highly effective against 
bacterial infections
23
. The mechanism of action for most AMPs is permeabilization of the bacterial 
cytoplasmic membrane, which is facilitated by their amphipathic structure
24
.  
The cationic region of AMPs confers a degree of selectivity for the membranes of bacterial cells over 
mammalian cells, which have negatively charged and neutral membranes, respectively. The 
hydrophobic portions of AMPs are supposed to mediate insertion into the bacterial cell membrane. 
Although AMPs possess many positive attributes, they have not been developed as drugs due to the 
poor pharmacokinetics of α-peptides. This problem creates an opportunity to develop peptoid mimics of 
AMPs as antibiotics and has sparked considerable research in this area
25
.
   
De Riccardis
26
 et al. investigated the antimicrobial activities of five new cyclic cationic hexameric α-
peptoids comparing their efficacy with the linear cationic and the cyclic neutral counterparts (figure 
1.4). 
 
                                                 
20 (a) Craik, D. J.; Cemazar, M.; Daly, N. L. Curr. Opin. Drug Discovery Dev. 2007, 10, 176; (b) Trabi, M.; Craik, 
D. J. Trend Biochem. Sci. 2002, 27, 132. 
21 (a) Maulucci, N.; Izzo, I.; Bifulco, G.; Aliberti, A.; De Cola, C.; Comegna, D.; Gaeta, C.; Napolitano, A.; Pizza, 
C.; Tedesco, C.; Flot, D.; De Riccardis, F. Chem. Commun. 2008, 3927; (b) Kwon, Y.-U.; Kodadek, T. Chem. 
Commun. 2008, 5704; (c) Vercillo, O. E.; Andrade, C. K. Z.; Wessjohann, L. A. Org. Lett. 2008, 10, 205; (d) Vaz, 
B.; Brunsveld, L. Org. Biomol. Chem. 2008, 6, 2988; (e) Wessjohann, L. A.; Andrade, C. K. Z.; Vercillo, O. E.; 
Rivera, D. G.. In Targets in Heterocyclic Systems; Attanasi, O. A., Spinelli, D., Eds.; Italian Society of Chemistry, 
2007; Vol. 10, pp 24–53; (f) Shin, S. B. Y.; Yoo, B.; Todaro, L. J.; Kirshenbaum, K. J. Am. Chem. Soc. 2007, 129, 
3218; (g) Hioki, H.; Kinami, H.; Yoshida, A.; Kojima, A.; Kodama, M.; Taraoka, S.; Ueda, K.; Katsu, T. 
Tetrahedron Lett. 2004, 45, 1091. 
22 (a) Chatterjee, J.; Mierke, D.; Kessler, H. Chem. Eur. J. 2008, 14, 1508; (b) Chatterjee, J.; Mierke, D.; Kessler, 
H. J. Am. Chem. Soc. 2006, 128, 15164; (c) Nnanabu, E.; Burgess, K. Org. Lett. 2006, 8, 1259; (d) Sutton, P. W.; 
Bradley, A.; Farràs, J.; Romea, P.; Urpì, F.; Vilarrasa, J. Tetrahedron 2000, 56, 7947; (e) Sutton, P. W.; Bradley, 
A.; Elsegood, M. R.; Farràs, J.; Jackson, R. F. W.; Romea, P.; Urpì, F.; Vilarrasa, J. Tetrahedron Lett. 1999, 40, 
2629. 
23 A. Peschel and H.-G. Sahl, Nat. Rev. Microbiol., 2006, 4, 529–536. 
24 R. E. W. Hancock and H.-G. Sahl, Nat. Biotechnol., 2006, 24, 1551–1557. 
25 For a review of antimicrobial peptoids, see: I. Masip, E. Pèrez Payà, A. Messeguer, Comb. Chem. High 
Throughput Screen., 2005, 8, 235–239. 





Figure 1.4. Structures of synthesized linear and cyclic peptoids described by De Riccardis at al. Bn 
= benzyl group; Boc= t-butoxycarbonyl group. 
 
The synthesized peptoids have been assayed against clinically relevant bacteria and fungi, including 




The purpose of this study was to explore the biological effects of the cyclisation on positively 
charged oligomeric N-alkylglycines, with the idea to mimic the natural amphiphilic peptide antibiotics. 
The long-term aim of the effort was to find a key for the rational design of novel antimicrobial 
compounds using the finely tunable peptoid backbone. 
The exploration for possible biological activities of linear and cyclic α-peptoids, was started with the 
assessment of the antimicrobial activity of the known
21a
 N-benzyloxyethyl cyclohomohexamer (Figure 
1.4, Block I). This neutral cyclic peptoid was considered a promising candidate in the antimicrobial 
                                                 
27 M. Benincasa, M. Scocchi, S. Pacor, A. Tossi, D. Nobili, G. Basaglia, M. Busetti, R. J. Gennaro, Antimicrob. 





















a behavior similar to that 
observed for valinomycin, a well known K
+
-carrier with powerful antibiotic activity
29
. However, 
determination of the MIC values showed that neutral chains did not exert any antimicrobial activity 
against a group of selected pathogenic fungi, and of Gram-negative and Gram-positive bacterial strains 
even at concentrations up to 1 mM. 
Detailed structure–activity relationship (SAR) studies
30
 have revealed that the amphiphilicity of the 
peptides/peptidomimetics and the total number of positively charged residues, impact significantly on 
the antimicrobial activity. Therefore, cationic versions of the neutral cyclic α-peptoids were planned 
(Figure 1.4, block I and block II compounds). In this study were also included the linear cationic 
precursors to evaluate the effect of macrocyclization on the antimicrobial activity. Cationic peptoids 
were tested against four pathogenic fungi and three clinically relevant bacterial strains. The tests showed 
a marked increase of the antibacterial and antifungal activities with cyclization. The presence of charged 
amino groups also influenced the antimicrobial efficacy, as shown by the activity of the bi- and 
tricationic compounds, when compared with the ineffective neutral peptoid. These results are the first 
indication that cyclic peptoids can represent new motifs on which to base artificial antibiotics.  
In 2003, Barron and Patch
31
 reported peptoid mimics of the helical antimicrobial peptide magainin-2 
that had low micromolar activity against Escherichia coli (MIC = 5–20 mM) and Bacillus subtilis (MIC 
= 1–5 mM).
 
The magainins exhibit highly selective and potent antimicrobial activity against a broad spectrum of 
organisms
5
. As these peptides are facially amphipathic, the magainins have a cationic helical face 
mostly composed of lysine residues, as well as hydrophobic aromatic (phenylalanine) and hydrophobic 
aliphatic (valine, leucine and isoleucine) helical faces. This structure is responsible for their activity
4
.  
Peptoids have been shown to form remarkably stable helices, with physical characteristics similar to 
those of peptide polyproline type-I helices.  In fact, a series of peptoid magainin mimics with this type 
of three-residue periodic sequences has been synthesized
4
 and tested against E. coli JM109 and B. 
subtulis BR151. In all cases, peptoids are individually more active against the Gram-positive species. 
The amount of hemolysis induced by these peptoids correlated well with their hydrophobicity. In 
summary, these recently obtain results demonstrate that certain amphipathic peptoid sequences are also 
capable of antibacterial activity. 
 
 
1.4.2 Molecular Recognition 
Peptoids are currently being studied for their potential to serve as pharmaceutical agents and as 
chemical tools to study complex biomolecular interactions. Peptoid–protein interactions were first 
demonstrated in a 1994 report by Zuckermann and co-workers,
8
 where the authors examined the high-
affinity binding of peptoid dimers and trimers to G-protein-coupled receptors.
 
These groundbreaking 
studies have led to the identification of several peptoids with moderate to good affinity and, more 
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importantly, excellent selectivity for protein targets that implicated in a range of human diseases. There 
are many different interactions between peptoid and protein, and these interactions can induce a certain 
inhibition, cellular uptake and delivery. Synthetic molecules capable of activating the expression of 
specific genes would be valuable for the study of biological phenomena and could be therapeutically 
useful. From a library of ~100000 peptoid hexamers, Kodadek and co-workers recently identified three 
peptoids (24-26) with low micromolar binding affinities for the coactivator CREB-binding protein 




This coactivator protein is involved in the transcription of a large number 
of mammalian genes, and served as a target for the isolation of peptoid activation domain mimics. Of 
the three peptoids, only 24 was selective for CBP, while peptoids 25 and 26 showed higher affinities for 
bovine serum albumin. The authors concluded that the promiscuous binding of 25 and 26 could be 
attributed to their relatively ―sticky‖ natures (i.e., aromatic, hydrophobic amide side chains).  
Inhibitors of proteasome function that can intercept proteins targeted for degradation would be 
valuable as both research tools and therapeutic agents. In 2007, Kodadek and co-workers
32
 identified the 
first chemical modulator of the proteasome 19S regulatory particle (which is part of the 26S proteasome, 
an approximately 2.5 MDa multi-catalytic protease complex responsible for most non-lysosomal protein 
degradation in eukaryotic cells). A ―one bead one compound‖ peptoid library was constructed by split 
and pool synthesis. 
 
Figure 1.5. Peptoid hexamers 24, 25, and 26 reported by Kodadek and co-workers and their 




Peptoid 24 was able to function as a transcriptional 
activation domain mimic (EC50 = 8 mM). 
 
                                                 




Each peptoid molecule was capped with a purine analogue in hope of biasing the library toward 
targeting one of the ATPases, which are part of the 19S regulatory particle. Approximately 100 000 
beads were used in the screen and a purine-capped peptoid heptamer (27, Figure 1.6) was identified as 




(by performing a ―glycine scan‖, similar to the ―alanine scan‖ in peptides) it was shown that just 
the core tetrapeptoid was necessary for the activity. 
Interestingly, the synthesis of the shorter peptoid 27 gave, in the experiments made on cells, a 3- to 
5-fold increase in activity relative to 28. The higher activity in the cell-based essay was likely due to 
increased cellular uptake, as 27 does not contain charged residues. 
 




1.4.3 Metal Complexing Peptoids 
A desirable attribute for biomimetic peptoids is the ability to show binding towards receptor sites. 
This property can be evoked by proper backbone folding due to:  
1) local side-chain stereoelectronic influences,  
2) coordination with metallic species,  
3) presence of hydrogen-bond donor/acceptor patterns.  
Those three factors can strongly influence the peptoids‘ secondary structure, which is difficult to 
observe due to the lack of the intra-chain C=O···H–N bonds, present in the parent peptides.  
Most peptoids‘ activities derive by relatively unstructured oligomers. If we want to mimic the 
sophisticated functions of proteins, we need to be able to form defined peptoid tertiary structure folds 
and introduce functional side chains at defined locations. Peptoid oligomers can be already folded into 
helical secondary structures. They can be readily generated by incorporating bulky chiral side chains 
                                                 











The unusual stability of the helical structure may be a consequence of the steric 
hindrance of backbone φ angle by the bulky chiral side chains
36
. 
Zuckermann and co-workers synthesized biomimetic peptoids with zinc-binding sites
8
, since zinc-
binding motifs in protein are well known. Zinc typically stabilizes native protein structures or acts as a 
cofactor for enzyme catalysis
37-38





The binding of zinc is typically mediated by cysteines and histidines
50-51
. In 
order to create a zinc-binding site, they incorporated thiol and imidazole side chains into a peptoid two-
helix bundle. 
Classic zinc-binding motifs, present in proteins and including thiol and imidazole moieties, were 
aligned in two helical peptoid sequences, in a way that they could form a binding site. Fluorescence 
resonance energy transfer (FRET) reporter groups were located at the edge of this biomimetic structure 
in order to measure the distance between the two helical segments and probe and, at the same time, the 




Figure 1.7. Chemical structure of 29, one of the twelve folded peptoids synthesized by Zuckermann, 




Folding of the two helix bundles was allowed by a Gly-Gly-Pro-Gly middle region. The study 
demonstrated that certain peptoids were selective zinc binders at nanomolar concentration. 
The formation of the tertiary structure in these peptoids is governed by the docking of preorganized 
peptoid helices as shown in these studies
40
.  
A survey of the structurally diverse ionophores demonstrated that the cyclic arrangement represents a 
common archetype equally promoted by chemical design
22f
 and evolutionary pressure.
 
Stereoelectronic 
effects caused by N- (and C-) substitution
22f 
and/or by cyclisation, dictate the conformational ordering of 
peptoids‘ achiral polyimide backbone. In particular, the prediction and the assessment of the covalent 
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constraints induced by macrolactamization appears crucial for the design of conformationally restricted 
peptoid templates as preorganized synthetic scaffolds or receptors.
 
In 2008 were reported the synthesis 





Figure 1.8. Structure of cyclic tri-, tetra-, hexa-, octa and deca- N-benzyloxyethyl glycines. 
 
It was found, for the flexible eighteen-membered N-benzyloxyethyl cyclic peptoid 32, high binding 






), while, for the rigid cis–
trans–cis–trans cyclic tetrapeptoid 31, there was no evidence of alkali metals complexation. The 
conformational disorder in solution was seen as a propitious auspice for the complexation studies. In 
fact, the stepwise addition of sodium picrate to 32, induced the formation of a new chemical species, 
whose concentration increased with the gradual addition of the guest. The conformational equilibrium 
between the free host and the sodium complex, resulted in being slower than the NMR-time scale, 
giving, with an excess of guest, a remarkably simplified 
1
H NMR spectrum, reflecting the formation of 
a 6-fold symmetric species (Figure 1.9). 
 
Figure 1.9. Picture of the predicted lowest energy conformation for the complex 32 with sodium. 
 
A conformational search on 32 as a sodium complex suggested the presence of an S6-symmetry axis 




this conformation, hampering the ring inversion up to 425 K.  The complexity of the r.t. 
1
H NMR 
spectrum recorded for the cyclic 33, demonstrated the slow exchange of multiple conformations on the 
NMR time scale. Stepwise addition of sodium picrate to 33, induced the formation of a complex with a 
remarkably simplified 
1
H NMR spectrum. With an excess of guest, we observed the formation of an 8-
fold symmetric species (Figure 1.10) was observed. 
 
Figure 1.10. Picture of the predicted lowest energy conformations for 33 without sodium cations. 
 
Differently from the twenty-four-membered 33, the N-benzyloxyethyl cyclic homologue 34 did not 
yield any ordered conformation in the presence of cationic guests. The association constants (Ka) for the 
complexation of 32, 33 and 34 to the first group alkali metals and ammonium, were evaluated in H2O–
CHCl3 following Cram‘s method (Table 1.1)
 41
. The results presented in Table 1.1 show a good degree 
of selectivity for the smaller cations. 
 
 
Table 1.1 R, Ka, and G
◦
 for cyclic peptoid hosts 32, 33 and 34 complexing picrate salt guests in CHCl3 at 25 
◦
C; figures within ±10% in multiple experiments, guest/host stoichiometry for extractions was assumed as 1:1. 
 
                                                 




The ability of cyclic peptoids to extract cations from bulk water to an organic phase prompted us to 
verify their transport properties across a phospholipid membrane.  
The two processes were clearly correlated although the latter is more complex implying, after 
complexation and diffusion across the membrane, a decomplexation step.
42-43 
In the presence of NaCl as 
added salt, only compound 32 showed ionophoric activity while the other cyclopeptoids are almost 
inactive. Cyclic peptoids have different cation binding preferences and, consequently, they may exert 
selective cation transport. These results are the first indication that cyclic peptoids can represent new 
motifs on which to base artificial ionophoric antibiotics. 
 
1.4.5 Catalytic Peptoids 
An interesting example of the imaginative use of reactive heterocycles in the peptoid field, can be 
found in the ―foldamers‖ mimics. ―Foldamers‖ mimics are synthetic oligomers displaying 
conformational ordering. Peptoids have never been explored as platform for asymmetric catalysis. 
Kirshenbaum
 
reported the synthesis of a library of helical ―peptoid‖ oligomers enabling the oxidative 






Figure 1.14. Oxidative kinetic resolution of enantiomeric phenylethanols 35 and 36. 
 
The TEMPO residue was covalently integrated in properly designed chiral peptoid backbones, which 
were used as asymmetric components in the oxidative resolution.  
The study demonstrated that the enantioselectivity of the catalytic peptoids (built using the chiral (S)- 
and (R)-phenylethyl amines) depended on three factors: 1) the handedness of the asymmetric 
environment derived from the helical scaffold, 2) the position of the catalytic centre along the peptoid 
backbone, and 3) the degree of conformational ordering of the peptoid scaffold. The highest activity in 
the OKR (e.e. > 99%) was observed for the catalytic peptoids with the TEMPO group linked at the N-
terminus, as evidenced in the peptoid backbones 39 (39 is also mentioned in figure 1.14) and 40 
(reported in figure 1.15). These results revealed that the selectivity of the OKR was governed by the 
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Figure 1.15. Catalytic biomimetic oligomers 39 and 40 
 
1.4.6 PNA and Peptoids Tagged With Nucleobases. 
Nature has selected nucleic acids for storage (DNA primarily) and transfer of genetic information 
(RNA) in living cells, whereas proteins fulfill the role of carrying out the instructions stored in the genes 
in the form of enzymes in metabolism and structural scaffolds of the cells. However, no examples of 
protein as carriers of genetic information have yet been identified.  
Self-recognition by nucleic acids is a fundamental process of life. Although, in nature, proteins are 
not carriers of genetic information, pseudo peptides bearing nucleobases, denominate ―peptide nucleic 
acids‖ (PNA, 41, figure 1.16),
4
 can mimic the biological functions of DNA and RNA (42 and 43, figure 
1.16). 
 
Figure 1.16. Chemical structure of PNA (19), DNA (20), RNA (21).  B = nucleobase 
 
The development of the aminoethylglycine polyamide (peptide) backbone oligomer with pendant 
nucleobases linked to the glycine nitrogen via an acetyl bridge now often referred to PNA, was inspired 
by triple helix targeting of duplex DNA in an effort to combine the recognition power of nucleobases 
with the versatility and chemical flexibility of peptide chemistry
4
. PNAs were extremely good structural 
mimics of nucleic acids with a range of interesting properties: 
 DNA recognition, 




1. RNA targeting 
2. DNA targeting 
3. Protein targeting 
4. Cellular delivery 
5. Pharmacology 
 Nucleic acid detection and analysis, 
 Nanotechnology, 
 Pre-RNA world. 
The very simple PNA platform has inspired many chemists to explore analogs and derivatives in 
order to understand and/or improve the properties of this class DNA mimics. As the PNA backbone is 
more flexible (has more degrees of freedom) than the phosphodiester ribose backbone, one could hope 
that adequate restriction of flexibility would yield higher affinity PNA derivates. 
The success of PNAs made it clear that oligonucleotide analogues could be obtained with drastic 
changes from the natural model, provided that some important structural features were preserved.  
The PNA scaffold has served as a model for the design of new compounds able to perform DNA 
recognition. One important aspect of this type of research is that the design of new molecules and the 
study of their performances are strictly interconnected, inducing organic chemists to collaborate with 
biologists, physicians and biophysicists. 
An interesting property of PNAs, which is useful in biological applications, is their stability to both 
nucleases and peptidases, since the ―unnatural‖ skeleton prevents recognition by natural enzymes, 
making them more persistent in biological fluids.
45
 The PNA backbone, which is composed by repeating 
N-(2 aminoethyl)glycine units, is constituted by six atoms for each repeating unit and by a two atom 
spacer between the backbone and the nucleobase, similarly to the natural DNA. However, the PNA 
skeleton is neutral, allowing the binding to complementary polyanionic DNA to occur without repulsive 
electrostatic interactions, which are present in the DNA:DNA duplex. As a result, the thermal stability 
of the PNA:DNA duplexes (measured by their melting temperature) is higher than that of the natural 
DNA:DNA double helix of the same length. 
In DNA:DNA duplexes the two strands are always in an antiparallel orientation (with the 5‘-end of 
one strand opposed to the 3‘- end of the other), while PNA:DNA adducts can be formed in two different 
orientations, arbitrarily termed parallel and antiparallel (figure 1.17), both adducts being formed at room 
temperature, with the antiparallel orientation showing higher stability.  
 
Figure 1.17. Parallel and antiparallel orientation of the PNA:DNA duplexes 
 
PNA can generate triplexes PAN-DNA-PNA, the base pairing in triplexes occurs via Watson-Crick 
and Hoogsteen hydrogen bonds (figure 1.18).  
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Figure 1.18. Hydrogen bonding in triplex PNA2/DNA: C+GC (a) and TAT (b) 
 
 
In the case of triplex formation, the stability of these type of structures is very high: if the target 
sequence is present in a long dsDNA tract, the PNA can displace the opposite strand by opening the 
double helix in order to form a triplex with the other, thus inducing the formation of a structure defined 




Figure 1.19. Mechanism of strand invasion of double stranded DNA by triplex formation 
 








Many modifications of the basic PNA structure have been proposed in order to improve their 
performances in term of affinity and specificity towards complementary oligonucleotide sequences. A 
modification introduced in the PNA structure can improve its properties generally in three different 
ways:  
i) Improving DNA binding affinity;  
ii) Improving sequence specificity, in particular for directional preference (antiparallel vs parallel) 
and mismatch recognition;  
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iii) Improving bioavailability, (cell internalization, pharmacokinetics, etc.). 
Structure activity relationships showed that the original design containing a 6-atom repeating unit 
and a 2-atom spacer between backbone and the nucleobase was optimal for DNA recognition. 
Introduction of different functional groups with different charges/polarity/flexibility have been 




These studies showed that a ―constrained 
flexibility‖ was necessary to have good DNA binding (figure 1.20). 
 
 









of the amide carbonyl groups away from the nucleobase (towards thebackbone) and their replacement 
with methylenes, resulted in a nucleosidated peptoid skeleton (44, figure 1.21). Theoretical calculations 
showed that the modification of the backbone had the effect of abolishing the ―strong hydrogen bond 
between the side chain carbonyl oxygen (α to the methylene carrying the base) and the backbone amide 
of the next residue‖, which was supposed to be present on the PNA and considered essential for the 
DNA hybridization. 
 
Figure 1.21. Peptoid nucleic acid 
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Another interesting report, demonstrating that the peptoid backbone is compatible with 




This finding was part of an exploratory 
work on the pairing properties of triazine heterocycles (as recognition elements) linked to peptide and 
peptoid oligomeric systems. In particular, when the backbone of the oligomers was constituted by 
condensation of iminodiacetic acid (45 and 46, Figure 1.22), the hybridization experiments, conducted 
with oligomer 45 and d(T)
12
, showed a T
m 
= 22.7 °C. 
 
Figure 1.22. Triazine-tagged oligomeric sequences derived from an iminodiacetic acid peptoid backbone. 
 
This interesting result, apart from the implications in the field of prebiotic chemistry, suggested the 
preparation of a similar peptoid oligomers (made by iminodiacetic acid) incorporating the classic 





Figure 1.23. Thymine-tagged oligomeric sequences derived from an iminodiacetic acid backbone 
 
The peptoid oligomers 47 and 48 showed thymine residues separated by the backbone by the same 
number of bonds found in nucleic acids (figure 1.24, bolded black bonds). In addition, the spacing 
between the recognition units on the peptoid framework was similar to that present in the DNA (bolded 
grey bonds). 
 
Figure 1.24. Backbone thymines positioning in the peptoid oligomer (47) and in the A-type DNA.  
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However, annealing experiments demonstrated that peptoid oligomers 47 and 48 do not hybridize 
complementary strands of d(A)
16 
or poly-r(A). It was claimed that possible explanations for those results 
resided in the conformational restrictions imposed by the charged oligoglycine backbone and in the high 
conformational freedom of the nucleobases (separated by two methylenes from the backbone).  
Small backbone variations may also have large and unpredictable effects on the nucleosidated 























Figure 1.25. Modification on the N

- in an unaltered PNA backbone 
 
Modification on the γ-nitrogen preserves the achiral nature of PNA and therefore causes no 
stereochemistry complications synthetically. 
Introducing such a side chain may also bring about some of the beneficial effects observed of a 
similar side chain extended from the R- or γ-C. In addition, the functional headgroup could also serve as 
a suitable anchor point to attach various structural moieties of biophysical and biochemical interest.  
Furthermore, given the ease in choosing the length of the peptoid side chain and the nature of the 
functional headgroup, the electrosteric effects of such a side chain can be examined systematically. 
Interestingly, they found that the length of the peptoid-like side chain plays a critical role in determining 
the hybridization affinity of the modified PNA.  In the Liu systematic study, it was found that short 
polar side chains (protruding from the γ-nitrogen of peptoid-based PNAs) negatively influence the 
hybridization properties of modified PNAs, while longer polar side chains positively modulate the 
nucleic acids binding. The reported data did not clarify the reason of this effect, but it was speculated 
that factors different from electrostatic interaction are at play in the hybridization. 
 
1.5 Peptoid synthesis 
The relative ease of peptoid synthesis has enabled their study for a broad range of applications. 
Peptoids are routinely synthesized on linker-derivatized solid supports using the monomeric or 
submonomer synthesis method. Monomeric method was developed by Merrifield
2
 and its synthetic 
procedures commonly used for peptides, mainly are based on solid phase methodologies (e.g. scheme 
1.1).  
The most common strategies used in peptide synthesis involve the Boc and the Fmoc protecting 
groups.  
                                                 





















Scheme 1.1. monomer synthesis of peptoids 
 
Peptoids can be constructed by coupling N-substituted glycines using standard α-peptide synthesis 
methods, but this requires the synthesis of individual monomers
4
, this is based by a two-step monomer 
addition cycle. First, a protected monomer unit is coupled to a terminus of the resin-bound growing 
chain, and then the protecting group is removed to regenerate the active terminus. Each side chain 
requires a separate N
α
-protected monomer.    
Peptoid oligomers can be thought of as condensation homopolymers of N-substituted glycine. There 
are several advantages to this method, but the extensive synthetic effort required to prepare a suitable set 
of chemically diverse monomers is a significant disadvantage of this approach. Additionally, the 
secondary N-terminal amine in peptoid oligomers is more sterically hindered than primary amine of an 
amino acid, for this reason coupling reactions are slower. 



















Scheme 1.2. Sub-monomeric synthesis of peptoids 
 
Sub-monomeric method consists in the construction of peptoid monomer from C- to N-terminus 
using N,N-diisopropylcarbodiimide (DIC)-mediated acylation with bromoacetic acid, followed by 
amination with a primary amine. This two-step sequence is repeated iteratively to obtain the desired 
oligomer. Thereafter, the oligomer is cleaved using trifluoroacetic acid (TFA) or by 
hexafluorisopropanol, scheme 1.2. Interestingly no protecting groups are necessary for this procedure. 
The availability of a wide variety of primary amines facilitates the preparation of chemically and 
structurally divergent peptoids.  
1.6  Synthesis of PNA monomers and oligomers 
The first step for the synthesis of PNA, is the building of PNA‘s monomer. The monomeric unit is 
constituted by an N-(2-aminoethyl)glycine protected at the terminal amino group, which is essentially a 
pseudopeptide with a reduced amide bond. The monomeric unit can be synthesized following several 
methods and synthetic routes, but the key steps is the coupling of a modified nucleobase with the 
secondary amino group of the backbone by using standard peptide coupling reagents (N,N'-
dicyclohexylcarbodiimide, DCC, in the presence of 1-hydroxybenzotriazole, HOBt). Temporary 
masking the carboxylic group as alkyl or allyl ester is also necessary during the coupling reactions. The 
                                                 




protected monomer is then selectively deprotected at the carboxyl group to produce the monomer ready 
for oligomerization. The choice of the protecting groups on the amino group and on the nucleobases 
depends on the strategy used for the oligomers synthesis. The similarity of the PNA monomers with the 
amino acids allows the synthesis of the PNA oligomer with the same synthetic procedures commonly 
used for peptides, mainly based on solid phase methodologies. The most common strategies used in 
peptide synthesis involve the Boc and the Fmoc protecting groups. Some ―tactics‖, on the other hand, 
are necessary in order to circumvent particularly difficult steps during the synthesis (i.e. difficult 
sequences, side reactions, epimerization, etc.). In scheme 1.3, a general scheme for the synthesis of PNA 






























































PGs: Semi-permanent protecting group
PGt: Temporary protecting group  
Scheme 1.3. Typical scheme for solid phase PNA synthesis. 
 
The elongation takes place by deprotecting the N-terminus of the anchored monomer and by 
coupling the following N-protected monomer. Coupling reactions are carried out with HBTU or, better, 
its 7-aza analogue HATU
57
 which gives rise to yields above 99%. Exocyclic amino groups present on 
cytosine, adenine and guanine may interfere with the synthesis and therefore need to be protected with 
semi-permanent groups orthogonal to the main N-terminal protecting group. 
In the Boc strategy the amino groups on nucleobases are protected as benzyloxycarbonyl derivatives 
(Cbz) and actually this protecting group combination is often referred to as the Boc/Cbz strategy. The 
Boc group is deprotected with trifluoroacetic acid (TFA) and the final cleavage of PNA from the resin, 
with simultaneous deprotection of exocyclic amino groups in the nucleobases, is carried out with HF or 
with a mixture of trifluoroacetic and trifluoromethanesulphonic acids (TFA/TFMSA). In the Fmoc 
strategy, the Fmoc protecting group is cleaved under mild basic conditions with piperidine, and is 
                                                 




therefore compatible with resin linkers, such as MBHA-Rink amide or chlorotrityl groups, which can be 
cleaved under less acidic conditions (TFA) or hexafluoisopropanol. Commercial available Fmoc 
monomers are currently protected on nucleobases with the benzhydryloxycarbonyl (Bhoc) groups, also 
easily removed by TFA. Both strategies, with the right set of protecting group and the proper cleavage 
condition, allow an optimal synthesis of different type of classic PNA or modified PNA. 
1.7 Aims of the work 
The objective of this research, is to gain new insights in the use of peptoids as tools for structural 
studies and biological applications. Five are the themes developed in the present thesis: 
 
1. Carboxyalkyl Peptoid PNAs. Nγ-carboxyalkyl modified peptide nucleic acids (PNAs), 
containing the four canonical nucleobases, were prepared via solid-phase oligomerization. The inserted 
modified peptoid monomers (figures 1.26: 50 and 51) were constructed through simple synthetic 







Figure 1.26. Modified peptoid monomers 
 
Synthesis of PNA oligomers  was realized by inserting modified peptoid monomers into a canonical 










Figure 1.27. Modified PNA. 
 
Thermal denaturation studies performed, in collaboration with Prof. R. Corradini from the University 
of Parma, with complementary antiparallel DNA strands, demonstrated that the length of the N
γ
-side 
chain strongly influences the modified PNAs hybridization properties. Moreover, multiple negative 
GTAGAT*50CACT–Gly–NH2,           52 
G T*50AGAT*50CAC T*50–Gly–NH2,  53 
GTAGAT*51CACT–Gly–NH2,           54 
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charges on the oligoamide backbone, when present on γ-nitrogen C6 side chains, proved to be beneficial 
for the oligomers water solubility and DNA hybridization specificity. 
 
2. Structural analysis of cyclopeptoids and their complexes. The aim of this work was the 
studies of structural properties of cyclopeptoids in their free and complexed form (figure 1.27: 56, 57 












































Figure 1.27. N-Benzyl-cyclohexapeptoid 56, N-benzyl-cyclotetrapeptoid 57 and N-metoxyethyl-
cyclohexapeptoid 58.  
 
The synthesis of hexa- and tetra- N-benzyl glycine linear oligomers and of hexa- N-metoxyethyl 
glycine linear oligomer (59, 60 and 61, figure 1.28), was accomplished on solid-phase (2-chlorotrityl 
















Figure 1.28. linear N-Benzyl-hexapeptoid 59, linear N-benzyl tetrapeptoid 60 and linear N-
metoxyethyl-hexapeptoid 61. 
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All cycles obtained were crystallized and caractherizated by X-ray analysis in collaboration with 
Dott. Consiglia Tedesco from the University of Salerno and Dott. Loredana Erra from European 
Synchrotron Radiation Facility (ESRF), Grenoble, France. 
 
3. Cationic cyclopeptoids as potential macrocyclic nonviral vectors. 
The aim of this work was the synthesis of three different cationic cyclopeptoids (figure 1.28: 62, 63 
and 64) to assess their efficiency in DNA cell transfection, in collaboration with Prof. G. Donofrio of 
























































    
Figure 1.29. Di-cationic cyclohexapeptoid 62, Tetra-cationic cyclohexapeptoid 63, Hexa-cationic 
cyclohexapeptoid 64. 
 
4. Complexation with Gd3+ of carboxyethyl cyclopeptoids as possible contrast agents in 
MRI. Three cyclopeptoids 65, 66 and 67 (figure 1.30) containing polar side chains, were synthesized 
and, in collaboration with Prof. S. Aime, of the University of Torino, the complexation properties with 
Gd
3+












































































Figure 1.29. Hexacarboxyethyl cyclohexapeptiod 65, Tricarboxyethyl ciclohexapeprtoid 66 and 
tetracarboxyethyl cyclopeptoids 67. 
 
5. Cyclopeptoids as mimetic of natural defensins59. In this work some linear and 
cyclopeptoids with specific side chains (-SH groups) were synthetized. The aim was to introduce, by 
means of sulfur bridges, peptoid backbone constrictions and to mimic natural defensins (figure 1.30, 
block I: 68 hexa-linear and related cycles 69 and 70; block II: 71 octa-linear and related cycles 72 and 
73; block III: 74 dodeca-linear and related cycles 75, 76 and  77; block IV: 78 dodeca-linear diprolinate 

















































Figure 1.30, block I. Structures of the hexameric linear (68) and corresponding cyclic 69 and 70. 
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Lehrer The Journal of Immunology, 2010, 515-520; b) D. Yang, A. Biragyn, D. M. Hoover, J. 













































































































































































































































































Figure 1.30, block IV. Structures of dodecameric linear diprolinate (78) and corresponding cyclic 













2. Carboxyalkyl Peptoid PNAs: Synthesis and Hybridization Properties. 
2.1 Introduction 
The considerable biological stability, the excellent nucleic acids binding properties, and the 
appreciable chemical simplicity, make PNA an invaluable tool in molecular biology.
60
 Unfortunately, 
despite the remarkable properties, PNA has two serious limitations: low water solubility
61




Considerable efforts have been made to circumvent these drawbacks, and a conspicuous number of 
new analogs have been proposed
63
, including those with the γ-nitrogen modified N-(2-aminoethyl)-
glycine (aeg) units
64
. In a contribution by the Nielsen group,
65
 an accurate investigation on the N
γ
-
methylated PNA hybridization properties was reported. In this study it was found that the formation of 
PNA-DNA (or RNA) duplexes was not altered in case of a 30% N
γ
-methyl nucleobase substitution. 
However, the hybridization efficiency per N-methyl unit in a PNA, decreased with the increasing of the 
N-methyl content. 
The negative impact of the γ-N alteration reported by Nielsen, did not discouraged further 
investigations. The potentially informational triazine-tagged oligoglycines systems,
66
 the oligomeric 
thymine-functionalized peptoids,
5d




 constitute convincing 
example of γ-nitrogen beneficial modification. In particular, the Liu group contribution,
5a
 revealed an 
unexpected electrosteric effect played by the N
γ
-side chain length. In their stringent analysis it was 
demonstrated that while short ω-amino N
γ
-side chains negatively influenced the modified PNAs 
hybridisation properties, longer ω-amino N
γ
-side chains positively modulated nucleic acids binding. It 
was also found that suppression of the positive ω-aminoalkyl charge (i.e. through acetylation) caused no 
reduction in the hybridization affinity, suggesting that factors different from mere electrostatic 
stabilizing interactions were at play in the hybrid aminopeptoid-PNA/DNA (RNA) duplexes
67
.  
Considering the interesting results achieved in the case of N-(2-alkylaminoethyl)-glycine units
5,6
, and 
on the basis of poor hybridization properties showed by two fully peptoidic homopyrimidine oligomers 
synthesized by our group,
5b
 it was decided to explore the effects of anionic residues at the γ-nitrogen in 
a PNA framework on the in vitro hybridization properties.  
                                                 
60 (a) Nielsen, P. E. Mol. Biotechnol. 2004, 26, 233-248; (b) Brandt, O.; Hoheisel, J. D. Trends Biotechnol. 2004, 
22, 617-622; (c) Ray, A.; Nordén, B. FASEB J. 2000, 14, 1041-1060. 
61 Vernille, J. P.; Kovell, L. C.; Schneider, J. W. Bioconjugate Chem. 2004, 15, 1314-1321. 
62 (a) Koppelhus, U.; Nielsen, P. E. Adv. Drug. Delivery Rev. 2003, 55, 267-280; (b) Wittung, P.; Kajanus, J.; 
Edwards, K.; Nielsen, P. E.; Nordén, B.; Malmstrom, B. G. FEBS Lett. 1995, 365, 27-29. 
63 (a) De Koning, M. C.; Petersen, L.; Weterings, J. J.; Overhand, M.; van der Marel, G. A.; Filippov, D. V. 
Tetrahedron 2006, 62, 3248–3258; (b) Murata, A.; Wada, T. Bioorg. Med. Chem. Lett. 2006, 16, 2933–2936; (c) 
Ma, L.-J.; Zhang, G.-L.; Chen, S.-Y.; Wu, B.; You J.-S.; Xia, C.-Q. J. Pept. Sci. 2005, 11, 812–817. 
64 (a) Lu, X.-W.; Zeng, Y.; Liu, C.-F. Org. Lett. 2009, 11, 2329-2332; (b) Zarra, R. ; Montesarchio, D.; Coppola, 
C.; Bifulco, G.; Di Micco, S.; Izzo, I.; De Riccardis, F. Eur. J. Org. Chem. 2009, 6113-6120; (c) Wu, Y.; Xu, J.-C.; 
Liu, J.; Jin, Y.-X. Tetrahedron 2001, 57, 3373-3381; (d) Y. Wu, J.-C. Xu. Chin. Chem. Lett. 2000, 11, 771-774. 
65 Haaima, G.; Rasmussen, H.; Schmidt, G.; Jensen, D. K.; Sandholm Kastrup, J.; Wittung Stafshede, P.; Nordén, B.; 
Buchardt, O.; Nielsen, P. E. New. J. Chem. 1999, 23, 833-840. 
66 Mittapalli, G. K.; Kondireddi, R. R.; Xiong, H.; Munoz, O.; Han, B.; De Riccardis, F.; Krishnamurthy, R.; 
Eschenmoser, A. Angew. Chem. Int. Ed. 2007, 46, 2470-2477. 
67 The authors suggested that longer side chains could stabilize amide Z configuration, which is known to have a 




The N-(carboxymethyl) and the N-(carboxypentamethylene) N
γ
-residues, present in the monomers 50 
and 51 (figure 2.1) were chosen in order to evaluate possible side chains length-dependent thermal 
denaturations effects, and with the aim to respond to the pressing water-solubility issue, which is crucial 





Figure 2.1.  Modified peptoid PNA monomers 
 
The synthesis of a negative charged N-(2-carboxyalkylaminoethyl)-glycine backbone (negative 
charged PNA are rarely found in literature)
69
 was based on the idea to take advantage of the availability 
of a multitude of efficient methods for the gene cellular delivery based on the interaction of carriers with 
negatively charged groups. Most of the nonviral gene delivery systems are, in fact, based on cationic 
lipids
70
 or cationic polymers
71
 interacting with negative charged genetic vectors. Furthermore, the 
neutral backbone of PNA prevents them to be recognized by proteins which interact with DNA, and 
PNA-DNA chimeras should be synthesized for applications such as transcription factors scavenging 
(decoy)
72
 or activation of RNA degradation by RNase-H (as in antisense drugs).  
This lack of recognition is partly due to the lack of negatively charged groups and of the 




In the present work we report the synthesis of the bis-protected thyminylated N
γ
-ω-carboxyalkyl 
monomers 50 and 51 (figure 2.1), the solid-phase oligomerization and the base-pairing behaviour of 
four oligomeric peptoid sequences 52-55 (figure 2.2) incorporating, in various extent and in different 
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n 32, n  = 1














Figure 2.2. Structures of target oligomers 52-55. T* represents the modified thyminylated N
γ
-ω-
carboxyalkyl monomers. T*50 incorporates monomer 50, T*51 incorporates monomer 51. 
 
The carboxy termini of the modified mixed purine/pyrimidine decamer PNA sequences were linked 
to a glycinamide unit. T*1 and T*2 represent the insertion of the modified 50 and 51 N
γ
-ω-carboxyalkyl 
monomer units, respectively. 
The mixed-base sequence has been chosen since it has been proposed by Nielsen and coworkers and 
subsequently used by several groups as a benchmark for the evaluation of the effect of modification of 
the PNA structure on PNA:DNA thermal stability
74
. 
2.2. Results and discussion 
2.2.1 Chemistry 
 The elaboration of monomers 50 and 51 (figure 2.1), suitable for the Fmoc-based oligomerization, 
took advantage of the chemistry utilized to construct the regular PNA monomers. In particular, the 
synthesis of the N-protected monomer 50 started with the t-Bu-glycine (82) glycidol amination
5
, as 
shown in scheme 2.1. N-fluorenylmethoxycarbonyl protection of the adduct 85, and subsequent diol 
oxidative cleavage, gave the labile aldehyde 86. Compound 86 was subjected to reductive amination in 
the presence of methylglycine to obtain the triply protected bis-carboxyalkyl ethylenediamine key 
intermediate 87.  
The 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU),  
promoted condensation of 87 with thymine-1-acetic acid gave the expected tertiary amide 88.  
Careful LiOH-mediated hydrolysis allowed to preserve the base-labile Fmoc group, affording the 
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GTAGAT*50CACT–Gly–NH2,           52 
G T*50AGAT*50CAC T*50–Gly–NH2,  53 
GTAGAT*51CACT–Gly–NH2,           54 





Scheme 2.1. Synthesis of the PNA monomer 50. Reagents and conditions: a) glycidol, DMF, 
DIPEA, 70°C, 3 days, 41%; b) fluorenylmethoxycarbonyl chloride (Fmoc-Cl), NaHCO3, 1,4-
dioxane/H2O, overnight, 63%; c) NaIO4, THF/H2O, 2h, 97%; d) H2NCH2COOCH3, NaHB(AcO)3, 
triethylamine in CH2Cl2, overnight, 70%;  e) thymine-1-acetic acid, Et3N, HATU in DMF, overnight, 
49%; f) LiOH
.
H2O, 1,4-dioxane /H2O, 0°C, 30 min., 69%. 
 
The synthesis of compound 51 required a different strategy, due to the low yields obtained in the 
glycidol opening induced by the t-butyl ester of the 6-aminocaproic acid (89, see the experimental 
section). A better electrophile was devised in the benzyl 2-iodoethylcarbamate (65,
75
 Scheme 2.2). The 
nucleophilic displacement gave the secondary amine 95, containing the Cbz-protected ethylendiamine 
core. Compound 95, after a straightforward protective group adjustment and a subsequent reductive 
amination, produced the fully protected bis-carboxyalkyl ethylenediamine key intermediate 98. This last 
was reacted with thymine-1-acetic acid and benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate (PyBOP), as condensing agent, and gave the amide 99. Finally, after careful 
chemoselective hydrolysis of the methyl ester, the required monomer 51 was obtained in acceptable 
yields.  
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Scheme 2.2. Synthesis of the PNA monomer 51. Reagents and conditions: a) t-Butanol, DMAP, DCC, CH2Cl2, 
overnight, 58%; b) H2, Pd/C (10 % w/w), acetic acid, methanol, 1h and 30 min., quant.; c) Cbz-Cl, CH2Cl2, 0°C, 
overnight, quant.; d) I2, imidazole, PPh3, CH2Cl2, 3h, 77%; e) K2CO3, CH3CN, reflux, overnight, 67%, f) 
fluorenylmethoxycarbonyl chloride (Fmoc-Cl), NaHCO3, 1,4-dioxane/H2O, overnight, 97%; g) H2, Pd/C (10 % 
w/w), acetic acid, methanol; 1h, quant.; h) ethyl glyoxalate, NaHB(AcO)3, triethylamine in CH2Cl2, overnight, 
25%; i) thymine-1-acetic acid, Et3N, PyBOP in DMF; overnight, 70% l) LiOH, 1,4-dioxane/H2O, 30 min., 30%.  
 
The oligomers 52-55 were manually assembled in a stepwise fashion on a Rink-amide NOVA-PEG 
resin solid support. The unmodified PNA monomers were coupled using 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluoro-phosphate (HBTU). HATU was used for the coupling reactions 
involving the less reactive secondary amino groups of the modified monomers 50 and 51. The decamers 
were detached from the solid support and quantitatively deprotected from the t-butyl protecting groups, 
using a 9:1 mixture of trifluoroacetic acid and m-cresol. The water-soluble oligomers were purified by 
RP-HPLC, yielding the desired 52-55 as pure compounds. Their identity was confirmed by MALDI-
TOF mass spectrometry. 
 
2.2.2  Hybridization studies  
In order to verify the ability of decamers 49-52 to bind complementary DNA, UV-monitored melting 






























95, R = H, R' = Cbz






































deoxyribonucleic strands (5 μM concentration, ε= 260 nm). Table 2.1 presents the thermal stability 
studies of the duplexes formed between the modified PNAs and the DNA anti-parallel strand, in 
comparison with the unmodified PNA.   
The data obtained clearly demonstrated that the distance of the negative charged carboxy group from 
the oligoamide backbone strongly affects the PNA:DNA duplex stability. In particular, when the γ-
nitrogen brings an acetic acid substituent (with a single methylene distancing the oligoamide backbone 
and the charged group, entry 2), a drop of 5.4 °C in Tm of the carboxypeptoid-PNA/DNA(ap) duplex is 
observed, when compared with unmodified PNA (entry 1). Triple insertion of monomer 50 (entry 3), 
results in a decrease of 2.6 °C per N-acetyl unit, showing no N
γ
-substitution detrimental additive effects 
on the annealing properties. In both cases the ability to discriminate closely related sequences is 
magnified, respect to the unmodified PNA.           
 
         Table 2.1. Thermal stabilities (Tm, °C) of modified PNA/DNA duplexes 












2 GTAGAT*50CACT–Gly–NH2, (52) 43.2 33.5 
3 GT*50AGAT*50CACT*50–Gly–NH2, (53) 40.7 34.4 
4 GTAGAT*51CACT–Gly–NH2, (54) 44.8 30.8 











For the binding of the N
γ
-caproic acid derivatives with the full-matched antiparallel DNA, the table 
shows an evident increase of the affinity (entry 4 and 5), when compared with the modified sequences 
with shorter side chains (entry 2 and 3). Comparison with the corresponding aegPNA showed, for the 
single insertion, a 3.8 °C Tm drop, while, for triple substitution, a Tm decrease of 1.5 °C per N
γ
-alkylated 
monomer. It is also worth noting, in both 54 and 55, the slight increase of the binding specificity (ΔTm = 
5.6 °C and 0.8 °C, entry 4 and 5) respect to unmodified PNA.        
In previous studies, reporting the performances of backbone modified PNA containing negatively 
charged monomers derived from amino acids, the drop in melting temperature was found to be 3.3 °C in 
the case of L-Asp monomer and 2.3° C in the case of D-Glu. The present results are in line with these 
data, with a decrease in melting temperatures which still allows stronger binding than natural DNA 
(entry 6). Thus it is possible to introduce negatively charged groups via alkylation of the amide nitrogen 
in the PNA backbone without significant loss of stability of the PNA-DNA duplex, provided that a five 





In this work, we have constructed two orthogonally protected N

--carboxy alkylated units. The 
successful insertion in PNA-based decamers, through standard solid-phase synthesis protocols, and the 
following hybridization studies, in the presence of DNA antiparallel strand, demonstrate that the N

-
substitution with negative charged groups is compatible with the formation of a stable PNA:DNA 
duplex. The present study also extends the observation that correlates the efficacy of the nucleic acids 




 expanding the validity also to N

--negative 
charged side chains. The newly produced structures can create new possibilities for PNA with 
functional groups enabling further improvement in their ability to perform  gene-regulation.  
 
2.4 Experimental section 
2.4.1 General Methods. 
All reactions involving air or moisture sensitive reagents were carried out under a dry argon or 
nitrogen atmosphere using freshly distilled solvents. Tetrahydrofuran (THF) was distilled from LiAlH4 
under argon. Toluene and CH2Cl2 were distilled from CaH2. Glassware was flame-dried (0.05 Torr) 
prior to use. When necessary, compounds were dried in vacuo over P2O5 or by azeotropic removal of 
water with toluene under reduced pressure. Starting materials and reagents purchased from commercial 
suppliers were generally used without purification unless otherwise mentioned. Reaction temperatures 
were measured externally; reactions were monitored by TLC on Merck silica gel plates (0.25 mm) and 
visualized by UV light, I2, or by spraying with H2SO4-Ce(SO4)2, phosphomolybdic acid or ninhydrin 
solutions and drying. Flash chromatography was performed on Merck silica gel 60 (particle size: 0.040-





C-NMR) pure materials. The NMR spectra were recorded on Bruker DRX 
400, (
1
H at 400.13 MHz, 
13
C at 100.03 MHz), Bruker DRX 250 (
1
H at 250.13 MHz, 
13
C at 62.89 MHz), 
and Bruker DRX 300 (
1
H at 300.10 MHz, 
13
C at 75.50 MHz) spectrometers. Chemical shifts () are 
reported in ppm relatively to the residual solvent peak (CHCl3,  = 7.26, 
13
CDCl3, : = 77.0; CD2HOD, 
 = 3.34, 
13
CD3OD,  = 49.0) and the multiplicity of each signal is designated by the following 
abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintuplet; m, multiplet; br, broad. 
Coupling costants (J) are quoted in Hz. Homonuclear decoupling, COSY-45 and DEPT experiments 
completed the full assignment of each signal. Elemental analyses were performed on a CHNS-O 
FlashEA apparatus (Thermo Electron Corporation) and are reported in percent abundance. High 
resolution ESI-MS spectra were performed on a Q-Star Applied Biosystem mass spectrometer. ESI-MS 
analysis in positive ion mode was performed using a Finnigan LCQ Deca ion trap mass spectrometer 
(ThermoFinnigan, San Josè, CA, USA) and the mass spectra were acquired and processed using the 
Xcalibur software provided by Thermo Finnigan. Samples were dissolved in 1:1 CH3OH/H2O, 0.1 % 
formic acid, and infused in the ESI source by using a syringe pump; the flow rate was 5 μl/min. The 
capillary voltage was set at 4.0 V, the spray voltage at 5 kV, and the tube lens offset at -40 V. The 
capillary temperature was 220 °C. MALDI TOF mass spectrometric analyses were performed on a 
PerSeptive Biosystems Voyager-De Pro MALDI mass spectrometer in the Linear mode using -cyano-
4-hydroxycinnamic acid as the matrix. HPLC analyses were performed on a Jasco BS 997-01 series, 




resulting residues were purified by semipreparative reverse-phase C18 (Waters, Bondapak, 10 μm, 
125Å, 7.8 × 300 mm).  
2.4.2 Chemistry  
 Tert-butyl 2-(2,3-dihydroxypropylamino)acetate (55). 
To a solution of glycidol (83, 436 μL, 6.56 mmol) in DMF (5 mL), glycine t-butyl ester (82, 1.00 g, 
5.96 mmol) in DMF (10 mL), and DIPEA (1600 μL, 8.94 mmol) were added. The reaction mixture was 
refluxed for three days. NaHCO3 (0.50 g, 5.96 mmol) was added and the solvent was concentrated in 
vacuo to give the crude product, which was purified by flash chromatography (CH2Cl2/CH3OH/NH3 2.0 
M solution in ethyl alcohol, from: 100/0/0.1 to 88/12/0.1) to give 84 (0.50 g, 41%) as a yellow pale oil; 
[Found: C, 52.7; H, 9.4. C9H19NO4 requires C, 52.67; H, 9.33%]; Rf (97/3/0.1, CH2Cl2/CH3OH/NH3 
2.0M solution in ethyl alcohol) 0.36; H (400.13 MHz CDC13) 1.42 (9H, s, (CH3)3C), 2.62 (1H, dd, J 
12.0, 7.7 Hz, CHHCH(OH)CH2OH), 2.71 (1H, dd, J 12.0, 2.9 Hz, CHHCH(OH)CH2OH), 3.28 (2H, br 
s, CH2COOt-Bu), 3.51 (1H, dd, J 11.0, 5.4 Hz,  CH2CH(OH)CHHOH), 3.62 (1H, dd, J 11.0, 1.2 Hz, 
CH2CH(OH)CHHOH), 3.72 (1H, m, CH2CH(OH)CH2OH);
  
C (100.03 MHz, CDCl3) 29.2, 52.6, 53.1, 








  (9H-fluoren-9-yl) methyl (tert-butoxycarbonyl) methyl 2,3dihydroxypropylcarbamate (85): 
To a solution of 84 (0.681 g, 3.33 mmol) in a 1:1 mixture of 1,4-dioxane/water (46 mL), NaHCO3 
(0.559 g, 6.66 mmol) was added. The mixture was sonicated until complete dissolution and, Fmoc-Cl 
(1.03 g, 3.99 mmol) was added. The reaction mixture was stirred overnight, then, through addition of a  
saturated solution of NaHSO4, the pH was adjusted to 3 and the solvent was concentrated in vacuo to 
remove the excess of 1,4-dioxane. The water layer was extracted with CH2Cl2 (three times), the organic 
phase was dried over MgSO4, filtered and the solvent evaporated in vacuo to give the crude product, 
which was purified by flash chromatography (CH2Cl2/CH3OH, from: 100/0 to 90/10) to give 85 (0.90 g, 
63%) as a yellow pale oil; [Found: C, 67.4; H, 6.9. C24H29NO6 requires C, 67.43; H, 6.84%]; Rf 
(95/5/0.1, CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol) 0.44; H (300.10 MHz CDC13, mixture 
of rotamers) 1.45 (9H, s, (CH3)3C), 3.04-3.25 (1.7 H, m, CH2CH(OH)CH2OH), 3.40 (0.3 H, m, 
CH2CH(OH)CH2OH), 3.43-3.92 (3H, m, CH2CH(OH)CH2OH, CH2CH(OH)CH2OH), 3.93 (2H, br s, 
CH2COOt-Bu), 4.22 (0.9H, m, CH-Fmoc and CH2-Fmoc), 4.42 (1.4H, br d. J  9.0 Hz, CH2-Fmoc), 4.61 
(0.7H, m, J 9.0 Hz, CH-Fmoc), 7.29 (2H,  br t, J 7.0 Hz, Ar. (Fmoc)), 7.38 (2H, br t, J 7.0 Hz, Ar. 
(Fmoc)), 7.57 (2H,  br d, J 9.0 Hz, Ar. (Fmoc)), 7.76 (2H, br d, J 9.0 Hz, Ar. (Fmoc); C (75.50 MHz, 
CDCl3, mixture of rotamers) 28.2, 47.4, 52.1, 52.3, 52.9, 53.2, 63.5, 64.0, 67.3, 68.1, 68.5, 70.1, 70.5, 









 (9H-fluoren-9-yl) methyl (tert-butoxycarbonyl) methylformylmethylcarbamate (86): 
To a solution of 85 (0.80 g, 1.87 mmol) in a 5:1 mixture of THF and water (5 mL), sodium periodate 
(0.44 g, 2.06 mmol) was added in one portion. The mixture was sonicated for 15 min and stirred for 
another 2 hours at room temperature. The reaction mixture was filtered, the filtrate was washed with 
CH2Cl2 and the solvent evaporated in vacuo. The crude product was dissolved in CH2Cl2/H2O, and the 




aldehyde 86 (0.72 g, 97%), as white solid; Rf (92/8 CH2Cl2/CH3OH) 0.56; crude 86 was used 
immediately in the subsequent reductive amination reaction; H (300.10 MHz CDC13, mixture of 
rotamers) 1.43 (4.05H, s, (CH3)3C), 1.45 (4.95H, s, (CH3)3C), 3.81 (0.9H, br s, CH2COO-tBu), 3.99 (2H, 
br s, CH2CHO), and CH2COO-tBu, overlapped), 4.08 (1.1H, s, CH2CHO), 4.22-4.19 (1H, m, CH-
Fmoc), 4.42 (1.1H, d, J 6.0 Hz, CH2-Fmoc), 4.50 (0.9H, d, J 6.0 Hz, CH2-Fmoc), 7.29 (0.9H, br t, J 7.0 
Hz, Ar. (Fmoc)), 7.38 (1.1H, t, J 7.0 Hz, Ar. (Fmoc)), 7.49 (0.9H, d, J 9.0 Hz, Ar. (Fmoc)), 7.56 (1.1H, 
d, J 9.0 Hz, Ar. (Fmoc)), 7.73 (2H, m, Ar. (Fmoc)), 9.35 (0.45H, br s, CHO), 9.64 (0.55H, br s, CHO); 
C (75.50 MHz, CDCl3) 28.2, 47.3, 50.6, 50.8, 57.8, 58.4, 68.1, 68.6, 82.6, 82.7, 120.2, 124.9, 125.2, 







 requires 396.1811. 
 
 (9H-fluoren-9-yl) methyl (tert-butoxycarbonyl) methyl 2-
((methoxycarbonyl)methylamino)ethylcarbamate (87): 
 To a solution of crude aldehyde 86 (0.72 g, 1.83 mmol) in dry CH2Cl2 (12 mL), a solution of glycine 
methyl ester hydrochloride (0.30 g, 2.39 mmol) and Et3N (0.41 mL, 2.93 mmol) was added. The 
reaction mixture was stirred for 1 h. Sodium triacetoxyborohydride (0.78 g, 3.66 mmol) was then added 
and the reaction mixture was stirred overnight at room temperature. The resulting mixture was washed 
with an aqueous saturated solution of NaHCO3 and the aqueous phase extracted with CH2Cl2 (three 
times). The organic phase was dried over MgSO4, filtered and the solvent evaporated in vacuo to give 
the crude product, which was purified by flash chromatography (AcOEt/petroleum ether/NH3 2.0M 
solution in ethyl alcohol, from: 40/60/0.1 to 90/10/0.1) to give 87 (0.60 g, 70%) as a colorless oil; 
[Found: C, 66.7; H, 6.9. C26H32N2O6 requires C, 66.65; H, 6.88%]; Rf (98/2/0.1, CH2Cl2/CH3OH/NH3 
2.0M solution in ethyl alcohol) 0.63; H (400.13 MHz CDC13, mixture of rotamers) 1.45 (9H, s, 
(CH3)3C), 2.56 (0.9H, t, J 6.0 Hz, N(Fmoc)CH2CH2NH), 2.83 (1.1H, t, J 6.0, N(Fmoc)CH2CH2NH), 
3.27 (0.9H, t, J 6.0 Hz, N(Fmoc)CH2CH2NH), 3.29 (0.9H, s, CH2COOMe), 3.44 (1.1H, s, 
CH2COOMe), 3.49 (1.1H, t, J 6.0 Hz, N(Fmoc)CH2CH2NH), 3.72 (3H, s, CH3), 3.91 (0.9H, s, 
CH2COOtBu), 3.96 (1.1H, s, CH2COOtBu), 4.21 (0.45H, t, J 6.0 Hz, CH2CHFmoc), 4.26 (0.55H, t, J 
6.0 Hz, CH2CHFmoc), 4.37 (1.1H, d, J 6.0 Hz, CH2CHFmoc), 4.51 (0.9H, d, J 6.0 Hz, CH2CHFmoc), 
7.29 (2 H, t, J 7.0 Hz, Ar. (Fmoc)), 7.39 (2 H, t, J 7.0 Hz, Ar. (Fmoc)), 7.58 (2 H, m, Ar. (Fmoc)), 7.75 
(2 H, d, J 7.0 Hz, Ar. (Fmoc)); C (100.03 MHz, CDCl3) 27.8, 47.0, 47.2, 47.4, 48.2, 48.6, 50.1, 50.3, 
50.5, 53.3, 67.2, 67.6, 81.5, 81.7, 119.7, 124.7, 124.9, 126.8, 127.5, 141.0, 143.7, 156.0, 156.2, 168.7, 









 Compound 88: 
To a solution of 87 (0.60 g, 1.28 mmol) in DMF (30 mL), thymine-1-acetic acid (0.35 g, 1.90 mmol), 
HATU (0.73 g, 1.90 mmol) and triethylamine (0.54 mL, 3.84 mmol) were added. The reaction mixture 
was stirred overnight, concentrated in vacuo, dissolved in CH2Cl2 (20 mL) and washed 1M HCl 
solution. The aqueous layer was extracted with CH2Cl2 (three times). The combined organic phases 
were dried over MgSO4, filtered and the solvent evaporated in vacuo to give a crude material, which 
was purified by flash chromatography (AcOEt/petroleum ether, from: 30/70 to 100/0) to give 88 (0.40 g, 




AcOEt/petroleum ether) 0.38; H (300.10 MHz CDC13, mixture of rotamers) 1.39-1.44 (9H, m, 
(CH3)3C), 1.88 (3H, br s, CH3-thymine), 2.99 (0.3H, m, CH2CH2N(Fmoc)), 3.08 (0.3H, m, 
CH2CH2N(Fmoc)), 3.52 (2.8H, m, CH2CH2N(Fmoc) and CH2CH2N(Fmoc)), 3.77-3.89 (3.6H, m, 
CH2CH2N(Fmoc) and CH3OOC), 3.96-4.38 (6H m, CH2-thymine, CH2COOCH3, CH2COO-tBu), 4.45-
4.80 (3H, m, CH(Fmoc) and CH2CH(Fmoc)), 6.90-7.06 (1H, complex signal, CH-thymine), 7.28 (2H, 
m, Ar. (Fmoc)), 7.41 (2H, t, J 7.0 Hz, Ar (Fmoc)), 7.55 (2 H, d, J 7.0 Hz, Ar. (Fmoc)), 7.75 (2H, t, J 7.0 
Hz, Ar. (Fmoc)), 8.86 (1H, br s, NH-thymine); C (75.5 MHz, CDCl3) 12.5, 28.2, 31.6, 36.6, 47.2, 47.4, 
47.5, 47.8, 48.2, 49.1, 50.6, 51.8, 52.1, 52.5, 53.0, 66.5, 68.2, 82.3, 82.5, 110.5, 120.2, 124.5, 124.8, 
125.14, 125.3, 127.3, 127.4, 127.5, 128.0, 128.1, 141.3, 141.4, 143.8, 144.0, 151.1, 156.4, 162.7, 164.4, 




, found 634.2767. C34H40N4O9
+
 requires 634.2765. 
 Compound 50:  
To a solution of 88 (0.40 g, 0.63 mmol) in a 1:1 mixture of 1,4-dioxane/water (8 mL) at 0 °C, 
LiOH
.
H2O (58 mg, 1.39 mmol) was added. The reaction mixture was stirred for 30 minutes and a 
saturated solution of NaHSO4 was added until pH~3. The aqueous layer was extracted with CH2Cl2 
(three times) and once with AcOEt. The combined organic phases were dried over MgSO4, filtered and 
the solvent evaporated in vacuo to give a crude material, which was purified by flash chromatography 
(CH2Cl2/CH3OH/ AcOH, from: 95/5/0.1 to 80/20/0.1) to give 50 (0.27 g, 69%) as a white solid; [Found: 
C, 63.0; H, 6.0. C33H37N3O9 requires C, 63.96; H, 6.02%]; Rf (9/1/0.1, CH2Cl2/CH3OH/NH3 2.0M 
solution in ethyl alcohol) 0.12; H (250.13 MHz CDC13, mixture of rotamers) 1.39-1.43 (9H, m, 
(CH3)3C), 1.83 (3H, br s, CH3 (thymine)), 3.03 (0.3H, m, CH2CH2N(Fmoc)), 3.17 (0.3H, m, 
CH2CH2N(Fmoc)), 3.55-3.72 (2.8H, m, CH2CH2N(Fmoc) and CH2CH2N(Fmoc)), 3.95-4.06 (6.6H m, 
CH2CH2N(Fmoc), CH2-thymine, CH2COOH, CH2COO-tBu), 4.14-4.77 (3H, m, CH(Fmoc) and 
CH2CH(Fmoc)), 6.97-7.11 (1H, complex signal, CH-thymine), 7.23-7.40 (4H, m, Ar. (Fmoc)), 7.55 (2 
H, d, J 7.0 Hz, Ar. (Fmoc)), 7.75 (2H, m, Ar. (Fmoc)), 10.00 (1H, br s, NH-thymine); C (75.50 MHz, 
CDCl3) 12.3, 28.2, 29.9, 46.4, 47.3, 48.7, 50.2, 50.9, 53.6, 68.3, 82.3, 82.6, 110.8, 120.2, 124.9, 125.2, 
125.3, 127.3, 127.5, 128.0, 141.4, 142.1, 143.8, 144.0, 151.7, 156.6, 165.0, 165.2, 168.2, 169.0, 169.2, 




, found 620.2611. C33H38N3O9
+
 requires 620.2608. 
 
 Benzyl 5-(tert-butoxycarbonyl)pentylcarbamate (90): 
To a solution of 89, (3.00 g, 11.3 mmol), DMAP (0.14 g, 1.13 mmol) and t-BuOH (1.30 mL, 13.9 
mmol), in dry CH2Cl2 (5.0 mL), a solution of DCC (13.6 mL, 13.6 mmol, 1.0 M in CH2Cl2) was added. 
The reaction mixture was filtered, the filtrate washed with CH2Cl2 and the solvent evaporated in vacuo 
to give the crude product, which was purified by flash chromatography (AcOEt/petroleum ether, from: 
10/90 to 100/0) to give 90 (2.10 g, 58%) as white solid; [Found: C, 67.2; H, 8.4. C14H19NO4 requires C, 
67.26; H, 8.47%]; Rf (97/3 CH2Cl2/CH3OH) 0.84;H (400.13 MHz CDC13) 1.31 (2H, q, J 6.5 Hz, 
CH2CH2CH2COOt-Bu), 1.41 (9H, s, COOC(CH3)3), 1.48 (2H, q, J 6.5 Hz, CH2CH2CH2NH), 1.56 (2H, 
q, J 6.5 Hz, CH2CH2CH2COOt-Bu), 2.18 (2H, t, J 6.5 Hz, CH2CH2CH2COOt-Bu), 3.15 (2H, q, J 6.5 
Hz, CH2CH2CH2NH), 4.91 (1H, br s, NH), 5.07 (2H, br s, CH2Bn), 7.32 (5H, m, Ar.); C (75.50 MHz, 





, found 322.2015. C18H28NO4
+





 Tert-butyl 6-aminohexanoate (91):  
To a solution of 90 (1.95 g, 6.07 mmol) in dry MeOH (150 mL), acetic acid (1.39 mL, 24.0 mmol) 
and palladium on charcoal (10% w/w, 0.19 g) were added. The reaction mixture was stirred under a 
hydrogen atmosphere at room temperature for 1 h and  filtered through celite. The solvent was 
evaporated in vacuo to give crude 91 (1.13 g, 100%, colorless oil) which was used in the next step 
without purification; Rf (95/5, CH2Cl2/CH3OH) 0.46; H (400.13 MHz CDC13) 1.33 (2H, q, J 6.5 Hz, 
CH2CH2CH2COOt-Bu), 1.39 (9H, s, COOC(CH3)3), 1.55 (2H, q, J 6.5 Hz,  CH2CH2CH2CH2CH2NH), 
1.62 (2H, q, J 6.5 Hz, CH2CH2CH2COOt-Bu), 2.17 (2H, t, J 6.5 Hz, CH2CH2CH2COOt-Bu), 2.84 (2H, t, 





, found 188.1647. C10H22NO2
+
 requires 188.1651. 
 Benzyl 2-hydroxyethylcarbamate (93): 
To a solution of ethanolamine (92, 2.00 g, 32.8 mmol) in dry CH2Cl2 (30 mL) at 0°C, a solution Cbz-
Cl (3.73 mL, 26.2 mmol) in dry CH2Cl2 (20 mL) was slowly added. The reaction mixture was stirred for 
2 hours at 0°C and at room temperature overnight. The resulting mixture was washed with an aqueous 
saturated solution of NaHCO3 and the aqueous phase extracted with CH2Cl2. (three times). The organic 
phase was dried over MgSO4, filtered and the solvent evaporated in vacuo to give crude 93 (5.11 g, 
100%, yellow pale oil) which was used in the next step without purification; Rf (92/8, CH2Cl2/CH3OH) 
0.47; H (250.13 MHz CDC13) 3.36 (2H, br t, J 6.5 Hz, CH2OH), 3.71 (2H, q, J 6.5 Hz, CH2NH), 5.11 
(2H, s, CH2Bn), 7.35 (5H, m, Ar.); C (62.89 MHz, CDCl3) 43.3, 61.7, 66.7, 127.9, 128.0, 128.4, 136.2, 




, found 196.0970. C10H14NO3
+
 requires 196.0974.  
 Benzyl 2-iodoethylcarbamate (94): 
To a solution of PPh3 (2.66 g, 10.2 mmol) in CH2Cl2 (10 mL), I2 (2.59 g, 10.2 mmol) in CH2Cl2 (10 
mL) was slowly added. The reaction mixture was stirred for 30 min. Imidazole (1.39 g, 20.4 mmol) in 
CH2Cl2 (10 mL) was then added and the reaction mixture was stirred for further 30 min. Finally, 93 
(1.00 g, 5.13 mmol) was added and the reaction mixture stirred for 3 hours. The resulting mixture was 
washed with an aqueous saturated solution of NaHCO3 and 10 %w/w of Na2S2O3  and the aqueous phase 
extracted with CH2Cl2 (three times). The organic phase was dried over MgSO4, filtered and the solvent 
evaporated in vacuo to give a crude material, which was purified by flash chromatography 
(AcOEt/petroleum ether, from: 0/100 to 100/0) to give 94 (1.20 g, 77%) as white amorphous solid; 
[Found: C, 39.4; H, 4.0. C10H12INO2 requires C, 39.36; H, 3.96%]; Rf (6/4, AcOEt/petroleum ether) 
0.88;H (250.13 MHz CDC13) 3.25 (2H, t, J  6.5 Hz, CH2I), 3.55 (2H, q, J 6.5 Hz, CH2NH), 5.11 (2H, 
s, CH2Bn), 7.36 (5H, m, Ar.); C (62.89 MHz, CDCl3) 5.1, 43.0, 66.5, 127.8, 128.1, 128.2, 136.0, 155.8; 




, found 305.9989. C10H13INO2
+ 
requires 305.9991. 
 Benzyl 2-(5-(tert-butoxycarbonyl)pentylamino) ethylcarbamate (95): 
To a solution of 91 (0.35 g, 1.87 mmol) in dry acetonitrile (10 mL), at reflux, K2CO3 (0.88 g, 6.38 
mmol) was added. The reaction mixture was stirred for 10 min. After that, a solution of 94 (0.40 g, 1.31 
mmol) in dry acetonitrile (5 mL), was added and the reaction mixture was stirred at reflux overnight. 
The product was filtered and the crude was purified by flash column chromatograph, (CH2Cl2/CH3OH, 
from: 100/0 to 90/10) to give 95 (0.32 g, 67%) as yellow light oil; [Found: C, 65.9; H, 8.6. C20H32N2O4 
requires C, 65.91; H, 8.62%]; Rf (93/7, CH2Cl2/CH3OH) 0.71;H (300.10 MHz CDC13) 1.35 (2H, q, J 
6.5 Hz, CH2CH2CH2CH2CH2NH), 1.43 (9H, s, COOC(CH3)3), 1.57 (2H, q, J 6.0 Hz, 




OOCCH2CH2), 2.82 (2H, t, J 6.0 Hz, CH2CH2CH2CH2CH2NH), 2.99 (2H, t, J 6.0 Hz, 
CONHCH2CH2NH), 3.46 (2H, q, J 6.0 Hz, CONHCH2CH2NH), 5.09 (2H, s, CH2Ar), 5.73 (1H, br s, 
NHCOO), 7.34 (5H, m, Ar.); C (75.50 MHz, CDCl3) 24.4, 26.2, 27.9, 35.0, 39.3, 48.4, 48.6, 66.6, 79.9, 




, found 365.2437. 
C20H33N2O4
+
 requires 365.2440. 
 Compound (96): 
 To a solution of 95 (0.32 g, 0.88 mmol) in a 1:1 mixture of 1,4-dioxane/water (20 mL), NaHCO3 
(148 mg, 1.76 mmol) was added. The mixture was sonicated until complete dissolution and, Fmoc-Cl 
(0.29 g, 1.12 mmol) was added. The reaction mixture was stirred overnight, then, through addition of a 
saturated of NaHSO4, the pH was adjusted to 3 and the solvent was concentrated in vacuo to remove the 
excess of dioxane. The water layer was extracted with CH2Cl2 (three times), the organic phase was dried 
over MgSO4, filtered and the solvent evaporated in vacuo to give the crude product, which was purified 
by flash chromatography (CH2Cl2/CH3OH, from: 100/0 to 98/2) to give 96 (0.50 g, 97%) as a yellow 
light oil; [Found: C, 71.7; H, 7.3. C35H42N2O6 requires C, 71.65; H, 7.22%]; Rf (95/5,  CH2Cl2/CH3OH) 
0.61; H (400.13 MHz CDC13, mixture of rotamers) 1.08-1.60 (15H, m, CH2CH2CH2CH2CH2N, 
COOC(CH3)3), 2.16 (2H, t, J 6.0 Hz, CH2COO), 2.85 (0.8H, br s, CH2CH2CH2CH2CH2N), 2.96 (2.4H, 
CONHCH2CH2N and CH2CH2CH2CH2CH2N), 3.13 (0.8H, br s, CONHCH2CH2N), 3.30 (2H, br s, 
CONHCH2CH2N), 4.19 (1H, br s, CH2CHFmoc), 4.53-4.57 (2H, br s, CH2CHFmoc), 5.05 (2H, br s, 
CH2Ar), 7.29 (7H, m, Ar. (Cbz) and Ar. (Fmoc)), 7.38 (2H, t, J 7.0 Hz, Ar. (Fmoc)), 7.55 (2 H, d, J 7.0 
Hz, Ar. (Fmoc)), 7.76 (2H, t, J 7.0 Hz, Ar. (Fmoc)); C (62.89 MHz, CDCl3) 24.5, 25.9, 27.8, 27.9, 35.2, 
39.2, 39.6, 46.2, 46.8, 47.1, 47.6, 66.3, 79.7, 119.6, 124.4, 126.8, 127.4, 127.8, 128.2, 136.4, 141.1, 









 Compound (97):  
To a solution of 96 (150 mg, 0.26 mmol) in dry MeOH (9 mL), acetic acid (29 μL, 0.512 mmol) and 
palladium on charcoal (10%w/w, 15 mg) were added. The reaction mixture was stirred under a 
hydrogen atmosphere at room temperature for 1 h and  filtered through celite. The solvent was 
evaporated in vacuo to give crude 97 (118 mg, 100%, colorless oil) which was used in the next step 
without purification; Rf (95/5, CH2Cl2/CH3OH) 0.13; H (300.10 MHz CDC13, mixture of rotamers) 
1.05-1.60 (15H, m, CH2CH2CH2CH2CH2N, COOC(CH3)3), 2.15 (2H, t, J 6.0 Hz, CH2COO), 2.60 (0.6H, 
br s, CH2CH2CH2CH2CH2N), 2.90-3.20 (4H, CONHCH2CH2N, CH2CH2CH2CH2CH2N, 
CONHCH2CH2N and CONHCH2CH2N), 3.38 (1.4H, br s, CONHCH2CH2N), 4.19 (1H, br s, 
CH2CHFmoc), 4.52 (2H, m, CH2CHFmoc), 7.38 (4H, m, Ar. (Fmoc)), 7.54 (2 H, d, J 7.0 Hz, Ar. 
(Fmoc)), 7.74 (2H, t, J 7.0 Hz, Ar. (Fmoc)); C (100.03 MHz, CDCl3) 22.6, 24.4, 24.7, 25.9, 26.1, 28.1, 
35.1, 25.4, 38.8, 42.4, 46.5, 47.3, 47.9, 53.4, 67.0, 80.1, 119.8, 119.9, 124.0, 124.6, 126.9, 127.1, 127.7, 







 requires 453.2748. 
 
 Compound (98):   
To a solution of 97 (115 mg, 0.26 mmol) in CH2Cl2 (5 mL), ethyl glyoxalate (33 μL, 0.33 mmol), 




stirred overnight. The resulting mixture was washed with an aqueous saturated solution of NaHCO3 and 
the aqueous phase extracted with CH2Cl2 (three times). The organic phase was dried over MgSO4, 
filtered and the solvent evaporated in vacuo to give the crude product, which was purified by flash 
chromatography (AcOEt/petroleum ether, from: 60/40 to 100/0) to give 98 (35 mg, 25%) as white light 
oil; [Found: C, 69.2; H, 7.9. C31H42N2O6 requires C, 69.12; H, 7.86%]; Rf (95/5/0.1, 
CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol) 0.46; H (300.10 MHz CDC13, mixture of 
rotamers) 1.00-1.80 (18H, m, CH2CH2CH2CH2CH2N, COOC(CH3)3 and COOCH2CH3), 2.18 (2H, t, J 
6.0 Hz, CH2COOC(CH3)3), 2.46 (0.8H, br s, CH2CH2CH2CH2CH2N), 2.74 (1.2H, br s, 
CH2CH2CH2CH2CH2N), 2.90-3.45 (6H, m, COCH2NHCH2CH2N,), 4.18-4.23 (3H, m, COOCH2CH3, 
CH2CHFmoc), 4.52 (2H, m, CH2CHFmoc), 7.31 (2 H, t, J 7 Hz, Ar. (Fmoc)), 7.39 (2 H, t, J 7 Hz, Ar. 
(Fmoc)),  7.57 (2 H, d, J 7 Hz, Ar. (Fmoc)), 7.75 (2H, t, J 7 Hz, Ar. (Fmoc)); C (100.03 MHz, CDCl3, 
mixture of rotamers) 14.1, 24.7, 26.1, 28.0, 35.3, 46.8, 47.3, 47.8, 50.6, 60.7, 66.5, 79.9, 119.8, 124.6, 







 requires 539.3121. 
 Compound (99):  
To a solution of 98 (100 mg, 0.186 mmol) in DMF (6 mL), thymine-1-acetic acid (55 mg, 0.30 
mmol), PyBOP (154 mg, 0.30 mmol) and triethylamine (83 μL, 0.60 mmol) were added. The reaction 
mixture was stirred overnight, concentrated in vacuo, dissolved in CH2Cl2 (20 mL) and washed 1M HCl 
solution. The aqueous layer was extracted with CH2Cl2 (three times). The combined organic phases 
were dried over MgSO4, filtered and the solvent evaporated in vacuo to give a crude material, which 
was purified by flash chromatography (AcOEt/petroleum ether, from: 30/70 to 100/0) to give 99 (92 
mg, 70%) as amorphous white solid; [Found: C, 64.7; H, 6.9. C38H48N4O9 requires C, 64.76; H, 6.86%]; 
Rf (6/40, AcOEt/petroleum ether) 0.11; H (250.13 MHz CDC13, mixture of rotamers) 1.00-1.60 (18H, 
m, CH2CH2CH2CH2CH2N, COOC(CH3)3 and COOCH2CH3), 1.89 (3H, s, CH3-thymine), 2.18 (2H, m, 
CH2COOC(CH3)3), 2.95-3.65 (6H, m, NHCH2CH2NCH2), 4.00-4.80 (9H, m, CH2OOCCH2NHCH2, 
CH2CHFmoc and CH2-thymine), 6.94-7.00 (1H, complex signal, CH-thymine), 7.39 (2 H, t, J 7.0 Hz, 
Ar. (Fmoc)), 7.42 (2 H, t, J 7.0 Hz, Ar. (Fmoc)),  7.56 (2 H, d, J 7.0 Hz, Ar. (Fmoc)), 7.76 (2H, t, J 7.0 
Hz, Ar. (Fmoc)), 8.43 (1H, br s, NH-thymine);
 
C (75.50 MHz, CDCl3, mixture of rotamers) 12.1, 13.9, 
24.6, 26.0, 28.0, 35.3, 46.4, 46.7, 47.2, 47.8, 48.1, 50.7, 61.7, 66.9, 80.1, 110.6, 111.0, 119.9, 124.6, 





, found 705.3498. C38H49N4O9
+
 requires 705.3500. 
 Compound (51): 
To a solution of 99 (175 mg, 0.25 mmol) in a 1:1 mixture of 1,4-dioxane/water (6 mL) at 0 °C, 
LiOH
.
H2O (23 mg, 0.55 mmol) was added. The reaction mixture was stirred for 30 minutes and 
saturated solution of NaHSO4 added until pH~3. The aqueous layer was extracted with CH2Cl2 (three 
times) and once with AcOEt. The combined organic phases were dried over MgSO4, filtered and the 
solvent evaporated in vacuo to give a crude material, which was purified by flash chromatography 
(CH2Cl2/CH3OH, from: 95/5 to 80/20) to give 51 (50 mg, 30%) as amorphous white solid; [Found: C, 
64.0; H, 6.6. C36H44N4O9 requires C, 63.89; H, 6.55%]; Rf (9/1/0.1, CH2Cl2/CH3OH/NH3 2.0M solution 
in ethyl alcohol) 0.22; H (400.13 MHz CDC13, mixture of rotamers) 1.00-1.50 (15H, m, 
CH2CH2CH2CH2CH2N and COOC(CH3)3), 1.86 (3H, s, CH3-thymine), 2.17 (2H, m, J 6.0 Hz, 




CH2CHFmoc and CH2-thymine), 7.02 (1H, br s, CH-thymine), 7.10-7.45 (4H, m, Ar. (Fmoc)), 7.57 (2 
H, d, J 7.0 Hz, Ar. (Fmoc)), 7.77 (2H, t, J 7.0 Hz, Ar. (Fmoc)); 10.00 (1H, br s, NH-thymine); C 
(100.03 MHz, CDCl3, mixture of rotamers) 13.5, 22.7, 25.9, 26.0, 27.3, 28.8, 29.4, 29.7, 36.6, 36.7, 
45.8, 47.8, 48.5, 48.8, 49.6, 54.7, 68.3, 81.4, 81.6, 111.8, 111.9, 121.2, 125.9, 126.5, 128.3, 129.0, 





, found 677.3185. C36H45N4O9
+
 requires 677.3187. 
 
 Low yield synthesis of tert-butyl 6-(2,3-dihydroxypropylamino) hexanoate and unwanted 
tert-butyl 6-(bis(2,3-dihydroxypropyl) amino) hexanoate: 
To a solution of glycidol (83, 134 μL, 2.02 mmol) in DMF (3 mL), t-butyl 6-aminohexanoate (91, 
456 mg, 2.44 mmol) in DMF (3 mL), and DIPEA (0.55 mL, 3.17 mmol) were added. The reaction 
mixture was refluxed for three days. NaHCO3 (320 mg, 1.79 mmol) was added and the solvent was 
concentrated in vacuo to give the crude product, which was purified by flash chromatography 
(CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol, from: 100/0/0.1 to 88/12/0.1) to give 100 (60 mg, 
11%) and 101 (320 mg, 47%). 100: yellow pale oil; [Found: C, 59.8; H, 10.5. C13H27NO4 requires C, 
59.74; H, 10.41%]; Rf (90/10/0.1, CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol) 0.31; H (300.10 
MHz CDC13) 1.31 (2H, q, J 6.5 Hz, CH2CH2CH2COOt-Bu), 1.43 (9H, s, COOC(CH3)3), 1.52 (2H, 
quint., J 6.5 Hz, CH2CH2CH2NH), 1.57 (2H, q, J 6.5 Hz, CH2CH2CH2COOt-Bu), 2.20 (2H, t, J 6.5 Hz, 
CH2CH2CH2COOt-Bu), 2.58 (2H, m, CH2NHCH2CH(OH)CH2(OH)), 2.69 (1H, dd, J 15.0, 6.0 Hz, 
NHCHHCH(OH)CH2(OH)), 2.80 (1H, dd, J 15.0, 3.0 Hz, CHHCH(OH)CH2(OH)), 3.59 (1H, dd, J 9.0, 
3.0 Hz, CH2CH(OH)CHH(OH)), 3.70 (1H, dd, J 9.0, 3.0 Hz, CH2CH(OH)CHH(OH)), 3.77 (1H, m, 
CH2CH(OH)CH2(OH)); C (62.89 MHz, CDCl3) 24.6, 26.4, 27.9, 28.7, 35.2, 49.2, 51.8, 65.1, 69.7, 




, found 262.2017. C13H28NO4
+
 requires 262.2018. 101: 
yellow oil; [Found: C, 57.3; H, 9.8. C16H33NO6 requires C, 57.29; H, 9.92%]; Rf (90/10/0.1, 
CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol) 0.44; H (400.13 MHz, CDC13, mixture of 
diastereoisomers) 1.27 (2H, q, J 6.5 Hz, CH2CH2CH2COOt-Bu), 1.43 (11H, m, COOC(CH3)3 and 
CH2CH2CH2NH), 1.57 (2H, q, J 6.5 Hz, CH2CH2CH2COOt-Bu), 2.19 (2H, t, J 6.5 Hz, 
CH2CH2CH2COOt-Bu), 2.40-2.60 (6H, m, CH2NH[(CH2CH(OH)CH2(OH)]2), 3.50 (2H, m, 
NH[CH2CH(OH)CHH(OH)]2), 3.63 (2H, m, NH[CH2CH(OH)CHH(OH)]2), 3.77 (2H, m, 
NH[CH2CH(OH)CH2(OH)]2); C (62.89 MHz, CDCl3, mixture of diastereoisomers) 26.1, 27.5, 28.0, 









2.4.3 General procedure for manual solid-phase oligomerization. 
PNA oligomers were assembled on a Rink amide PEGA resin using the above obtained Fmoc-
























Rink amide PEGA resin (50 – 100 mg) was first swelled in CH2Cl2 for 30 minutes. Normal PNA 
monomers (from Link Technologies) was provided by Advance Biosystem Italia srl. The Fmoc group 
was then deprotected by 20% piperidine in DMF (8 min x 2). The resin was washed with DMF and 
CH2Cl2 and was indicated to be positive by the Kaiser test. The resin was preloaded with a Fmoc-
Glycine and subsequently, the coupling of the monomers (PNA or PNA modified) was conducted with 
either one of the following two methods (A and B). Method A: monomer (5 eq), HBTU (4.9 eq) and 
DIPEA (10 eq); method B: modified monomer (2 eq), HATU (2 eq) and DIPEA (10 eq). When the 
monomer was coupled to a primary amine, i.e., to a classic PNA monomer, method A was used; when 
the coupling was to a secondary amine, i.e., to a modified PNA monomer, method B was used. The 
coupling mixture was added directly to the Fmoc-deprotected resin. The coupling reaction required 30 
minutes at room temperature for the introduction of both normal and modified monomers, in case of 
method B the coupling time was raised to 6 h, and the resin was then washed by DMF/ CH2Cl2. The 
Fmoc deprotection and monomer coupling cycles were continued until the coupling of the last residue. 
After every coupling the oligomer was capped by adding 5% acetic anhydride and 6% DIPEA in DMF 
and the reaction vessel was shaken for 1 min (twice), and subsequently washed with a solution of 5% of 
DIPEA in DMF. The resin was always washed thoroughly with DMF/ CH2Cl2.  The cleavage from the 
resin was achieved by addition of a solution of 90% TFA and 10% m-cresol. The PNA was then 
precipitated adding 10 volumes of diethyl ether, cooled at -18°C for at least 2 h and finally collected 
through centrifugation (5 minutes @ 5000 rpm). The resulting residue was redisolved in H2O and 
purified by semipreparative reverse-phase C18 (Waters, Bondapak, 10 μm, 125Å, 7.8 × 300 mm) 
gradient elution from 100% H2O (0.1% TFA, eluent A) to 60% CH3CN (0.1%TFA, eluent B) in 30 min. 
The product was then lyophilized to get a white solid. MALDI-TOF MS analysis confirmed the 
expected structures for the four oligomers (49-52), with peaks at the following m/z values: compound 49 
m/z (MALDI-TOF MS – negative mode) 2839 (M–H)
–
, calcd. for C112H140N59O33
–
 2839.11, 60%; 
compound 50 m/z (MALDI-TOF MS – negative mode) 2955 (M–H)
–
, calcd. For C116H144N59O37
–
 
2955.12, 57%; compound 51 m/z (MALDI-TOF MS – negative mode) 2895 (M–H)
–
, calcd. for 
C116H148N59O33
–





 3123.31, 65%. 
2.4.4 Thermal denaturation studies 
DNA oligonucleotides were purchased from CEINGE Biotecnologie avanzate s.c. a r.l.  
The PNA oligomers and DNA were hybridized in a buffer 100 mM NaCl, 10 mM sodium phosphate 
and 0.1 mM EDTA, pH 7.0. The concentrations of PNAs were quantified by measuring the absorbance 
(A260) of the PNA solution at 260 nm. The values for the molar extinction coefficients (ε260) of the 
individual bases are: ε260 (A) = 13.7 mL/(μmole x cm), ε260 (C)= 6.6 mL/(μmole x cm), ε260 (G) = 11.7 
mL/(μmole x cm), ε260 (T) = 8.6 mL/(μmole x cm) and molar extinction coefficient of PNA was 
calculated as  the sum of these values according to sequence. 
The concentrations of DNA and modified PNA oligomers were 5 μM each for duplex formation. The 
samples were first heated to 90 °C for 5 min, followed by gradually cooling to room temperature. 
Thermal denaturation profiles (Abs vs. T) of the hybrids were measured at 260 nm with an UV/Vis 
Lambda Bio 20 Spectrophotometer equipped with a Peltier Temperature Programmer PTP6 interfaced 
to a personal computer. UV-absorption was monitored at 260 nm from in a 18-90°C range at the rate of 
1 °C per minute. A melting curve was recorded for each duplex. The melting temperature (Tm) was 






3. Structural analysis of cyclopeptoids and their complexes  
3.1. Introduction 
Many small proteins include intramolecular side-chain constraints, typically present as disulfide 
bonds within cystine residues. 
The installation of these disulfide bridges can stabilize three-dimensional structures in otherwise 
flexible systems. Cyclization of oligopeptides has also been used to enhance protease resistance and cell 
permeability. Thus, a number of chemical strategies have been employed to develop novel covalent 





well as many other approaches.
2 
Because peptoids are resistant to proteolytic degradation
79
, the 
objectives for cyclization are aimed primarily at rigidifying peptoid conformations. Macrocyclization 
requires the incorporation of reactive species at both termini of linear oligomers that can be synthesized 
on suitable solid support. Despite extensive structural analysis of various peptoid sequences, only one 
X-ray crystal structure has been reported of a linear peptoid oligomer.
80
 In contrast, several crystals of 
cyclic peptoid hetero-oligomers have been readily obtained, indicating that macrocyclization is an 
effective strategy to increase the conformational order of cyclic peptoids, relative to linear oligomers. 
For example, the crystals obtained from hexamer 102 and octamer 103 (figure 3.1) provided the first 
high-resolution structures of peptoid hetero-oligomers determined by X-ray diffraction. 
 
102                                               103 
Figure 3.1. Cyclic peptoid hexamer 102 and octamer 103. The sequence of cis/trans amide bonds 
depicted is consistent with X-ray crystallographic studies. 
 
Cyclic hexamer 102 reveals a combination of four cis and two trans amide bonds, with the cis bonds 
at the corners of a roughly rectangular structure, while the backbone of cyclic octamer 103 exhibits four 
cis and four trans amide bonds. Perhaps the most striking observation is the orientation of the side 
chains in cyclic hexamer 102, (figure 3.2) as the pendant groups of the macrocycle alternate in opposing 
directions relative to the plane defined by the backbone. 
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In the crystalline state, the packing of the cyclic hexamer appears to be directed by two dominant 
interactions. The unit cell (figure 3.2, bottom) contains a pair of molecules, in which the polar groups 
establish contacts between the two macrocycles. The interface between each unit cell is defined 
predominantly by aromatic interactions between the hydrophobic side chains. X-ray crystallography of 
peptoid octamer 103 reveals structure that retains many of the same general features as observed in the 
hexamer (figure 3.3). 
 
Figure 3.3. Cyclic octamer 103.
7
 Top: Equatorial view relative to the cyclic backbone. Bottom: Axial 
view, backbone dimensions 8.0 x 4.8 Ǻ. 
 
The unit cell within the crystal contains four molecules (figure 3.4). The macrocycles are assembled 
in a hierarchical manner, and associate by stacking of the oligomer backbones. The stacks interlock to 
form sheets, and finally the sheets are sandwiched to form the three-dimensional lattice. It is notable that 






Figure 3.4. Cyclic octamer 103. Top: The unit cell contains four macrocycles. Middle: Individual 
oligomers form stacks. Bottom: The stacks arrange to form sheets, and sheets are propagated to form the 
crystal lattice. 
 
Cyclic α and β-peptides, by contrast, can form stacks organized through backbone hydrogen-bonding 
networks 
81-82
. Computational and structural analyses for a cyclic peptoid trimer 30, tetramer 31, and 




Figure 3.5. Trimer 30, tetramer 31, and hexamer 32 were also reported by my research group. 
 
Theoretical and NMR studies for the trimer 30 suggested the backbone amide bonds to be present in 
the cis form. The lowest energy conformation for the tetramer 31 was calculated to contain two cis and 
two trans amide bonds, which was confirmed by X-ray crystallography. Interestingly, the cyclic 
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hexamer 32 was calculated and observed to be in an all-trans form subsequent to the coordination of 
sodium ions within the macrocycle. Considering the interesting results achieved in these cases, we 
decided to explore influences of chains (benzyl- and metoxyethyl) in the cyclopeptoids‘ backbone, when 
we have just benzyl groups and metoxyethyl groups. So, we have synthesized three different molecules: 
a N-benzyl cyclohexapeptoid 56, a N-benzyl cyclotetrapeptoid 57, a N-metoxyethyl cyclohexapeptoid 













































Figure 3.6. N-Benzyl-cyclohexapeptoid 56, N-benzyl-cyclotetrapeptoid 57 and N-metoxyethyl-
cyclohexapeptoid 58. 
 
3.2 Results and discussion 
3.2.1 Chemistry 
The synthesis of linear hexa- (104) and tetra- (105) N-benzyl glycine oligomers and of linear hexa- 
N-metoxyethyl glycine oligomer (106), was accomplished on solid-phase (2-chlorotrityl resin) using the 
―sub-monomer‖ approach,
84
  (scheme 3.1). 
                                                 





























Scheme 3.1. ―Sub-monomer‖ approach for the synthesis of linear tetra- (104) and hexa- (105) N-
benzyl glycine oligomers and of linear hexa-N-metoxyethyl glycine oligomers (106). 
  
All the reported compounds were successfully synthesized as established by mass spectrometry, with 
isolated crude yields between 60 and 100% and purities greater than 90 % by HPLC analysis.
85
 
Head-to-tail macrocyclization of the linear N-substituted glycines were realized in the presence of 
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Figure 3.7. Cyclization of oligomers 104, 105 and 106. 
 
Several studies in model peptide sequences have shown that incorporation of N-alkylated amino acid 




By reducing the energy barrier for interconversion 
between amide cisoid and transoid forms, such sequences may be prone to adopt turn structures, 
facilitating the cyclization of linear peptides.
87
 Peptoids are composed of N-substituted glycine units, 
and linear peptoid oligomers have been shown to readily undergo cis/trans isomerization. Therefore, 
peptoids may be capable of efficiently sampling greater conformational space than corresponding 
peptide sequences,
88 
allowing peptoids to readily populate states favorable for condensation of the N- 
and C-termini. In addition, macrocyclization may be further enhanced by the presence of a terminal 
secondary amine, as these groups are known to be more nucleophilic than corresponding primary 




3.2.2 Structural Analysis 
Compounds 56, 57 and 58 were crystallized and subjected to an X-ray diffraction analysis. For the 
X-ray crystallographic studies were used different crystallization techniques, like as: 
1. slow evaporation of solutions; 
2. diffusion of solvent between two liquids with different densities; 
3. diffusion of solvents in vapor phase; 
4. seeding. 
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Table 3.1. Results of crystallization of cyclopeptoid 56. 
# SOLVENT 1 SOLVENT 2 Technique Results 
1 CHCl3  Slow evaporation Crystalline 
 precipitate 
2 CHCl3 CH3CN Slow evaporation Precipitate 
3 CHCl3 AcOEt Slow evaporation Crystalline  
precipitate 
4 CHCl3 Toluene Slow evaporation Precipitate 
5 CHCl3 Hexane Slow evaporation Little crystals 
6 CHCl3 Hexane Diffusion in vapor phase Ne dlelike  
crystals 




Hexane Diffusion in vapor phase  
with seeding 
Ne dlelike  
crystals 
9 CHCl3 Acetone Slow evaporation Crystalline  
precipitate 
10 CHCl3 AcOEt Diffusion in  
vapor phase 
Crystals 












Table 3.2. Results of crystallization of cyclopeptoid 57. 
# SOLVENT 1 SOLVENT 2 SOLVENT 3 Technique Results 




2 CHCl3   Slow 
 evaporation 
Precipitate 











Table 3.3. Results of crystallization of cyclopeptoid 58. 
# SOLVENT 1 SOLVENT 2 SOLVENT 3 Technique Results 
1 CHCl3   Slow  
evaporation 
Crystals 
2 CHCl3 CH3CN  Slow  
evaporation 
Precipitate 
3 AcOEt CH3CN  Slow  
evaporation 
Precipitate 























Trough these crystallizations, we had some crystals suitable for the analysis.  Conditions #6 and #7 
(compound 56, table 3.1), gave two types of crystals (structure 56A and 56B, figure 3.8) 
 







                                 
56A                                                 56B 
 
Figure 3.8. Structures of N-Benzyl-cyclohexapeptoid 56A and 57B. 
 












Figure 3.9. Structures of N-Benzyl-cyclotetrapeptoid 57. 




















Table 3.4 reports the crystallographic data for the resolved structures 56A, 56B, 57 and 58. 
Compound 56A 56B 57 58 
Formula C54 H54 N6 O6· 2H2O C54 H54 N6 O6 C36 H36 N4 O4 C30 H54 N6 O12 
P.M. (g mol
-1 
) 919.03 883.03 588.69 513.36 
Dim. crist. (mm) 0.7 x 0.2 x 0.1 0.2 x 0.3 x 0.08 0.3 x 0.3 x 0.07 0.3 x 0.1x 0.05 















1.54178 1.54178 1.54178 1.54178 
Cristalline system monoclinic triclinic orthorhombic triclinic 































) 9725(27) 1169(3) 2986.9(14) 1113.1(5) 
Z 8 1 4 2 
Dcalc (g cm
-3 






) 0.638 0.663 0.692 2.105 
Total reflection 7007 2779 2253 2648 
Observed  
reflecti 
on (I>2I ) 
4883 1856 1985 1841 
R1 (I>2I) 0.1345 0.0958 0.0586 0.1165 
Rw 0.4010 0.3137 0.2208 0.3972 
 
3.2.3 Structural analysis of N-Benzyl-cyclohexapeptoid 56A. 
 
Initially, single crystals of N-benzylcyclohexapeptoid 56 were formed by slow evaporation of 
solvents (chloroform/hexane=1/0.5). Optimal conditions of crystallization were in chloroform, trough 
vapor phase diffusion of hexane (external solvent) and with seeding. These techniques gave air stable 
needlelike crystals (34A).  
The crystals show a monoclinic crystalline cell with the following parameters: a = 45.73(7) Å, b = 
9.283(14) Å, c = 23.83(4) Å, β = 105.97(4)°, V = 9725(27) Å
3
, C2/c space group.  Eight molecules of 56 
and 4 molecules of water were present in the elementary cell. Water molecules are on a binary 
symmetry axis and they formed a bridge trough a hydrogen bond with a carbonyl group of 
cyclopeptoids, between two molecules of equivalent cyclopeptoids. These water molecules formed a 
water channel  (figure 3.11). The peptoid backbone of 56A showed an overall rectangular form, with  


















































View along the axis c 
 
Figure 3.11. Hydrogen bond between water and two equivalent cyclopeptoids. Blue and pink benzyl group are 
pseudo parallel to each other, while yellow benzyl group are pseudo perpendicular to each other. 
 
3.2.4 Structural analysis of N-Benzyl-cyclohexapeptoid 56B. 
Cyclohexamer 56 was formed two different crystals (#6 and #7, table 3.1). In condition #7 it formed 
prismatic crystals and showed a triclinic structure (56B). The cell parameters were: a = 9.240(12)Å, b = 
11.581(13)Å, c = 11.877(17)Å, α = 109.06(2)°, β = 101.62(5)°, γ = 92.170(8)°, V = 1169(3) Å
3
, the 
space group is: P1. 





Monoclinic (56A) and Triclinic (56B) structures of cyclopeptoid 56 showed the same backbone, but 













Figure 3.12. superposition of two structures 56A and 56B. 
 
Triclinic crystalline cell [a = 9.240(12)Å, b = 11.581(13)Å, c = 11.877(17)Å, α = 109.06(2)°, β = 
101.62(5)°, γ = 92.170(8)°] is been compared with monoclinic cell [a = 45.73(7) Å, b = 9.283(14) Å, c 
= 23.83(4) Å, β = 105.97(4)°], and we could see a new triclinic cell similar to the first, if we applied the 
following operation on triclinic cell. 
 
 
 a’  0 1 0  a  b 
b’  = 0 0 1  b  =  c 





a = 11.877(17)Å, b = 9.240(12)Å, c = 11.581(13)Å, α = 92.170(8)°, β 109.06(2)°, γ= 101.62(5)°, so  
aM=4 aT, bM=bT e cM=2cT.  
The triclinic cell was considered a distortion of the monoclinic cell. In figure 3.13 were reported the 



























                   View along the axis b                                      View along the axis c 
 
Figure 3.13. Crystalline structure of 56B. 
 
3.2.5 Structural analysis of N-Benzyl-cyclotetra peptoid 57. 
Cyclotetramer 57 was obtained by slowly evaporation of solvent (CH2Cl2) as colorless prismatic and 
stable crystals (figure 3.14). They presented an orthorhombic crystalline cell [a = 10.899(3) Å, b = 
10.055(3) Å, c = 27.255(7) Å, V = 2986.9(14) Å
3 
] and they belonged to space group Pbca. 
X-Ray structure of 57 showed a cis-trans-cis-trans (ctct) stereochemical arrangement; benzyl group 













View along the axis b 
Figure 3.14. Crystalline structure of 57. 
 
3.2.6 Structural analysis of N-metoxyethyl-cyclohexapeptoid 58. 
Single crystal (58) was obtained in slowly evaporation of solvent (AcOEt/ACN) as colorless 
prismatic and stable crystals. They were present triclinic crystalline cell with parameters cell: a = 
8.805(3) Å, b = 11.014(2) Å, c = 12.477(2) Å, α = 70.97(2)°, β = 77.347(16)°, γ = 89.75(2)°, V = 
1113.1(5) Å
3





H-NMR studies confirmed the presence of a complex species of 58 and it was analyzed by X-ray 













Figure 3.15. X-ray structure of 58. 
 
The structure obtained, showed a unique all-trans peptoid bond configuration, with the carbonyl 
groups alternately pointing toward the sodium cation and forcing the N-linked side chains to assume an 
alternate pseudo-equatorial arrangement. X-ray showed the presence of an anion (hexafluorophosphate), 
too. Hexafluorophosphate is present as counterion of the coupling agent (PyBop). The structure of  58 
was described like a coordination polymer, in fact two sodium atoms (figure 3.16) were coordinated 







































Figure 3.16.  (a) View along the axis a; (b) perspective view of the rows in the crystalline cell of 58. 
 
3.3 X-ray analysis on powder of 56A and 56B. 
Polymorphous crystalline structures of 56A and 56B were analyzed to confirm analogy between 
polymorphous species. Crystals were obtained by tests #6 and #7 (table 3.1) and were ground in a 
mortar until powder. The powder was put into capillaries (0.05 mm) and X-ray spectra were acquired in 
a range of 4°-45° of 2. X-ray spectra have confirmed crystallinity of the sample, as well as his 
polymorphism (figure 3.17). 
 
Figure 3.17. Diffraction profiles for 56A (a) and 56B (b). 
 
Diffraction profiles acquired, were indexed using data on the monoclinic and triclinic unit cell. In 
particular, on the left of spectra, peaks were similar for both polymorphs. Instead, on the right of 






In this chapter, the synthesis and structural characterization of three cyclopeptoids (56, 57 and 58) 
were reported.  
For compound 56, two different polymorph structures were isolated (56A and 56B); crystalline 
structure of 56A shows a monoclinic cell and a water channel. Instead, crystalline structure of 56B, 
presents a triclinic cell without water channel. Backbone‘s conformation of 56A and 56B is similar 
(cctcct), but benzyl groups‘ conformation is different. X-ray analysis on powders of 56A and 56B, has 
confirmed  the non coexistence of the monoclinic and triclinic structures in the same sample. N-
benzylcyclotetrapeptoid 57 presents an orthorhombic cell and a conformation ctct.  
Finally, N-metoxyethylcyclohexapeptoid 58, has been isolated as sodium ion complex. The 
crystalline structure consists of rows of cyclopeptoids and sodium ions, hexafluophosphate ions are in 
the gaps. Backbone‘s conformation results to be all trans (tttttt) and sodium ions are coordinated with 
secondary interactions to the oxygens of carbonyl groups and to the oxygens of methoxy groups. 
3.5 Experimental section 
3.5.1 General Methods. 
All reactions involving air or moisture sensitive reagents were carried out under a dry argon or 
nitrogen atmosphere using freshly distilled solvents. Tetrahydrofuran (THF) was distilled from LiAlH4 
under argon. Toluene and CH2Cl2 were distilled from CaH2. Glassware was flame-dried (0.05 Torr) 
prior to use. When necessary, compounds were dried in vacuo over P2O5 or by azeotropic removal of 
water with toluene under reduced pressure. Starting materials and reagents purchased from commercial 
suppliers were generally used without purification unless otherwise mentioned. Reaction temperatures 
were measured externally; reactions were monitored by TLC on Merck silica gel plates (0.25 mm) and 
visualized by UV light, I2, or by spraying with H2SO4-Ce(SO4)2, phosphomolybdic acid or ninhydrin 
solutions and drying. Flash chromatography was performed on Merck silica gel 60 (particle size: 0.040-





C-NMR) pure materials. The NMR spectra were recorded on Bruker DRX 
400, (
1
H at 400.13 MHz, 
13
C at 100.03 MHz), Bruker DRX 250 (
1
H at 250.13 MHz, 
13
C at 62.89 MHz), 
and Bruker DRX 300 (
1
H at 300.10 MHz, 
13
C at 75.50 MHz) spectrometers. Chemical shifts () are 
reported in ppm relatively to the residual solvent peak (CHCl3,  = 7.26, 
13
CDCl3, : = 77.0; CD2HOD, 
 = 3.34, 
13
CD3OD,  = 49.0) and the multiplicity of each signal is designated by the following 
abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintuplet; m, multiplet; br, broad. 
Coupling costants (J) are quoted in Hz. Homonuclear decoupling, COSY-45 and DEPT experiments 
completed the full assignment of each signal. Elemental analyses were performed on a CHNS-O 
FlashEA apparatus (Thermo Electron Corporation) and are reported in percent abundance. High 
resolution ESI-MS spectra were performed on a Q-Star Applied Biosystem mass spectrometer. ESI-MS 
analysis in positive ion mode was performed using a Finnigan LCQ Deca ion trap mass spectrometer 
(ThermoFinnigan, San Josè, CA, USA) and the mass spectra were acquired and processed using the 
Xcalibur software provided by Thermo Finnigan. Samples were dissolved in 1:1 CH3OH/H2O, 0.1 % 
formic acid, and infused in the ESI source by using a syringe pump; the flow rate was 5 μl/min. The 
capillary voltage was set at 4.0 V, the spray voltage at 5 kV, and the tube lens offset at -40 V. The 




equipped with a quaternary pumps Jasco PU-2089 Plus, and an UV detector Jasco MD-2010 Plus. The 
resulting residues were purified by semipreparative reverse-phase C18 (Waters, Bondapak, 10 μm, 
125Å, 7.8 × 300 mm).  
3.5.2 Synthesis 
Linear peptoid oligomers 104, 105 and 106 were synthesized using a sub-monomer solid-phase 
approach
11
. In a typical synthesis 2-chlorotrityl chloride resin (2,α-dichlorobenzhydryl-polystyrene 
crosslinked with 1% DVB; 100–200 mesh; 1.2 mmol/g, 600 mg, 0.720 mmol) was swelled in dry DMF 
(6 mL) for 45 min and washed twice with dry DCM (6 mL). 
The first sub-monomer was attached onto the resin by adding 120 mg (1.2 eq, 0.86 mmol) of 
bromoacetic acid in dry DCM (6 mL) and 502 μL of DIPEA (4.0 mmol) on a shaker platform for 40 min 
at room temperature, followed by washing with dry DCM (6 mL) and then with DMF (6 x 6 mL). To the 
bromoacetylated resin was added a DMF solution (1 M, 7 mL) of the desired amine (benzylamine -10 
eq, 772 mg, 7.20 mmol- or methoxyethylamine -10 eq, 541 mg, 620 μl, 7.20 mmol- the commercially 
available [Aldrich]) the mixture was left on a shaker platform for 30 min at room temperature, then the 
resin was washed with  DMF (6 x 6 mL). Subsequent bromoacetylation reactions were accomplished by 
reacting the aminated oligomer with a solution of bromoacetic acid in DMF (1.2 M, 6 mL) and 1.23 mL 
of DIC for 40 min at room temperature. The filtered resin was washed with DMF (6 x 6 mL) and treated 
again with the amine in the same conditions reported above. This cycle of reactions was iterated until 
the target oligomer was obtained (hexa- 104 and tetralinears 105 and 106 peptoids). 
The cleavage was performed by treating twice the resin, previously washed with DCM (6 x 6 mL), 
with 6 mL of 20% HFIP in DCM (v/v) on a shaker platform at room temperature for 30 min and 5 min, 
respectively. The resin was then filtered away and the combined filtrates were concentrated in vacuo. 
The final products were dissolved in 50% acetonitrile in HPLC grade water and analysed by RP-HPLC 
(purity >95% for all the oligomers, conditions: 5% to 100% B in 30 min [A: 0.1% TFA in water, B: 
0.1% TFA in acetonitrile], flow: 1.0 mL/min, 220 nm. C18 reversed-phase analytical column [Waters, 
μBondapak, 10 lm, 125 Å, 3.9 mm x 300 mm]) and ESI mass spectrometry. The linear oligomers 75, 76 
and 77 were subjected to the cyclization reaction without further purification. 
 
 Compound 104: m/z (ES) 901 (MH+); (HRES) MH+, found 901.4290 C54H57N6O7
+ 
requires 
901.4289. 100 %. 
 
 Compound 105: m/z (ES) 607 (MH+); (HRES) MH+, found 607.2925 C36H39N4O5
+ 
requires 
606.2920. 100 %. 
 
 Compound 106: m/z (ES) 709 (MH+); (HRES) MH+, found 709.3986 C30H57N6O13
+ 
requires 
709.3984. 100 %. 
 
3.5.3 General cyclization reaction (synthesis of 56, 57 and 58) 
A solution of the linear peptoid (104, 105 and 106), previously co-evaporated three times with 





 Linear 104 (37 mg, 0.0611 mmol) was dissolved in DMF dry (5 mL) and the mixture was 
added drop-wise by syringe pump in 2 h to a stirred solution of PyBop (127 mg, 4 eq, 0.244 mmol) and 
DIPEA (49 mg, 6.2 eq, 66 μl, 0.319 mmol) in dry DMF (15 mL) at room temperature in anhydrous 
atmosphere. 
 Linear 105 (300 mg, 0.333 mmol) was dissolved in DMF dry (20 mL) and the mixture was 
added drop-wise by syringe pump in 2 h to a stirred solution of PyBop (4.0 eq, 692 mg, 1.37 mmol) and 
DIPEA (6.0 eq, 360 µl, 2.06 mmol) in dry DMF (20 mL) at room temperature in anhydrous atmosphere. 
 Linear 106 (1224 mg, 0.316 mmol) was dissolved in DMF dry (20 mL) and the mixture was 
added drop-wise by syringe pump in 2 h to a stirred solution of PyBop (655 mg, 4 eq, 1.26 mmol) and 
DIPEA (254 mg, 6.2 eq, 342 μl, 1.96 mmol) in dry DMF (85 mL) at room temperature in anhydrous 
atmosphere. 
 
After 12 h the resulting mixtures were concentrated in vacuo, diluted with CH2Cl2 (20 mL) and a 
solution of HCl (1 N, 20 mL). The single mixture was extracted with CH2Cl2 (2 x 20 mL) and the 
combined organic phases were washed with water (12 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.  
All cyclic products were dissolved in 50% acetonitrile in HPLC grade water and analysed by RP-
HPLC (purity >85% for all the cyclic oligomers).  
Eluition conditions: 5%-100% B in 30 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], 
flow: 1.0 mL/min, 220 nm. C18 reversed-phase analytical column [Waters, lBondapak, 10 lm, 125 Å, 
3.9 mm x 300 mm] and ESI mass spectrometry (zoom scan technique). 
The crude residues (56, 57 and 58) were purified by HPLC on a C18 reversed-phase preparative 
column, conditions: 20%-100% B in 40 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 
2.0 mL/min, 220 nm. The samples were dried in a falcon tube under low pressure. 
 
 Compound 56: δH (300.10 MHz CDC13) 7.15 (30 H, m, H Ar); 4.40 (12H, br., -NCHHCO, -







requires 882.4105. HPLC: tR: 19.9 min. 
 Compound 57: H ( 250 MHz, CDCl3) 7.23 (20 H, br. H Ar ), 5.55 (2 H, br. d., J 14 Hz, -
NCHHCO), 5.40 (2 H, br. d., J 14.5 Hz, -NCHHCO), 4.40 (6 H, m., J 17 Hz, -CH2Ph), 3.72 (2 H, br. d., 
J 14.2 Hz, -NCHHCO), 3.50 (4 H, br. d., J 14.5 Hz, -NCHHCO, -CH2Ph). C (75 MHz, CDCl3) 168.94 
(CO x 2), 167.78 (CO x 2), 135,72 (Cq-Ar x 2), 135,15 (Cq-Ar x 2), 128.91 (C-Ar x 8), 128.56 ( C-Ar x 
4), 127.82 (C-Ar x 4), 127.52 ( C-Ar x 4), 50.29 ( C x 2), 49.30 (C x 2), 48.82 (C x 2), 47.14 (C x 2). 




, found 589.2740 C36H37N4O4
+
 requires 589.2737. HPLC: tR: 
18.0 min. 
 
 Compound 58: H (250 MHz, CDCl3) 4.63 (3 H, br. d., J 17 Hz, -NCHHCO), 3.88 (3 H, br. 
d., J 17 Hz, -NCHHCO), 3.48 (48 H, m., -NCHHCO, -CH2CH2OCH3). C (400 MHz, CDCl3, mixture of 
rotamers) 171. 5, 171.0, 179.6, 170.1, 170.0, 169.8, 169.7, 169.5, 169.3, 169.1, 168.9, 168.7, 168.2, 
168.1, 71.7, 71.5, 71.4, 71.3, 71.0, 70.8, 70.6 (bs), 70.2 (bs), 70.0 (bs),, 69.8 (bs),69.5 (bs), 69.3 (bs), 
69.1 (bs), 68.8 (bs), 68.7 (bs), 59.1 (bs), 58.9 (bs), 58.6 (bs), 58.2 (bs), 53.4 (bs), 52.4 (bs), 52.2 (bs), 









, found 691.3810 C30H55N6O12
+
 requires 691.3800. HPLC: tR: 11.8 min. 
 
3.5.4 General method of X-ray analysis 
X-ray analysis were made with Bruker D8 ADVANCE utilized glass capillaries Lindemann and 
diameters of 0.5 mm. CuKα was used as radiations with wave length collimated (1.5418 Å) and 
parallelized using Göbel Mirror. Ray dispersion was minimized with collimators (0.6 - 0.2 - 0.6) mm. 
Below, I report diffractometric on powders analysis of 56A and 56B. 
 X-ray analysis on powders obtained by crystallization tests. 
Crystals were obtained by crystallization #6 of 56, they were ground into a mortar and introduced 
into a capillary of 0.5 mm. Spectra was registered on rotating capillary between 2 = 4° and 2 = 45°, 
the measure was performed in a range of 0.05° with a counting time of 3s. In a similar way, was 
analyzed crystal #7 of 56. 
 X-ray analysis on single crystal of 56A. 
56A was obtained by #6 table 3, in chloroform with diffusion in vapor phase of hexane (extern 
solvent) and subsequently with seeding. These crystals were needlelike and air stable. A crystal of 
dimension of 0.7 x 0.2 x 0.1 mm was pasted on a glass fiber and examined to room temperature with a 
diffractometer for single crystal Rigaku AFC11, and with a detector CCD Saturn 944 using a rotating 
anode of Cu and selecting a wave length CuKα (1.54178 Å). Elementary cell was monoclinic with 
parameters a = 45.73(7) Å, b = 9.283(14) Å, c = 23.83(4) Å, β = 105.97(4)°, V = 9725(27) Å3, Z=8 and 
belonged to space group C2/c. 
Data reduction 
7007 reflections were measured, 4883 were strong (F2 >2ζ (F2 )). Data were corrected, for Lorentz 
and polarization effects. The linear absorption coefficient for CuKα was 0.638 cm-1 without correction. 
Resolution and refinement of the structure 
Resolution program was called SIR200290 and it was based on representations theory for evaluation 
of the structure semivariant in 1, 2, 3 and 4 phases. It is more based on multiple solution technique and 
on selection of most probable solutions technique, too. The structure was refined with least-squares 
techniques using the program SHELXL9791 







considering all reflections, even the weak. 
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Considering only strong reflections (I>2ζ(I)). 
The corresponding disagreement index RW2, calculating all the reflections is 0.4, while R1 is 0.13. 
For thermal vibration was used an anisotropic model. Hydrogen atoms were collocated in canonic 
positions and were included into calculations.  
Rietveld analysis 
Rietveld method represents a structural refinement technique and it use the continue diffraction 
profile of a spectrum on powders.
92
 
Refinement procedure consists in least-squares techniques using GSAS93 like program.  
This analysis was conducted on diffraction profile of monoclinic structure 34A. Atomic parameters, 
of structural model of single crystal, were used without refinement. Peaks profile was defined by a 
pseudo Voigt function, combining it with a special function, which consider asymmetry. This asymmetry 
derives by axial divergence.94 The background was modeled manually, using GUFI95 like program. Data 
were refined for parameters cell, profile and zero shift. Similar procedure was used for triclinic structure 
56B. 
 
 X-ray analysis on single crystal of 56B. 
56B was obtained by #7 table 3.1, by chloroform with diffusion in vapor phase of hexane (extern 
solvent). These crystals were colorless, prismatic and air stable. A crystal (dimension: 0.2 x 0.3 x 0.08 
mm) was pasted on a glass fiber and was examined to room temperature with a diffractometer for single 
crystal Rigaku AFC11, and with a detector CCD Saturn 944 using a rotating anode of Cu and selecting a 
wave length CuKα (1.54178 Å). Elementary cell was triclinic with parameters a = 9.240(12) Å, b = 
11.581(13) Å, c = 11.877(17) Å, α = 109.06(2)°, β = 101.62(5)°, γ = 92.170(8)°, V = 1169(3) Å3  Z = 1 
and belonged to space group P1. 
Data reduction 
2779 reflections were measured, 1856 were strong (F2 >2ζ (F2 )). Data were corrected, for Lorentz 
and polarization effects. The linear absorption coefficient for CuKα was 0.663 cm-1 without correction.  
Resolution and refinement of the structure 
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The corresponding disagreement index RW2, calculating all the reflections is 0.31, while R1 is 0.09. 
For thermal vibration was used  an anisotropic model. Hydrogen atoms were collocated in canonic 
positions and included into calculations.  
 
 X-ray analysis on single crystal of 57. 
57 was obtained by #1 table 3.2, by slowly evaporation of dichloromethane. These crystals were 
colorless, prismatic and air stable. A crystal of dimension of 0.3 x 0.3 x 0.07 mm was pasted on a glass 
fiber and was examined to room temperature with a diffractometer for single crystal Rigaku AFC11, and 
with a detector CCD Saturn 944 using a rotating anode of Cu and selecting a wave length CuKα 
(1.54178 Å). Elementary cell is triclinic with parameters a = 10.899(3) Å, b = 10.055(3) Å, c = 
27.255(7) Å, V = 2986.9(14) Å3 , Z=4 and belongs to space group Pbca. 
 
Data reduction 
2253 reflections were measured, 1985 were strong (F2 >2ζ (F2 )). Data were corrected, for Lorentz 
and polarization effects. The linear absorption coefficient for CuKα was 0.692 cm-1 without correction.  
 
Resolution and refinement of the structure 
The corresponding disagreement index RW2, calculating all the reflections is 0.22, while R1 is 0.05. 
For thermal vibration is used  an anisotropic model. Hydrogen atoms were collocated in canonic 
positions and included into calculations.  
 
 X-ray analysis on single crystal of 58. 
58 was obtained by #5 table 5, by slowly evaporation of ethyl acetate/acetonitrile. These crystals 
were colorless, prismatic and air stable. A crystal (dimension: 0.3 x 0.1 x 0.05mm) was pasted on a glass 
fiber and was examined to room temperature with a diffractometer for single crystal Rigaku AFC11, and 
with a detector CCD Saturn 944 using a rotating anode of Cu and selecting a wave length CuKα 
(1.54178 Å). 
Elementary cell was triclinic with parameters a = 8.805(3) Å, b = 11.014(2) Å, c = 12.477(2) Å, α = 
70.97(2)°, β = 77.347(16)°, γ = 89.75(2)°, V = 1113.1(5) Å3, Z=2 and belonged to space group P1. 
 
Data reduction 
2648 reflections were measured, 1841 were strong (F2 >2ζ (F2 )). Data were corrected, for Lorentz 
and polarization effects. The linear absorption coefficient for CuKα was 2.105 cm-1 without correction.  
 
Resolution and refinement of the structure 
The corresponding disagreement index RW2, calculating all the reflections is 0.39, while R1 is 0.11. 
For thermal vibration was used  an anisotropic model. Hydrogen atoms were collocated in canonic 













4. Cationic cyclopeptoids as potential macrocyclic nonviral vectors 
 
4.1 Introduction 
Viral and nonviral gene transfer systems have been under intense investigation in gene therapy for 
the treatment and prevention of multiple diseases
96
. Nonviral systems potentially offer many advantages 
over viral systems, such as ease of manufacture, safety, stability, lack of vector size limitations, low 
immunogenicity, and the modular attachment of targeting ligands
97
. Most nonviral gene delivery 
systems are based on cationic compounds— either cationic lipids
2
 or cationic polymers
98
— that 
spontaneously complex with a plasmid DNA vector by means of electrostatic interactions, yielding a 
condensed form of DNA that shows increased stability toward nucleases. 
Although cationic lipids have been quite successful at delivering genes in vitro, the success of these 
compounds in vivo has been modest, often because of their high toxicity and low transduction 
efficiency. 
A wide variety of cationic polymers have been shown to mediate in vitro transfection, ranging from 
proteins [such as histones
99
 and high mobility group (HMG) proteins
100
] and polypeptides (such as 
polylysine
3,101
, short synthetic peptides
102,103
, and helical amphiphilic peptides
104,105
) to synthetic 




, and glucaramide polymers
109
). 
Although the efficiencies of gene transfer vary with these systems, a large variety of cationic structures 
are effective. Unfortunately, it has been difficult to study systematically the effect of polycation 
structure on transfection activity. 
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Since the first report in 1987
110
, cell transfection mediated by cationic lipids (Lipofection, figure 4.1) 
has become a very useful methodology for inserting therapeutic DNA into cells, which is an essential 
step in gene therapy
111
. 














Figure 4.1. Cell transfection mediated by cationic lipids  
 
It is well-known that oligoguanidinium compounds (polyarginines and their mimics, guanidinium 
modified aminoglycosides, etc.) efficiently penetrate cells, delivering a large variety of cargos.
16b,117
  
Ungaro et al. reported
21c
 that calix[n]arenes bearing guanidinium groups directly attached to the 
aromatic nuclei (upper rim) are able to condense plasmid and linear DNA and perform cell transfection 
in a way which is strongly dependent on the macrocycle size, lipophilicity, and conformation. 
Unfortunately, these compounds are characterized by low transfection efficiency and high cytotoxicity 
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especially at the vector concentration required for observing cell transfection (10-20 μM), even in the 
presence of the helper lipid DOPE (dioleoyl phosphatidylethanolamine).
16c,118 
Interestingly, Ungaro et al. found that attaching guanidinium (figure 4.2, 107) moieties at the 





Figure 4.2. Calix[4]arene like a new class of cytofectines. 
 
One member of this family (figure 4.2), when formulated with DOPE, performed cell transfection 
quite efficiently and with very low toxicity, surpassing a commercial lipofectin, widely used for gene 
delivery. Ungaro et al reported in a communication
119
 the basic features of this new class of cationic 




Figure 4.3. Nonmacrocyclic cationic lipids, gemini-type. 
 
The ability of compounds 107 a-c and 108 to bind plasmid DNA pEGFP-C1 (4731 bp) was assessed 
through gel electrophoresis and ethidium bromide displacement assays
11
. Both experiments evidenced 
that the macrocyclic derivatives 107 a-c bind to plasmid more efficiently than 108. To fully understand 
the structure–activity relationship of cationic polymer delivery systems, Zuckermann
120
 examined a set 
of cationic N-substituted glycine oligomers (NSG peptoids) of defined length and sequence. A diverse 
set of peptoid oligomers, composed of systematic variations in main-chain length, frequency of cationic 
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side chains, overall hydrophobicity, and shape of side chain, were synthesized. Interestingly, only a 
small subset of peptoids were found to yield active oligomers. Many of the peptoids were capable of 
condensing DNA and protecting it from nuclease degradation, but only a repeating triplet motif 
(cationic-hydrophobic-hydrophobic) was found to have transfection activity. Furthermore, the peptoid 
chemistry lends itself to a modular approach to the design of gene delivery vehicles; side chains with 
different functional groups can be readily incorporated into the peptoid, and ligands for targeting 
specific cell types or tissues can be appended to specific sites on the peptoid backbone. These data 
highlight the value of being able to synthesize and test a large number of polymers for gene delivery. 
Simple analogies to known active peptides (e.g., polylysine) did not directly lead to active peptoids. The 
diverse screening set used in this article, revealed that an unexpected specific triplet motif was the most 
active transfection reagent. Whereas, some minor changes lead to improvement in transfection, other 
minor changes abolished the capability of the peptoid to mediate transfection. In this context, they 
speculate that whereas the positively charged side chains interact with the phosphate backbone of the 
DNA, the aromatic residues facilitate the packing interactions between peptoid monomers. In addition, 
the aromatic monomers are likely to be involved in critical interactions with the cell membrane during 
transfection. Considering the interesting results reported, we decided to investigate on the potentials of 
cyclopeptoids in the binding with DNA and the possible impact of the side chains (cationic and 
hydrophobic) towards this goal. Therefore, we have synthesized the three cyclopeptoids reported in 
figure 4.4 (62, 63 and 64) which show a different ratio between the charged and the nonpolar side 




































































Figure 4.4. Dicationic cyclohexapeptoid 62, tetracationic cyclohexapeptoid 63, hexacationic 
cyclohexapeptoid 64. 
 
4.2 Results and discussion 
4.2.1 Synthesis 
In order to obtain our targets first step was the synthesis of the amine submonomer N-t-Boc-1,6-
















Scheme 4.1.  N-Boc protection. 
 
The synthesis of the three N-protected linear precursors (112, 113 and 114, scheme 4.2) was 












                                                 






































Scheme 4.2. ―Sub-monomer‖ approach for the synthesis of hexa-linears (112, 113 and 114). 
Head-to-tail macrocyclizations of the linear N-substituted glycines were realized in the presence of 
HATU in DMF, according to our previous results.
122
 Cyclization of oligomers 112, 113 and 114 proved 
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Scheme 4.3. Protected cyclopeptoids 115, 116 and 117. 
 
All cyclic products were deprotected with 33% TFA in CH2Cl2 to give quantitative  yields of  
cyclopeptoids 62, 63 and 64. 
 
4.2.2 Biological tests. 
In collaboration with Donofrio‘s group, biological activity evaluation was performed. All 
cyclopeptoids synthesized for this study should complex spontaneously plasmid DNA, owing to an 
extensive network of electrostatic interactions. The binding of the cationic peptoid to plasmid DNA 
should result in neutralization of negative charges in the phosphate backbone of DNA. This interaction 
can be measured by the inability of the large electroneutral complexes obtained to migrate toward the 
cathode during electrophoresis on agarose gel. The ability of peptoids to complex with DNA was 
evaluated by incubating peptoids with plasmid DNA at a 3:1 (+/-) charge ratio and analyzing the 
complexes by agarose gel electrophoresis. Peptoids tested in this experiment were not capable of 
completely retarding the migration of DNA into the gel. In this experiment, cyclopeptoids 62, 63 and 64 




peptoid backbone as well as the degree of hydrophobicity of the side chains have a dramatic effect on 
the ability to form homogenous complexes with DNA in high yield.  
 
4.3 Conclusions  
In this project three different cyclopeptoids 62, 63 and 64, decorated with cationic side chains, were 
synthetized. Biological evaluation demonstrated that they were not able to act as DNA vectors. A 
possible reason of these results could be that spatial orientation (see in chapter 3) of the side chains in 
cyclopeptoids did not assure the correct coordination and the binding with DNA.  
 
4.4 Experimental section 
4.4.1 Synthesis 
 Compound 111 
Di-tert-butyl carbonate (0.4 eq., 7.51g, 0.034 mmol) was added to 1,6-diaminohexane (10 g, 0.086 
mmol) in CH3OH/Et3N (9/1) and the reaction was stirred overnight. The solvent was evaporated and the 
residue was dissolved in DCM (20 mL) and extracted using a saturated solution of NaHCO3 (20 mL). 
Then water phase was washed with DCM (3 · 20 ml). The combined organic phase was dried over 
Mg2SO4 and concentrated in vacuo to give a pale yellow oil. The compound was purified by flash 
chromatography (CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol, from: 100/0/0.1 to 70/30/0.1) to 
give 81 (0.51 g, 30%) as a yellow light oil; [Found: C, 61.1; H, 11.2; N, 12.9; O,14.8. C11H24N2O2 
requires C, 61.07; H, 11.18; N, 12.95; O, 14.79%]; Rf (98/2/0.1, CH2Cl2/CH3OH/NH3 2.0M solution in 
ethyl alcohol) 0.63; δH (250 MHz, CDCl3)  4.84 (brs, 1H,  NH-Boc),  2.97-2.94 (bq, 2H, CH2-NH-Boc,  
J = 7.5 MHz),  2.56-2.51 (t,  2H,  CH2NH2,  J 7.0  MHz),  1.8 (brs, 2H, NH2), 1.30 (s,  9H,  (CH3)3); 








4.4.2 General procedures for linear oligomers 112, 113 and 114. 
Linear peptoid oligomers 112, 113 and 114 were synthesized using a sub-monomer solid-phase 
approach
11
. In a typical synthesis 2-chlorotrityl chloride resin (2,α-dichlorobenzhydryl-polystyrene 
crosslinked with 1% DVB; 100–200 mesh; 1.33 mmol/g, 400 mg, 0.532 mmol) was swelled in dry 
DMF (4 mL) for 45 min and washed twice with dry DCM (4 mL). 
The first sub-monomer was attached onto the resin by adding 120 mg (1.2 eq, 0.63 mmol) of 
bromoacetic acid in dry DCM (4 mL) and 370 μL of DIPEA (2.10 mmol) on a shaker platform for 40 
min at room temperature, followed by washing with dry DCM (4 mL) and then with DMF (4 x 4 mL). 
To the bromoacetylated resin was added a DMF solution (1 M, 5.3 mL) of the desired amine 
(benzylamine -10 eq- or 111 -10 eq-) the mixture was left on a shaker platform for 30 min at room 
temperature, then the resin was washed with DMF (4 x 4 mL). Subsequent bromoacetylation reactions 
were accomplished by reacting the aminated oligomer with a solution of bromoacetic acid in DMF (1.2 
M, 5.3 mL) and 823 μL of DIC for 40 min at room temperature. The filtered resin was washed with 
DMF (4 x 4 mL) and treated again with the amine in the same conditions reported above. This cycle of 
reactions was iterated until the target oligomer was obtained (112, 113 and 114 peptoids). The cleavage 
was performed by treating twice the resin, previously washed with DCM (6 x 6 mL), with 4 mL of 20% 




resin was then filtered away and the combined filtrates were concentrated in vacuo. The final products 
were dissolved in 50% acetonitrile in HPLC grade water and analysed by RP-HPLC (purity >95% for 
all the oligomers, conditions: 5% to 100% B in 30 min [A: 0.1% TFA in water, B: 0.1% TFA in 
acetonitrile], flow: 1.0 mL/min, 220 nm. C18 reversed-phase analytical column [Waters, μBondapak, 10 
μm, 125 Å, 3.9 mm x 300 mm]) and ESI mass spectrometry. The linear oligomers 112, 113 and 114 
were subjected to the cyclization reaction without further purification. 
 




, found 1119.6485 
C62H87N8O11
+
 requires 1119.6489. 100%. 
 




, found 1337.8690 
C70H117N10O15
+
 requires 1337.8694. 100%. 
 




, found 1556.0910 
C78H147N12O19
+
 requires 1556.0900. 100%. 
 
4.4.3 General cyclization reaction (synthesis of 115, 116 and 117) 
A solution of the linear peptoid (112, 113 and 114), previously co-evaporated three times with 
toluene, was prepared under nitrogen in dry DMF (20 mL).  
 Linear 112 (1.0 eq., 104 mg, 0.093 mmol) was dissolved in DMF dry (10 mL) and the 
mixture was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (3.1 eq., 112.0 mg, 
0.29 mmol) and DIPEA (6.0 eq., 97 µl, 0.55 mmol) in dry DMF (20 mL) at room temperature in 
anhydrous atmosphere. 
 Linear 113 (1.0 eq., 217.0 mg, 0.162 mmol) was dissolved in DMF dry (10 mL) and the 
mixture was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (3.1 eq., 191.1 mg, 
0.50 mmol) and DIPEA (6.0 eq, 174.6 µl, 1.00 mmol ) in dry DMF (20 mL) at room temperature in 
anhydrous atmosphere. 
 Linear 114 (1.0 eq., 112.0 mg, 0.072 mmol) was dissolved in DMF dry (10 mL) and the 
mixture was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (3.1 eq, 84.7 mg, 
0.223 mmol) and DIPEA (6.2 eq, 76 µl, 0.43 mmol) in dry DMF (20 mL) at room temperature in 
anhydrous atmosphere. 
After 12 h the resulting mixtures were concentrated in vacuo, diluted with CH2Cl2 (20 mL) and a 
solution of HCl (0.1 N, 20 mL). The single mixture was extracted with CH2Cl2 (2 x 20 mL) and the 
combined organic phases were washed with water (12 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.  
All protected cyclic 115, 116 and 117 were dissolved in 50% acetonitrile in HPLC grade water and 
analysed by RP-HPLC (purity >85% for all the cyclic oligomers, conditions: 5%-100% B in 30 min [A: 
0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 1.0 mL/min, 220 nm. C18 reversed-phase 
analytical column [Waters, μBondapak, 10 μm, 125 Å, 3.9 mm x 300 mm]) and ESI mass spectrometry 





The crude residues were purified by HPLC on a C18 reversed-phase preparative column, conditions: 
20%-100% B in 40 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 2.0 mL/min, 220 
nm. The samples were dried in a falcon tube under low pressure. 
 
 Compound 115: δH (400 MHz, CD3CN:CDCl3 (9:1), mixture of conformers) 7.34-7.06 (m, 
20H, H-Ar), 5.19 (br s, 2H, NH), 4.80-3.60 (m, 20H, NCH2Ph, -COCH2N- overlapped), 3.33-3.09 (m, 
4H, -CH2N), 3.02-2.96 (m, 4H, -CH2NHBoc), 1.38 (br s, 18 H,  C(CH3)3); 1.38-1.17 (m,  16 H, (CH2)4); 




, found 1101.3785. C62H85N8O10
+
 requires 1101.3780. HPLC: 
tR: 20.6 min. 
 
 Compound 116: δH (400 MHz,  CD3OD,  mixture of conformers) 7.46-7.32 (m, 10H, H-Ar), 
4.90-3.20 (m, 24H, NCH2Ph,  -COCH2N- -CH2N overlapped with HDO e MeOD), 3.07-2.84 (m, 8H, -
CH2NHBoc), 1.48 (br s, 36 H,  C(CH3)3); 1.72-1.17 (m,  32 H, (CH2)4). δC (100 MHz, CDCl3, mixture of 
conformers) 170.6, 169.0, 168.9, 1586.3, 156.1, 155.8, 155.7, 144.4, 143.4, 143.3, 140.8, 140.7, 136.2, 
136.0, 127.9, 127.5, 127.4, 126.9, 126.4, 124.5, 119.4, 81.7, 81.6, 67.5, 67.0, 66.0, 65.9, 59.8, 50.4, 







 requires 1319.7128. HPLC: tR: 21.2 min. 
 
 Compound 117: δH (250 MHz, CD3OD, mixture of conformers) 4.90-3.20 (m, 24H, -
COCH2N-,-CH2N overlapped with HDO e MeOD), 3.10-2.85 (m, 12H, -CH2NHBoc), 1.44 (br s, 54 H,  
C(CH3)3); 1.72-1.20 (m,  48 H, (CH2)4). δC (62.5 MHz, CD3OD , mixture of conformers) 173.5 (bs), 
172.3 (bs), 171.9 (bs), 171.7 (bs), 171.2 (bs), 170.9 (bs), 170.6 (bs), 170.2 (bs), 158.5, 79.7, 50.6 (bs) , 
50.0 - 48.0 (overlapped with MeOD),  41.2, 40.6 (bs), 30.9, 29.7 (bs), 29.4 (bs), 28.8, 27.6 (bs). 24%, 




, found 1538.0480. C78H145N12O18
+
 requires 1538.0476. HPLC: tR: 
22.5 min. 
 
4.4.4 General deprotection reaction (synthesis of  62, 63 and 64) 
Protected cyclopeptoids 115 (34 mg, 0.030 mmol), 116 (38.9 mg, 0.029 mmol) and 117 (26 mg, 
0.017mmol), were dissolved in a mixture of DCM and TFA (9/1, 4 mL) and the reaction was stirred for 
two hours. After, products were precipitated in cold Ethyl Ether (20 mL) and centrifuged. Solids were 
recuperated with a quantitative yield. 
 
 Compound 62: δH (250 MHz, MeOD, mixture of conformers) 7.38-7.01 (m,  20H,  H-Ar), 4.80 
- 3.30 (m, 24H, NCH2Ph,  -COCH2N, -CH2N overlapped with  HDO and MeOD), 3.00-2.83 (m, 4H, -
CH2NH3
+
), 1.75 -1.30 (m, 16 H, (CH2)4); δC (75  MHz,  MeOD, mixture of conformers) 174.2 (bs), 
172.1 (bs), 171.5 (bs), 171.1 (bs), 171.0 (bs), 162.2 (bs, CF3COO-), 138.2 (bs), 138.0 (bs), 137.5 (bs),  
137.1 (bs), 131.1 (bs), 130.2, 129.7, 129.3, 129.0, 128.6, 128.3, 127.0, 54.8, 53.8, 52.8, 52.1 (bs), 50.8 





, found 916.1800. C53H72N8O6
3+
 requires 916.1797. 
 
 Compound 63: δH (300 MHz, CD3OD, mixture of conformers) : 7.44-7.31 (m,  10H,  H-Ar), 















 Compound 64: δH(300 MHz, CD3OD, mixture of conformers)  4.90-3.16 (m, 24H, -
COCH2N-, -CH2N overlapped with HDO and MeOD), 3.10-2.89 (m, 12H, -CH2NH3
+
), 1.72-1.25 (m,  








4.4.5 DNA preparation and storage.  
Plasmid DNA was purified through cesium chloride gradient centrifugation (T. Maniatis, E.F. 
Fritsch, J. Sambrook, in Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor 
Laboratory: New York, 1989). A stock solution of the plasmid 0.350 M in milliQ water (Millipore 
Corp., Burlington, MA) was stored at -20 °C. 
 
4.4.6 Electrophoresis mobility shift assay (EMSA) 
Binding reactions were performed in a final volume of 14 µL with 10 µl of 20 mM Tris/HCl pH 8, 1 
µL of plasmid (1 µg of pEGFP-C1) and 3 µL of compound 62, 63 and 64 at different final 
concentrations, ranging from 25 to 200 µM. Binding reaction was left to take place at room temperature 
for 1 h; 5 µL of 1 g/mL in H2O of glycerol was added to each reaction mixture and loaded on a TA (40 
mM Tris–Acetate) 1% agarose gel. At the end of the binding reaction 1 L (0.01 mg) of ethidium 
bromide solution is added. The gel was run for 2.5 h in TA buffer at 10 V/cm. EDTA was omitted from 

































Tomography of magnetic resonance (Magnetic Resonance Imaging, MRI) has gained great 
importance in the last three decades in medicinal diagnostics as an imaging technique with a superior 
spatial resolution and contrast. The most important advantage of MRI over the competing radio-
diagnostic methods such as X-Ray Computer Tomography (CT), Single-Photon Emission Computed 
Tomography (SPECT) or Positron Emission Tomography (PET) is definitely the absence of harmful 
high-energy radiations. Moreover, MRI often represents the only reliable diagnostic method for, 
e.g.cranial abnormalities or multiple sclerosis
123
. In the course of time, it was found that in some 
examinations of, e.g. the gastrointestinal tract or cerebral area, the information obtained from a simple 
MRI image might not be sufficient. In these cases, the administration of a suitable contrast enhancing 
agent (CA) proved to be extremely useful. Quite soon, it was verified that the most capable class of CAs 
could be some compounds containing paramagnetic metal ions. 
These drugs would be administered to a patient in order to (1) improve the image contrast between 
normal and diseased tissue and/or (2) indicate the status of organ function or blood flow
124
. The image 
intensity in 
1
H NMR imaging, largely composed of the NMR signal of water protons, depend on the 
nuclear relaxation times. Complexes of paramagnetic transition and lanthanide ions, which can decrease 
the relaxation times of nearby nuclei via dipolar interactions, have received attention as potential 
contrast agents. Paramagnetic contrast agents are an integral part of this trend: they are unique among 
diagnostic agents. In tissue, these agents are not visualized directly on the NMR image but are detected 
indirectly by virtue of changes in proton relaxation behavior. Moreover, the expansion of these agents 
offers interesting challenges for investigators in the chemical, physical, and biological sciences
1
. These 
comprise the design and synthesis of stable, nontoxic, and tissue-specific metal complexes and the 
quantitative understanding of their effect on nuclear relaxation behavior in solution and in tissue. 
Physical principles of MRI rely on the monitoring of the different distribution and properties of water in 
the examined tissue and also on a spatial variation of its proton longitudinal (T1) and transversal (T2) 
magnetic relaxation times
125
. All CAs can be divided (according to the site of action) into extracellular, 
organ-specific and blood pool agents. Historically, the chemistry of the T1-CAs has been explored more 
extensively as the T1 relaxation time of diamagnetic water solutions is typically five-times longer than T2 
and, consequently easier to be shortened
1
. From the chemical point of view, T1-CAs are complexes of 
paramagnetic metal ions, such as Fe(III), Mn(II) or Gd(III), with suitable organic ligands.  
Gadolinium (III) is an optimal relaxation agents for its high paramagnetism (seven unpaired 
electrons) and for its properties in term of electronic relaxation
126
. The presence of paramagnetic Gd 
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(III) complexes causes a dramatic enhancement of the water proton relaxation rates and then allows to 
add physiological information to the impressive anatomical resolution commonly obtained in the 
uncontrasted images. 
Other general necessities of contrast agent for MRI are low toxicity, rapid excretion after 
administration, good water solubility and low osmotic potential of the solutions clinically used. 
However, the main problem of the medical utilizations of heavy metal ions like the Gd(III) ion is a 
significant toxicity of their ―free‖ (aqua-ion) form. Thus, for clinical use of gadolinium(III), it must be 
bound in a complex of high stability and, even more importantly, it must show a long term resistance to 
a transmetallation/transchelation loss of the Gd(III) ion. High chelate stability is essential for lanthanide 
complexes in medicine because lanthanide ions have known toxicity via their interaction with Ca(II) 
binding sites. So, the preferred metal complexes, in addition to showing high thermodynamic (and 
possibly kinetic) stability, should present at least one water molecule in their inner coordination sphere, 
in rapid exchange with the bulk solvent, in order to affect strongly the relaxation of all solvent protons. 
The Gd (III) chelate efficiency is commonly evaluated in vitro by the measure of its relaxivity (r1), 
that, for commercial contrast agents as Magnevist (DTPA, 118), Doratem (DOTA, 119), Prohance (HP-




(20 MHz and 
39°C).














Figure 5.1. Commercial contrast agents. 
 
The observed water proton longitudinal relaxation rate in a solution containing a paramagnetic metal 






 is the water relaxation rate in 
the absence of the paramagnetic compound, R1p
is 
represents the contribution due to exchange of water 
molecules from the inner coordination sphere of the metal ion to the bulk water and R1p
os
 is the 
contribution of solvent molecules diffusing in the outer coordination sphere of the paramagnetic center. 




1p) referred to a 1 mm concentration of a 
given Gd(III) chelate is called its relaxivity
2
. 
The inner sphere contribution is directly proportional to the molar concentration of the complex-Gd, 
to the number of water molecules coordinated to the paramagnetic center, q, and inversely proportional 
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to the sum of the mean residence lifetime, τM, of the coordinate water protons and their relaxtion time, 
T1M (eq. 5.2). 
5.2 Eq.                 
)τ(5.55
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The latter parameter is directly proportional to the sixth power of the distance between the metal 
center and the coordinated water protons (r) and depends on the molecular reorientational time, τR, of the 
chelate, on the electronic relaxation times, TiE, (i=1 , 2), of the unpararied electrons of the metal and on 
the applied magnetic field strength itself (eq. 5.3 and 5.4). 






























































For resume all parameters: 
 q is the number of water molecules coordinated to the metal ion;  
 tM is their mean residence lifetime;  
 T1M is their longitudinal relaxation time;  
 S is the electron spin quantum number;  
 γS and γH are the electron and the proton nuclear magnetogyric ratios; 
  rGd–H is the distance between the metal ion and the protons of the coordinated water 
molecules;  
 ωH and ωS are the proton and electron Larmor frequencies, respectively;  
 tR is the reorientational correlation time; 
 ηS1 and ηS2 are the longitudinal and transverse electron spin relaxation times. 




1p on magnetic field is very significant, because the analysis of the 
magnetic field dependence permits the determination of the major parameters characterizing the 
relaxivity of Gd (III) chelate.  
A significant step for the design and the characterization of more efficient contrast agents is 
represented by the investigation of the relationships between the chemical structure and the factors 
determining the ability to enhance the water protons relaxation rates. The overall relaxivity can be 
correlated with a set of physico-chemical parameters, which characterize the complex structure and 









Figure 5.2. Model of Gd(III)-based contrast agent in solution. 
 
Therefore, considering the importance of the contrast agents based on Gd (III), the cyclopeptoids 
complexing ability of sodium and the analogy between ionic ray of sodium (1.02 Ǻ) and gadolinium 
(0.94 Ǻ), the design and the synthesis of cyclopeptoids as potential Gd(III) chelates were realized. 
Consequently, taking inspiration from the commercial CAs, three different cyclopeptoids (figure 5.3: 65, 
66 and 67) containing polar and soluble side chains, were prepared and their complexing ability of Gd 








































































Figure 5.3. Hexacarboxyethyl cyclohexapeptoid 65, Tricarboxyethyl ciclohexapeptoid 66 and 






5.2 Lariat ether and click chemistry. 
 
Cyclopeptoid 67 reminds a lariat ether. Lariat ethers are macrocyclic polyether compounds having 
one or more donor-group-bearing sidearms. Sidearms can be attached either to carbon (carbon-pivot 
lariat ethers) or to nitrogen (nitrogen-pivot lariat ethers). When more than one sidearm is attached, the 
number of them is designated using standard prefixes and the Latin word bracchium, which means arm. 







 are strongly bound by these ligands
128
. 
We have expanded the lariat ethers concept to cyclopeptoids as well as macrocycles and we have 
included molecules having sidearms that contain a donor group. These sidearms were incorporated into 
the cyclic skeleton with a practical and rapid method: the ―click chemistry‖. It consists in a chemistry 
tailored to generate substances quickly and reliably by joining small units together. Of the reactions 
comprising the click universe, the ―perfect‖ example is the Huisgen 1,3-dipolar cycloaddition
129
 of 
alkynes to azides to form 1,4-disubsituted-1,2,3-triazoles (scheme 5.1). The copper(I)-catalyzed reaction 
is mild and very efficient, requiring no protecting groups, and no purification in many cases.
130
 The 
azide and alkyne functional groups are largely inert towards biological molecules and aqueous 
environments, which allows the use of the Huisgen 1,3-dipolar cycloaddition in target guided 
synthesis
131
 and activity-based protein profiling. The triazole has similarities to the ubiquitous amide 
moiety found in nature, but unlike amides, is not susceptible to cleavage. Additionally, they are nearly 















Scheme 5.1. Huisgen 1,3-dipolar cycloaddition. 
 
Cu(II) salts in presence of  ascorbate is used for preparative synthesis of 1,2,3-triazoles, but it is 
problematic in bioconjugation applications. However, tris[(1-benzyl-1H-1,2,3-triazol-4-




Therefore, an important intermediate has been a cyclopeptoid containing two alkyne groups in the 
sidearms chains (122, figure 5.4). 
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Figure 5.4. Cyclopeptoid intermediate. 
5.3 Results and discussion 
5.3.1 Synthesis 
 
Initially, the synthesis of the linear precursors was accomplished through solid-phase mixed 
approach (―submonomer‖ and ‗‗monomer‘‘ approach) consisting in an alternate attachment of the N-
fluorenylmethoxycarbonyl,N‘-carboxymethyl-β-alanine, (126, scheme 5.2), and a two step construction 































Scheme 5.2. Synthesis of monomer N-fluorenylmethoxycarbonyl,N‘- carboxymethyl-β-alanine. 
 
 DIC and HATU-induced couplings and chemoselective deprotections yielded the required oligomers 





































All linear compounds were successfully synthesized as established by mass spectrometry, with 
isolated crude yields between 62 and 70% and purities greater than 90 % by HPLC. Head-to-tail 
macrocyclizations of the linear protect N-substituted glycines were realized in the presence of HATU in 







































































































Figure 5.6. Synthesis of Protected cyclopeptoids. 
 
The Boc-protected cyclic precursors (130 and 131) were deprotected with trifluoroacetic acid (TFA), 
to afford 65 and 66. While, Boc-protected cyclic 122 was reacted with azide 132, through click 
chemistry to afford protected cyclic 133 (figure 5.7). 
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Figure 5.7. Click chemistry reaction. 
Finally, cyclopeptoid 133 was deprotected, in presence of trifluoroacetic acid (TFA) in CH2Cl2, to 
afford 67. 
 
5.3.2. Stability evaluation of 65 and 66 as metal complexes.  
The degree of toxicity of a metal chelate is related to its in vivo degree of dissociation before 
excretion.  
The relaxation rate of the cyclopeptoid solutions (~2 mM), was evaluated. Cyclopeptoids 65 and 66 









The relaxation rate linearly increased adding Gd(III). Its pendence represents the relaxivity (R1p) of 
complex Gd-65 and Gd-66. When Gd(III) was added in excess, the line changes its pendence and 
followes the relaxivity increase typical of Gd aquaion (R1p= 13 mM
-1s-1).   
 
                         R1oss = R1W + r1p[Gd-CP]                    Eq. 5.5 
CP = cyclopeptoid 
R1W is the water relaxation rate in absence of the paramagnetic compound (= 0.38). Purity was been 
of 73% and 56% for 65 and 66, respectively. From these data, we calculated the complexes relaxivity, 








for Gd-65 and Gd-66, respectively. These values resulted higher, 





By measuring solvent longitudinal relaxation rates over a wide range of magnetic fields with a field-
cycling spectrometer that rapidly switches magnetic field strength over a range corresponding to proton 
Larmor frequencies of 0.01–70 MHz, we calculate important relaxivity parameters. The data points 
represent the so-called nuclear magnetic relaxation dispersion (NMRD), profile that can be adequately 
fitted to yield the values of the relaxation parameters (figure 5.9).  
 
Figure 5.9. 1/T1 NMRD profiles for Gd-65 and Gd-66 
 
The efficacy of the CA, measured as the ability of its 1 mM solution to increase the longitudinal 
relaxation R1 (=1/T1) of water protons, is called relaxivity and labeled r1. According to the well 
established Solomon-Boembergen-Morgan theory and its improvement, called generalized SBM
134
, the 
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Electronic relaxation parameters (
2
 e v) were similar for complexes Gd-65 and Gd-66 and 
comparable to commercial contrast agents.  
From the data reported (see q and qass) appears that Gd-65 and Gd-66 complexes coordinate directly 
(in the inner sphere, see figure 5.2) 3 water molecules and about 14-15 water molecules in the second 
coordination sphere. 
Finally, we have also tested the stability of the complex Gd-65 in solution using EDTA as competitor 
(logKEDTA=17.35) in a titration (figure 5.10, increased EDTA amounts into Gd-65 solution, 0.918 mM, 
pH 7). Being stability constant of Gd-EDTA complex known, and once knew Gd-65 relaxivity, it was 
possible to fit these experimental data and obtain stability constant of the examined complex.    
  
Figure 5.10. Tritation profile of Gd-65 with EDTA. 
 
The stability constant was determinated to be logKGd-65 = 15.95 resulting too low for possible in vivo 
applications. The stability studies for the complexes Gd-66 and Gd-67 are in progress. 
5.4 Experimental section 
5.4.1 Synthesis 
 Compound 125 
To a solution of β-alanine hydrochloride 124 (3.0 g, 16.5 mmol) in DMF dry (5 mL), DIPEA (5.74 
mL, 33.0 mmol) and ethyl bromoacetate (0.93 mL, 8.25 mmol) were added. The reaction mixture was 
stirred overnight, concentrated in vacuo, dissolved in CH2Cl2 (20 mL) and washed with brine solution. 
The aqueous layer was extracted with CH2Cl2 (three times). The combined organic phases were dried 
over MgSO4, filtered and the solvent evaporated in vacuo to give a crude material 125 (3.0 g, 100 %, 




9.0 Hz, CH3CH2), 1.47 (9H, s, C(CH3)3), 2.74 (2H, t, J 6.0 Hz, NHCH2CH2CO), 3.09 (2H, t, J 9.0 Hz, 
NHCH2CH2CO), 3.65 (2H, s, CH2NHCH2CH2CO), 4.26 (2H, q, J 15.0 Hz); δC (75.50 MHz, CDCl3) 
14.01, 27.97, 33.50, 44.30, 49.14, 60.41, 81.44, 168.88, 170.77. m/z (ES) 232 (MH+); (HRES) MH+, 
found 232.1552. C11H22NO4
+ requires 232.1549. 
 
 Compound 126 
To a solution of 125 (3.0 g, 13.0 mmol) in 1,4-dioxane (30 mL) at 0°C, LiOH•H2O (0.587 g, 14.0 
mmol) in H2O (30 mL) was added. After two hours, NaHCO3 (1.42 g, 9.9 mmol) and  Fmoc-Cl (4.33 g, 
9.9 mmol) were added. The reaction mixture was stirred overnight. Subsequently, KHSO4 (until pH= 3) 
was added and concentrated in vacuo, dissolved in CH2Cl2 (20 mL). The aqueous layer was extracted 
with CH2Cl2 (three times). The combined organic phases were dried over MgSO4, filtered and the 
solvent evaporated in vacuo to give a crude material (5.8 g g, yellow oil), which was purified by flash 
chromatography (CH2Cl2/CH3OH, from: 100/0 to 80/20, 0.1% ACOH) to give 126 (50 mg, 30%). δH 
(300.10 MHz, CDCl3, mixture of rotamers) 1.44 (9H, s, C(CH3)3), 2.32 (1.2H, t, J 6.4 Hz,  
NHCH2CH2CO, rot. a) 2.58 (0.8H, t, J 6.0 Hz, NHCH2CH2CO, rot. b), 3.45 (1.2H, t, J 6.3 Hz, 
NHCH2CH2CO, rot. a), 3.59 (0.8H, t, J 5.9 Hz, NHCH2CH2CO, rot. b), 4.05 (0.8H, s, 
CH2NHCH2CH2CO, rot. b), 4.13 (1.2H, s, CH2NHCH2CH2CO, rot. a), 4.20 (0.4H, t, J 6.0 Hz,  
CH2CHFmoc, rot. b), 4.28 (0.6H, t, J 6.0 Hz, CH2CHFmoc, rot. a), 4.45 (1.2H, d, J 6.3 Hz, 
CH2CHFmoc, rot. b), 4.55 (0.8H, d, J 6.0 Hz, CH2CHFmoc, rot. a), 7.19-7.44 (4H, m, Ar. (Fmoc)),  
7.53 (0.8H, d, J 7.3 Hz, Ar. (Fmoc), rot. b), 7.59 (1.2H, d, J 7.3 Hz, Ar. (Fmoc), rot. a), 7.73 (0.8H, t, J 
7.3 Hz, Ar. (Fmoc), rot. b), 7.78 (1.2H, t, J 7.3 Hz, Ar. (Fmoc), rot. a). δC (62.89 MHz, CDCl3, mixture 
of rotamers) 27.90, 34.42, 34.60, 44.38, 45.09, 47.03 (× 2), 49.71, 49.99, 67.59, 80.87, 119.84, 124.70 
(× 2), 125.16 (× 2), 126.91, 127.00, 127.59 (× 2), 128.08, 128.89, 141.19, 143.62, 155.63, 156.24, 









5.4.2 Linear compounds 127, 128 and 129. 
Linear peptoids 127, 128 and 129, were synthesized by alternating submonomer and monomer solid-
phase method using standard manual Fmoc solid-phase peptide synthesis protocols. Typically 0.20 g of 
2-chlorotrityl chloride resin (Fluka; 2,α-dichlorobenzhydryl-polystyrene crosslinked with 1% DVB; 
100-200 mesh; 1.20 mmol/g) was swelled in dry DCM (2 mL) for 45 min and washed twice in dry 
DCM (2 mL). To the resin, monomer 126 (68 mg, 0.16 mmol) and DIPEA (0.11 mL, 0.64 mmol) in dry 
DCM (2 mL) were added and putted on a shaker platform for 1h and 15 min at room temperature, 
washes with dry DCM (3 × 2mL) and then with DMF (3 × 2 mL) followed. The resin was capped with a 
solution of DCM/CH3OH/DIPEA. The Fmoc group was deprotected with 20% piperidine/DMF (v/v, 3 
mL) on a shaker platform for 3 min and 7 min respectively, followed by extensive washes with DMF (3 
× 3 mL), DCM (3 × 3 mL) and DMF (3 × 3 mL). Subsequently, for compound 130, the resin was 
incubated with a solution of monomers 126 (0.64 mmol), HATU (0.24 g, 0.62 mmol), DIPEA (220 μL, 
1.28 mmol) in dry DMF (2 mL) on a shaker platform for 1 h, followed by extensive washes with DMF 
(3 × 2 mL), DCM (3 × 2 mL) and DMF (3 × 2 mL). For compounds 128 and 129, instead, 
bromoacetylation reactions were accomplished by reacting the oligomer with a solution of bromoacetic 




room temperature. Subsequent specific amine was added (methoxyethyl amine: 0.17 mL, 2.0 mmol or 
propargyl amine: 0.15 mL, 2.4 mmol). 
Chloranil test was performed and once the coupling was complete the Fmoc group was deprotected 
with 20% piperidine/DMF (v/v, 3 mL) on a shaker platform for 3 min and 7 min respectively, followed 
by extensive washes with DMF (3 × 3 mL), DCM (3 × 3 mL) and DMF (3 × 3 mL). The yields of 
loading step and of the following coupling steps were evaluated interpolating the absorptions of 
dibenzofulvene-piperidine adduct (λmax = 301, ε = 7800 M-1 cm-1), obtained in Fmoc deprotection 
step (the average coupling yield was 63-70%).  
The synthesis proceeded until the desired oligomer length was obtained. The oligomer-resin was 
cleaved in 4 mL of 20% HFIP in DCM (v/v).  The cleavage was performed on a shaker platform for 30 
min at room temperature the resin was then filtered away. The resin was treated again with 4 mL of 20% 
HFIP in DCM (v/v) for 5 min, washed twice with DCM (3 mL), filtered away and the combined filtrates 
were concentrated in vacuo. The final products were dissolved in 50% ACN in HPLC grade water and 
analysed by RP-HPLC and ESI mass spectrometry. 
 




, found 1129. 6500 
C54H93N6O19
+
 requires 1129.6425. 80%. 




, found 919.5248 
C42H75N6O16
+
 requires 919.5240. 75% 




, found 949.5138 
C43H73N6O15
+
 requires 949.5134. 85% 
 
5.4.3 General cyclization reaction (synthesis of 130, 131 and 122) 
A solution of the linear peptoid (127, 128 and 129), previously co-evaporated three times with 
toluene, was prepared under nitrogen in dry DMF (20 mL).  
 Linear 127 (0.110 g, 0.097 mmol) was dissolved in DMF dry (8 mL) and the mixture was 
added drop-wise by syringe pump in 2 h to a stirred solution of HATU (0.15 g, 0.39 mmol) and DIPEA 
(0.10 mL, 0.60 mmol) in dry DMF (25 mL) at room temperature in anhydrous atmosphere. 
 Linear 128 (0.056 g, 0.061 mmol) was dissolved in DMF dry (5 mL) and the mixture was 
added drop-wise by syringe pump in 2 h to a stirred solution of HATU (0.093 g, 0.244 mmol) and 
DIPEA (0.065 mL, 0.38 mmol) in dry DMF (15 mL) at room temperature in anhydrous atmosphere. 
 Linear 129 (0.050 g, 0.053 mmol) was dissolved in DMF dry (4.5 mL) and the mixture was 
added drop-wise by syringe pump in 2 h to a stirred solution of HATU (0.080 g, 0.211 mmol) and 
DIPEA (0.057 mL, 0.333 mmol) in dry DMF (13.5 mL) at room temperature in anhydrous atmosphere. 
 
After 12 h the resulting mixtures were concentrated in vacuo, diluted with CH2Cl2 (20 mL) and a 
solution of HCl (0.1 N, 20 mL). The single mixture was extracted with CH2Cl2 (2 x 20 mL) and the 
combined organic phases were washed with water (12 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.  
All cyclic products were dissolved in 50% acetonitrile in HPLC grade water and analysed by RP-




Eluition conditions: 5%-100% B in 30 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], 
flow: 1.0 mL/min, 220 nm. C18 reversed-phase analytical column [Waters, lBondapak, 10 lm, 125 Å, 
3.9 mm x 300 mm]) and ESI mass spectrometry (zoom scan technique). 
The crude residues (130, 131 and 122) were purified by HPLC on a C18 reversed-phase preparative 
column, conditions: 20%-100% B in 40 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 
2.0 mL/min, 220 nm. The samples were dried in a falcon tube under low pressure. 
 
 Compound 130: δH (300.00 MHz, CDCl3, mixture of conformers) 1.44 (54H, br s, C(CH3)3), 
2.54-3.58 (24H, m, CH2CH2COOt-Bu), 3.94-4.50 (12H, m, CH2 intranular). δC (62.89 MHz, CDCl3, 
mixture of conformers) 27.99, 29.63, 33.20, 33.72, 34.02, 34.15, 34.74, 43.80, 44.33, 44.58, 45.04, 
45.31, 45.55, 45.72, 45.94, 46.76, 47.56, 47.74, 48.58, 48.96, 49.77, 50.04, 50.37, 51.02, 52.77, 53.23, 
53.40, 80.58, 81.41, 167.65, 167.76, 167.93, 168.19, 168.32, 168.56, 168.86, 168.90, 169.02, 169.15, 
169.28, 169.38, 169.51, 169.93, 170.27, 170.38, 170.62, 170.69, 170.78, 170.91, 170.96, 171.14, 







requires 1111.6390. HPLC: tR 20.05 min.  
 
 Compound 130 with sodium picrate: δH (400 MHz, CD3CN:CDCl3 9:1, 25 °C, soluzione 4.0 
mM) 1.44 (54H, s, C(CH3)3), 2.56 (12H, t, J 8.0 Hz, CH2CH2COOt-Bu), 3.47 (6H, m, CHHCH2COOt-
Bu), 3.61 (6H, m, CHHCH2COOt-Bu), 3.92 (6H, d, J 16.0 Hz, -OCCHHN, pseudoequatorial), 4.61 (6H, 
d, J 20.0 Hz, -OCCHHN, pseudoaxial), 8.77 (3H, s, Picrate). δC (100 MHz, CD3CN:CDCl3 9:1, 25 °C, 
solution 4.0 mM) 28.46, 34.78, 45.50, 50.20, 82.27, 127.24, 128.22, 143.10, 170.15, 171.73. 
 Compound 131: δH (400.10 MHz, CDCl3, mixture of conformers) 1.43-146 (54H, br s, 
C(CH3)3), 3.25-3.60 (33H, m, CH2CH2COOt-Bu e CH2CH2OCH3), 3.94-4.65 (12H, m, CH2 intranular). 
δC (62.89 MHz, CDCl3, mixture of conformers) 29.13, 29.33, 29.56, 35.01, 35.41, 45.17, 46.35, 47.20, 
49.62, 49.92, 50.61, 53.97, 59.93, 60.26, 72.80, 81.95, 81.10, 82.69, 114.01, 118.00, 160.61, 160.72, 





, found 901.5138. C42H73N6O15
+ 
requires 901.5134. HPLC: tR 15.05 min.  
 
 Compound 131 with sodium picrate: δH (400 MHz, CD3CN:CDCl3 9:1, solution 4.0 mM) 
1.44 (27H, s, C(CH3)3), 2.56 (6H, t, J 8.0 Hz, CH2CH2COOt-Bu),  3.32 (9H, s, CH2CH2OCH3), 3.47-
3.70 (18H, m, CHHCH2COOt-Bu e CHHCH2COOt-Bu e CH2CH2OCH3), 3.81 (3H, d, J 16.7 Hz, -
OCCHHN, pseudoequatorial), 3.89 (3H, d, J 17.0 Hz, -OCCHHN, pseudoequatorial) 4.64 (3H, d, J 16.7 
Hz, -OCCHHN, pseudoaxial), 4.68 (3H, d, J 16.6 Hz, -OCCHHN, pseudoaxial), 8.74 (3H, s, Picrate). 
 
 Compound 122: δH (400.10 MHz, CDCl3, mixture of conformers) 1.43-144 (36H, br s, 
C(CH3)3), 2.15-2.80 (10H, m, CH2CH2COOt-Bu e CH2CCH), 3.50-4.65 (24H m, CH2CCH,  CH2 
intranular e CH2CH2COOt-Bu). (62.89 MHz, CDCl3, mixture of conformers) 27.87, 29.50, 33.59, 34.16, 
36.53, 36.71, 36.98, 43,78, 44.02, 44.21, 44.37, 45.09, 46.87, 47.55, 47.67, 47.80, 48.66, 49.03, 49.25, 
49.91, 50.16, 50.53, 50.91, 52.97, 53.29,  72.36, 72.50, 72.86, 80.56, 81.27, 81.36, 157.86, 158.63, 





, found 931.5029. C46H71N6O14
+ 






5.4.4 Synthesis of 133 by click chemistry. 
Compound 122 (0.010 g, 0.011 mmol) was dissolved in CH3OH (55 μL) and compound 132 (0.015 g  
0.066 mmol) was added and the reaction was stirred for 15 minutes. Subsequent, a solution of CuSO4 
penta hydrate (0.001 g, 0.0044 mmol) and sodium ascorbate (0.0043 g, 0.022 mmol) in water (110 μL) 
was  slowly added. The reaction was stirred overnight. After, at the solution H2O (0.3 ml) was added and 
the single mixture was extracted with CH2Cl2 (2 x 20 mL) and the combined organic phases were 
washed with water (12 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
crude residue 133 was purified by HPLC on a C18 reversed-phase preparative column, conditions: 20%-
100% B in 40 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 2.0 mL/min, 220 nm. The 
samples were dried in a falcon tube under low pressure (53 %). δH (400.10 MHz, CDCl3, mixture of 
conformers) 1.42 (36H, br s, C(CH3)3), 2.54 (8H, m, CH2CH2COOt-Bu), 3.30-5.05 (62H, m, 
CH2CH2COOt-Bu, NCH2C=CH, CH2 etilen-glicole, CH2 intranulari e OCH3,), 7.90 (2H, m, C=CH). δC 
(100.03 MHz, CDCl3, mixture of conformers) 14.02, 22.56, 28.04, 29.62, 31.93, 32.99, 33.73, 42.27, 
43.01, 44.48, 45.01, 45.64, 48.38, 48.91, 49.44, 50.60, 53.34, 58.92, 69.15, 69.99, 70.52, 71.89, 80.54, 
80.69, 80.80, 80.92, 81.36, 113.87, 116.40, 124.16, 124.35, 124.46, 124.65, 124.74, 125.32, 125.47, 





, found 1397.7780. C64H109N12O22
+ 
requires 1397.7779. HPLC: tR 18.30 min.  
 
5.4.5 General deprotection reaction (synthesis of 65, 66 and 67) 
Protected cyclopeptoids 130 (0.058 g, 0.052mmol), 131 (0.018 g, 0.020 mmol) and 122 (0.010 g, 
0.0072 mmol), were dissolved in a mixture of m-cresol and TFA (1/9, 1.3 mL for 130, 0.5 mL for 131, 
0.18 mL for 122) and the reaction was stirred for one hour. After, products were precipitated in cold 
Ethyl Ether (20 mL) and centrifuged. Solids were recuperated with a quantitative yield. 
 
 Compound 65: δH (300.00 MHz, CDCl3, mixture of conformers) 1.44 (54H, br s, C(CH3)3), 
2.54-3.58 (24H, m, CH2CH2COOt-Bu), 3.94-4.50 (12H, m, CH2 intranular). δc (62.89 MHz, CDCl3, 
mixture of conformers) 27.99, 29.63, 33.20, 33.72, 34.02, 34.15, 34.74, 43.80, 44.33, 44.58, 45.04, 
45.31, 45.55, 45.72, 45.94, 46.76, 47.56, 47.74, 48.58, 48.96, 49.77, 50.04, 50.37, 51.02, 52.77, 53.23, 
53.40, 80.58, 81.41, 167.65, 167.76, 167.93, 168.19, 168.32, 168.56, 168.86, 168.90, 169.02, 169.15, 
169.28, 169.38, 169.51, 169.93, 170.27, 170.38, 170.62, 170.69, 170.78, 170.91, 170.96, 171.14, 




, found 775.2638. 
C30H43N6O18
+ 
requires 775.2635. HPLC: tR 4.05 min.  
 
 Compound 65 with sodium picrate: δH (400.10 MHz, CD3CN/D2O/MeOD=2/1/1, spettro 
1.5:1 complesso) 2.60 (12H, m,  CH2CH2COOH), 3.40  (6H, m, CHHCH2COOH, overlapped with 
water signal), 3.54 (6H, m, CHHCH2COOH), 3.85 (6H, d, J 16.5 Hz, -OCCHHN, pseudoequatorial), 
4.72 (6H, d, J 17.1 Hz, -OCCHHN, pseudoaxial), 8.68 (3H, s, Picrate). 
 Compound 66: δH (300.00 MHz, CDCl3, mixture of rotamers) 3.24-4.80 (45H, complex 
signal, CH2CH2OCH3, CH2CH2COOH, CH2 intranular). δc (62.89 MHz, CD3CN:MeOD=9:1, mixture of 
rotamers) 14.59, 31.43 32.14, 32.58, 43.59, 44.00, 44.60, 45.04, 45.74, 49.31, 49.69, 50.04, 57.57, 
57.77, 57,85, 58.02, 58.29, 65.51, 69.42, 69.57, 70.11, 70.21, 70.35, 168.70, 168.91, 168.98, 169.34, 








, found 733.3259. C30H49N6O15
+ 
requires 733.3256. HPLC: 
tR 8.43 min.  
 
 Compound 66 with sodium picrate: δH (300.00 MHz, CDCl3, mixture of rotamers) 2.61 (6H, 
br s, CH2CH2COOH, overlapped with water signal), 3.30 (9H, s, CH2CH2OCH3), 3.50-3.60 (18H, m, 
CHHCH2COOH, CHHCH2COOH e CH2CH2OCH3), 3.77 (3H, d, J 21.0 Hz, -OCCHHN, 
pseudoequatorial), 3.84 (3H, d, J 21.0 Hz, -OCCHHN, pseudoequatorial), 4.64 (3H, d, J 15.0 Hz, -
OCCHHN, pseudoaxial), 4.83 (3H, d, J 15.0 Hz, -OCCHHN, pseudoaxial), 8.68 (3H, s, picrate). 
 
 Compound 67: δH (400.10 MHz, CDCl3, mixture of rotamers) 2.99-3.07 (8H, m, 
CH2CH2COOt-Bu), 3.70 (6H, s, OCH3), 3.80-5.50 (56H, m, CH2CH2COOt-Bu, NCH2C=CH, CH2 








































6. Cyclopeptoids as mimetic of natural defensins. 
6.1 Introduction 
The efficacy of antimicrobial  host defense in animals can be attributed to the ability of the immune 
system to recognize and neutralize microbial invaders quickly and specifically. It is evident that innate 
immunity is fundamental in the recognition of microbes by the naive host.
135
 After the recognition step, 
an acute antimicrobial response is generated by the recruitment of inflammatory leukocytes or the 
production of antimicrobial substances by affected epithelia. In both cases, the host‘s cellular response 
includes the synthesis and/or mobilization of antimicrobial peptides that are capable of directly killing a 
variety of pathogens.
136




Defensins are small cationic peptides that form an important part of the innate immune system. 
Defensins are a family of evolutionarily related vertebrate antimicrobial peptides with a characteristic β-
sheet-rich fold and a framework of six disulphide-linked cysteines
3
. Hexamers of defensins create 
voltage-dependent ion channels in the target cell membrane causing permeabilization and, ultimately, 
cell death.
137
 Three defensin subfamilies have been identified in mammals: α-defensins, β-defensins, and 
the cyclic θ-defensins (figure 6.1)
138
. 
      
α-defensin                                         
                                                 
135 Hoffmann  J. A.,  Kafatos  F. C., Janeway C. A ., Ezekowitz R. A. Science, 1999, 284, 1313-1318. 
136 Selsted M. E, and Ouelette A. J. Nature immunol., 2005, 6, 551-557. 
137 a) Kagan, B.L., Selsted, M.E., Ganz, T. Lehrer, R.I. Proc. Natl Acad. Sci. USA, 1990, 87, 210–214. b) 
Wimley, W.C., Selsted, M.E. White, S.H. Protein Sci., 1994, 3, 1362–1373. 








Figure 6.1. Defensins profiles. 
 
Defensins show broad anti-bacterial activity
139
 as well as anti-HIV properties
140
. The anti-HIV-1 
activity of α-defensins was recently shown to consist of a direct effect on the virus, combined with a 
serum-dependent effect on infected cells
141
. Defensins are constitutively produced by neutrophils
142
 or 
produced in the Paneth cells of the small intestine.  
Given that no gene for θ-defensins has been discovered, it is thought that θ-defensins is a proteolytic 
product of one or both of α-defensins and β-defensins. α-defensins and β-defensins are active against 
Candida albicans and are chemotactic for T-cells, whereas θ-defensins is not
143
. α-Defensins and β-
defensins have recently been observed to be more potent than θ-defensins against the Gram negative 
bacteria Enterobacter aerogenes and Escherichia coli as well as the Gram positive Staphylococcus 
aureus and Bacillus cereus
9
. Considering that peptidomimetics are much stable and better performing 
than peptides in vivo, we have supposed that peptoids‘ backbone could mimic natural defensins. For this 
reason we have synthesized some peptoids with sulphide side chains (figure 6.2, block I, II, III and IV), 
and explored the conditions for disulfide bond formation. 
 
                                                 
139 a) Ghosh, D., Porter, E., Shen, B., Lee, S.K., Wilk, D., Drazba, J., Yadav, S.P., Crabb, J.W., Ganz, T. Bevins, 
C.L. Nat. Immunol., 2002, 3, 583–590.b) Salzman, N.H., Ghosh, D., Huttner, K.M., Paterson, Y. Bevins, C.L. 
Nature, 2003, 422, 522–526. 
140 a) Zhang, L., Yu, W., He, T., Yu, J., Caffrey, R.E., Dalmasso, E.A., Fu, S., Pham, T., Mei, J., Ho, J.J. Science, 
2002, 298, 995–1000. b) 7. Zhang, L., Lopez, P., He, T., Yu, W.  Ho, D.D. Science, 2004, 303, 467. 
141 Chang, T.L., Vargas, J.J., Del Portillo, A. Klotman, M.E. J. Clin. Invest., 2005, 115, 765–773. 
142 Yount, N.Y., Wang, M.S., Yuan, J., Banaiee, N., Ouellette, A.J. Selsted, M.E. . J. Immunol., 1995, 155, 4476–
4484. 























































































































































































































































































































Figure 6.2, block IV. Structures of dodecameric linear diprolinate (78) and corresponding cyclic 79, 





Disulfide bonds play an important role in the folding and stability of many biologically important 
peptides and proteins. Despite extensive research, the controlled formation of intramolecular disulfide 
bridges still remains one of the main challenges in the field of peptide chemistry.
144
  
The disulfide bond formation in a peptide is normally carried out using two main approaches:  
(i) while the peptide is still anchored on the resin;  
(ii) after the cleavage of the linear peptide from the solid support. 
Solution phase cyclization is commonly carried out using air oxidation and/or mild basic 
conditions.
10 
Conventional methods in solution usually involve high dilution of peptides to avoid 
intermolecular disulfide bridge formation. On the other hand, cyclization of linear peptides on the solid 




Several methods for disulfide bond formation were evaluated. Among them a recently reported on-
bead method was investigated
 





6.2 Results and discussion 
6.2.1 Synthesis 
In order to explore the possibility to form disulfide bonds in cyclic peptoids, we had to preliminarly 
synthesized the linear peptoids 68, 71, 74 and 78 (Figure XX.X). 
To this aim, we constructed the amine submonomer N-t-Boc-1,4-diaminobutane 134
146
, and the 
amine submonomer S-tritylaminoethanethiol 137
147




















Scheme 6.1. N-Boc protection and S-trityl protection.  
 
The synthesis of the liner peptoids was carried out on solid-phase (2-chlorotrityl resin), using the 
―sub-monomer‖ approach
148
. The identity of compounds 68, 71, 74 and 78 was established by mass 
spectrometry, with isolated crudes yield between 60 and 100% and purity greater than 90 % by 
                                                 
144 Galanis A. S., Albericio F.,  Grøtli M. Peptide Science, 2008, 92, 23-34. 
145 a) Albericio, F.; Hammer, R. P.; Garcìa-Echeverrıìa, C.; Molins, M. A.; Chang, J. L.; Munson, M. C.; Pons, 
M.; Giralt, E.; Barany, G. Int J Pept Protein Res 1991, 37, 402–413. b). Annis, I.; Chen, L.; Barany, G. J Am Chem 
Soc 1998, 120, 7226–7238. 
146 Krapcho, A. P.;  Kuell, C. S. Synth. Commun 1990, 20, 2559–2564. 
147 Kocienski, P. J. Protecting Group, 3rd ed.; Georg Thieme Verlag: Stuttgart, 2005. 







Head-to-tail macrocyclization of the linear N-substituted glycines was performed in the presence of 














































































Figure 6.3. Protected cyclopeptoids 138, 139, 140 and 141.  
 
The subsequent step was the detritylation/oxidation reactions. Triphenylmethyl (trityl) is a common 
S-protecting group.
150
 Typical ways for detritylation usually employ acidic conditions, either with protic 
acid
151
 (e.g. trifluoroacetic acid) or Lewis acid
152
 (e.g., AlBr3). Oxidative protocols have been recently 
                                                 
149 Analytical HPLC analyses were performed on a Jasco PU-2089 quaternary gradient pump equipped with an 
MD-2010 plus adsorbance detector using C18 (Waters, Bondapak, 10 μm, 125Å,  3.9 × 300 mm), reversed phase 
columns. 
150 For comprehensive reviews on protecting groups, see: (a) Greene, T. W.; Wuts, P. G. M. Protective Groups in 
Organic Synthesis, 2nd ed.; Wiley: New York, 1991; (b) Kocienski, P. J. Protecting Group, 3rd ed.; Georg Thieme 
Verlag: Stuttgart, 2005. 
151 (a) Zervas, L.; Photaki, I. J. Am. Chem. Soc. 1962, 84, 3887; (b) Photaki, I.; Taylor-Papadimitriou, J.; 
Sakarellos, C.; Mazarakis, P.; Zervas, L. J. Chem. Soc. C 1970, 2683; (c) Hiskey, R. G.; Mizoguchi, T.; Igeta, H. J. 
Org. Chem. 1966, 31, 1188. 




developed for the deprotection of trityl thioethers
153
. Among them, iodinolysis
154
 in a protic solvent, 
such as methanol, is also used
16
. Cyclopeptoids 138, 139, 140 and 141 and linear peptoids 74 and 78 
were thus exposed to various deprotection/oxidation protocols. All reactions tested are reported in Table 
6.1. 
 
Table 6.1. Survey of the detritylation/oxidation reactions. 
 
One of the detritylation methods used (with subsequent disulfide bond formation, entry 1), was 
proposed by Wang et al.
155
 (figure 6.4). This method provides the use of a catalyst, such as CuCl into an 
aquose solvent and it gives cleavage and oxidation of S-triphenylmethyl thioether. 
 
Figure 6.4. CuCl-catalyzed cleavage and oxidation of S-triphenylmethyl thioether. 
                                                 
153 Gregg, D. C.; Hazelton, K.; McKeon, T. F., Jr. J. Org. Chem. 1953, 18, 36. b) Gregg, D. C.; Blood, C. A., Jr. 
J. Org. Chem. 1951, 16, 1255. c) Schreiber, K. C.; Fernandez, V. P. J. Org. Chem. 1961, 26, 2478. d) Kamber, B.; 
Rittel, W. Helv. Chim. Acta 1968, 51, 2061.e) Li, K. W.; Wu, J.; Xing, W. N.; Simon, J. A. J. Am. Chem. Soc. 1996, 
118, 7237. 
154
 K. W. Li, J. Wu, W. Xing, J. A. Simon J. Am. Chem. Soc. 1996, 118, 7236-7238. 
 
155 Ma M., Zhang X., Peng L. and Wang J. Tetrahedron Letters 2007, 48, 1095–1097. 


























































9 I2 (5 eq.)
154
 CH3OH >70% 
141 
 
9 I2 (5 eq.)
154
 CH3OH >70% 
74 
 
9 I2 (5 eq.)
154
 CH3OH >70% 
78 
 
9 I2 (5 eq.)
154






For compound 138, Wang‘s method was applied, but it was not able to induce the sulfide bond 
formation. Probably, the reaction was condizioned by acquose solvent and by a constrain conformation 
of cyclohexapeptoid 138. In fact, the same result was obtained using 1% TFA in the presence of 5% 
triethylsilane (TIS
17
, entry 2, table 6.1), in the case of iodinolysis in acetic acid/water, and in the 
presence of DMSO (entries 3 and 4).   
One of the reasons hampering the closure of the disulfide bond, in compound 138, could have been 
the distance between the two-disulfide terminals. For this reason, a larger cyclooctapeptoid 139 has been 
synthesized, and similar reactions were performed on the cyclic octamer. Unfortunately, reactions 
carried out on cyclo 139, were inefficient, perhaps for the same reasons seen for the cyclo hexameric 
138. To overcome this disvantage, cyclo dodecamers 140 and 141 were synthesized. Compound 141 
containing two prolines units, in order to induce folding
156
 of the macrocycle and bring the thiol groups 
closer.
 
Therefore, dodecameric linears 74 and 78, and cyclics 140 and 141 were subjectd to an iodinolysis 
reaction, reported by Simon
154
 et al. This reaction provided the use of methanol such as a protic solvent 
and iodine for cleavage and oxidation. By HPLC and high-resolution MS analysis, compound 76, 77, 80 
and 81 were observed with good yelds (>70%).  
 
6.3 Conclusions 
Differents cyclopeptoids with thiol groups were synthesized, with standard protocol of synthesis on 
solid phase and macrocyclization. Many proof of oxdidation were performed, but only iodinolysis 
reaction, were efficient to obtain desidered compound. 
 
6.4 Experimental section 
6.4.1 Synthesis 
 
 Compound  135 
Di-tert-butyl dicarbonate (0.4 eq., 10 g, 0.046 mmol) was added to 1,4-diaminobutane (10 g, 0.114 
mmol) in CH3OH/Et3N (9/1) and the reaction was stirred overnight. The solvent was evaporated and the 
residue was dissolved in DCM (20 mL) and extracted using a saturated solution of NaHCO3 (20 mL). 
Then water phase was washed with DCM (3 · 20 ml). The combined organic phase was dried over 
Mg2SO4 and concentrated in vacuo to give a pale yellow oil. The compound was purified by flash 
chromatography (CH2Cl2/CH3OH/NH3 2.0M solution in ethyl alcohol, from: 100/0/0.1 to 70/30/0.1) to 
give 135 (0.51 g, 30%) as a yellow light oil; Rf (98/2/0.1, CH2Cl2/CH3OH/NH3 2.0M solution in ethyl 
alcohol) 0.63; δH (300 MHz, CDCl3)  4.68 (brs, 1H,  NH-Boc),  3.12 (bq, 2H, CH2-NH-Boc,  J = 7.5 





, found 189.1600. C9H21N2O2
+
 requires 189,1598. 
 
                                                 




 Compound 137 
Aminoethanethiol hydrocloride (5 g, 0.044 mol) was dissolved in 12.5 mL of TFA. 
Triphenylcarbinol (11.5 g, 0.044 mol) was added to the solution portionwise under stirring at room 
temperature, until the solution became clear. The reaction mixture, a dense deeply red liquid, was left 
aside for 1 h and the poured in 200 mL of water under vigorous stirring. The suspension of the white 
solid was alkalinized with triethylamine and filtered and the solid washed with water alkaline for TEA. 
After drying, 18 g of the crude solid of 137, slightly impure for TrOH, was obtained. The compound 
was used in the next step without purification, yeld:100%. Rf (98/2/0.1, CH2Cl2/CH3OH/NH3 2.0M 
solution in ethyl alcohol) 0.63; δH (250 MHz, CDCl3) 2.34 (t, 2H, CH2-STr, J=7.5 Hz),  3.41 (t,  2H,  




, found 320.1470. 
C21H22NS
+
 requires 320,1467. δC (100 MHz, CDCl3) 31.9 (CH2-STr), 40.1 (CH2NH2), 68.0 (C(Ph)3), 
127.8-128.5-128.9 (CH trityl), 145.7 (Cq trityl). 
6.4.2 General procedures for linear oligomers 68, 71, 74 and 78. 
Linear peptoid oligomers 68, 71, 74 and 78 were synthesized using a sub-monomer solid-phase 
approach
11
. In a typical synthesis 2-chlorotrityl chloride resin (2,α-dichlorobenzhydryl-polystyrene 
crosslinked with 1% DVB; 100–200 mesh; 1.33 mmol/g, 400 mg, 0.532 mmol) was swelled in dry 
DMF (4 mL) for 45 min and washed twice with dry DCM (4 mL). 
The first sub-monomer was attached onto the resin by adding 120 mg (1.2 eq, 0.63 mmol) of 
bromoacetic acid in dry DCM (4 mL) and 370 μL of DIPEA (2.10 mmol) on a shaker platform for 40 
min at room temperature, followed by washing with dry DCM (4 mL) and then with DMF (4 x 4 mL). 
To the bromoacetylated resin was added a DMF solution (1 M, 5.3 mL) of the desired amine 
(isobutylamine -10 eq- or 135 -10 eq- or 137 -10 eq) the mixture was left on a shaker platform for 30 
min at room temperature, then the resin was washed with DMF (4 x 4 mL). Subsequent 
bromoacetylation reactions were accomplished by reacting the aminated oligomer with a solution of 
bromoacetic acid in DMF (1.2 M, 5.3 mL) and 823 μL of DIC for 40 min at room temperature. The 
filtered resin was washed with DMF (4 x 4 mL) and treated again with the amine in the same conditions 
reported above. This cycle of reactions was iterated until the target oligomer was obtained (68, 71, 74  
and 78 peptoids). The cleavage was performed by treating twice the resin, previously washed with DCM 
(6 x 6 mL), with 4 mL of 20% HFIP in DCM (v/v) on a shaker platform at room temperature for 30 min 
and 5 min, respectively. The resin was then filtered away and the combined filtrates were concentrated 
in vacuo. The final products were dissolved in 50% acetonitrile in HPLC grade water and analysed by 
RP-HPLC (purity >95% for all the oligomers, conditions: 5% to 100% B in 30 min [A: 0.1% TFA in 
water, B: 0.1% TFA in acetonitrile], flow: 1.0 mL/min, 220 nm. C18 reversed-phase analytical column 
[Waters, μBondapak, 10 μm, 125 Å, 3.9 mm x 300 mm]) and ESI mass spectrometry. The linear 
oligomers 68, 71, 74 and 78 were subjected to the cyclization reaction without further purification. 
 




, found 1419,7497 
C80H107N8O11S2
+
 requires 1419,7495. 100% 
 




, found 1415,7912 
C82H111N8O9S2
+









, found  1868,1278 
C106H155N12O13S2
+
 requires  1868,1273. 100% 
 




, found 1836,0650 
C104H147N12O13S2
+
 requires 1836,0647. 100%. 
 
6.4.3 General cyclization reaction (synthesis of 138, 139, 140 and 141). 
A solution of the linear peptoid (68, 71, 74 and 78), previously co-evaporated three times with 
toluene, was prepared under nitrogen in dry DMF (20 mL).  
 Linear 68 (1.0 eq., 200 mg, 0.141 mmol) was dissolved in DMF dry (10 mL) and the mixture 
was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (4.0 eq., 214 mg, 0.564 
mmol) and DIPEA (6.2 eq., 152 µl, 0.874 mmol) in dry DMF (37 mL) at room temperature in 
anhydrous atmosphere. 
 Linear 71 (1.0 eq., 140.0 mg, 0.099 mmol) was dissolved in DMF dry (10 mL) and the 
mixture was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (4.0 eq., 150 mg, 
0.396 mmol) and DIPEA (6.2 eq, 168 µl, 0.614 mmol) in dry DMF (23 mL) at room temperature in 
anhydrous atmosphere. 
 Linear 74 (1.0 eq., 100.0 mg, 0.054 mmol) was dissolved in DMF dry (8 mL) and the 
mixture was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (4.0 eq, 81.0 mg, 
0.214 mmol) and DIPEA (6.2 eq, 58 µl, 0.33 mmol) in dry DMF (10 mL) at room temperature in 
anhydrous atmosphere. 
 Linear 78 (1.0 eq., 100.0 mg, 0.055 mmol) was dissolved in DMF dry (8 mL) and the 
mixture was added drop-wise by syringe pump in 2 h to a stirred solution of HATU (4 eq, 83.0 mg, 
0.218 mmol) and DIPEA (6.2 eq, 59 µl, 0.34 mmol) in dry DMF (10 mL) at room temperature in 
anhydrous atmosphere. 
After 12 h the resulting mixtures were concentrated in vacuo, diluted with CH2Cl2 (20 mL) and a 
solution of HCl (0.1 N, 20 mL). The single mixture was extracted with CH2Cl2 (2 x 20 mL) and the 
combined organic phases were washed with water (12 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo.  
All protected cyclic 138, 139, 140 and 141 were dissolved in 50% acetonitrile in HPLC grade water 
and analysed by RP-HPLC (purity >85% for all the cyclic oligomers, conditions: 5%-100% B in 30 min 
[A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 1.0 mL/min, 220 nm. C18 reversed-phase 
analytical column [Waters, μBondapak, 10 μm, 125 Å, 3.9 mm x 300 mm]) and ESI mass spectrometry 
(zoom scan technique). 
The crude residues were purified by HPLC on a C18 reversed-phase preparative column, conditions: 
20%-100% B in 40 min [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 2.0 mL/min, 220 
nm. The samples were dried in a falcon tube under low pressure. 
 
 Compound 138: δH (400 MHz, CD3CN:CDCl3 (9:1), mixture of conformers) 7.39-7.21 (m, 
30H, H-Ar), 4.21-2.48 (m, 34H, NCH2CH2CH2CH2NHCO(CH3)3, -COCH2N-, NCH2CH(CH3)2, 
CH2CH2STr,  overlapped), 1.43 (m, 26 H, NCH2CH2CH2CH2NHCO(CH3)3); 0.72-0.90 (m,  12 H, 




, found 1401,7395. C80H105N8O10S2
+
 requires 





 Compound 139: δH (400 MHz, CD3OD, mixture of conformers) 7.60-7.20 (m, 30H, H-Ar), 
4.90-2.34 (m, 38H, NCH2CH(CH3)2,  CH2CH2STr,  -COCH2N- overlapped), 1.45-0.70 (m,  36H, 




, found 1397,7810. C82H109N8O8S2
+
 requires 
1397,7804. HPLC: tR: 27.1 min. 
 
 Compound 140: δH (400 MHz, CD3OD, mixture of conformers) 7.60-7.20 (m, 30H, H-Ar), 
4.90-2.23 (m, 62H, NCH2CH(CH3)2,  CH2CH2STr,  -COCH2N- overlapped), 1.45-0.70 (m,  60H, 




, found 1850,1170. C106H153N12O12S2
+
 requires 
1850,1167. HPLC: tR: 33.0 min. 
 
 Compound 141: δH (400 MHz, CD3OD, mixture of conformers) 7.60-7.20 (m, 30H, H-Ar), 
4.90-2.23 (m, 70H, NCH2CH(CH3)2,  CH2CH2STr,  -COCH2N-, CHCH2CH2CH2NCO overlapped), 




, found 1804,0390. 
C103H143N12O12S2
+
 requires 1804,0384. HPLC: tR: 29.1 min. 
 
6.4.4 General Deprotection/Oxidation reactions reported in table 6.1 (synthesis of 69-70, 72-73, 
75-76-77 and 79-80-81). 
 
 General procedure for Entry 1. 
Compound 68 (30 mg, 0.021 mmol) was dissolved in CH2Cl2 (1.0 mL), and to this solution was 
successively added CuCl (0.9 mg, 0.009 mmol) and H2O (0.8 mg, 0.042 mmol), then the reaction bottle 
was sealed with a rubber plug. The reaction was conducted under ultrasonic irradiation for 3–7 h until 
detritylation was complete as judged by HPLC/MS.  
 
 General procedures for Entry 2 and 5. 
Compound 68 (27 mg, 0.019 mmol) and Compound 139 (20 mg, 0.014 mmol) was dissolved in a 
mixture of TFA/H2O/Et3SiH (92.5/5/2.5) and the reaction was stirred for 1h and 30min. After, products 
were precipitated in cold Ethyl Ether (20 mL) and centrifuged. Products recuperated was analyzed by 
HPLC/MS. 
 
 General procedure of Entry 3 
Compound 68 (5 mg, 0.007 mmol) was dissolved in 17.5 mL solution mixture of AcOH-H2O (4/1) 
containing 9 mg of I2 (0.035 mmol, 5 equivalents). The reaction mixture was stirred for 3 h, then 
mixture was concentrated in vacuo and analyzed by HPLC/MS. 
 
 General procedure for Entry 4 and 6 
Compound 68 (10 mg, 0.014 mmol) and compound 139 (10 mg, 0.011 mmol) were dissolved in 
about 11-13 mL of CH3CN and 5% of DMSO and then DIPEA (24 μL, 0.14 mmol for 68, and 19 μL, 
0.11 mmol for 139) were added. The mixtures were stirred for overnight. Mixtures were concentrated in 






 General procedure for Entry 7 
Compound 139 (1.5 mg, 0.0016 mmol) was dissolved in about 1.6 mL of CH3CN and 5% of DMSO 
and then DBU (2.4 μL, 0.016 mmol) were added. The mixture was stirred for overnight. Mixture was 
concentrated in vacuo and analyzed by HPLC/MS. 
 General procedure for Entry 8 
Compound 139 (1.5 mg, 0.0016 mmol) was dissolved in about 1.28 mL of THF and K2CO3 (aq) 
(0.32 mL, 0.2 M) was added. The mixture was stirred for overnight. Mixture was concentrated in vacuo 
and analyzed by HPLC/MS. 
 
 General procedure for Entry 9 
 A solution of iodine (7 mg, 0.027 mmol, 5 eq.) in CH3OH (4 mL, ~10
-3
M) was stirred vigorously 
and compound 139 (5.0 mg, 0.005 mmol), compound 140 (8 mg, 0.004 mml), compound 141 (10 mg, 
0.005 mmol), compound 74 (10 mg, 0.005 mmol), compound 78 (10 mg, 0.005 mmol) in about 1 mL of 
CH3OH were respectively added. The reactions were stirred for overnight and then were quenched by 
the addition of aqueous ascorbate (0.2 M) in pH 4.0 citrate (0.2 M) buffer (4 mL). The colorless 
mixtures extracted were poured into 1/1 saturated aqueous NaCl and CH2Cl2. The aqueous layer were 
extracted with CH2Cl2 (3 x 10 mL). The organic phases recombined were concentrated in vacuo and the 
crudes were purified by HPLC/MS. 
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